	<rdf:RDF xmlns:admin="http://webns.net/mvcb/" xmlns="http://purl.org/rss/1.0/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:prism="http://purl.org/rss/1.0/modules/prism/" xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:syn="http://purl.org/rss/1.0/modules/syndication/">
	<channel rdf:about="https://biorxiv.org">
	<admin:errorReportsTo rdf:resource="mailto:biorxiv@cshlpress.edu"/>
	<title>Collection : <? echo $this_gname; ?></title>
	<link>https://biorxiv.org</link>
	<description>
	This feed contains articles for Collection "<? echo $this_gname; ?>"
	</description>

		<items>
	<rdf:Seq>
		</rdf:Seq>
	</items>
	<prism:eIssn/>
	<prism:publicationName>bioRxiv</prism:publicationName>
	<prism:issn/>

	<image rdf:resource=""/>
	</channel>
	<image rdf:about="">
	<title>bioRxiv/medRxiv</title>
	<url/>
	<link>https://biorxiv.org</link>
	</image>
	<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.13.26365424v1?rss=1">
<title>
<![CDATA[
A Genome-Wide Association Study in the Chilean admixed population reveals four new loci for COVID-19 severity and susceptibility 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.13.26365424v1?rss=1"
</link>
<dc:creator>Espinosa-Parrilla, Y.</dc:creator>
<dc:creator>Fuentes-Guajardo, M.</dc:creator>
<dc:creator>Carvajal-Silva, L.</dc:creator>
<dc:creator>Aguilar-Valdes, K.</dc:creator>
<dc:creator>Signore, I. A.</dc:creator>
<dc:creator>Arevalo, T. V.</dc:creator>
<dc:creator>Zapata-Contreras, D.</dc:creator>
<dc:creator>Donoso, G.</dc:creator>
<dc:creator>Zuniga-Pacheco, P.</dc:creator>
<dc:creator>Valenzuela-Jorquera, H.</dc:creator>
<dc:creator>Rosso Villanelo, S. A.</dc:creator>
<dc:creator>Tobar-Calfucoy, E. A.</dc:creator>
<dc:creator>Yanez, C. E.</dc:creator>
<dc:creator>Carvajal, F.</dc:creator>
<dc:creator>Saez Hidalgo, J. M.</dc:creator>
<dc:creator>Sanhueza, S.</dc:creator>
<dc:creator>Quiroga, R. A.</dc:creator>
<dc:creator>Martinez, M. F.</dc:creator>
<dc:creator>Cerpa, L. C.</dc:creator>
<dc:creator>Varela, N. M.</dc:creator>
<dc:creator>Cappelli, C. L.</dc:creator>
<dc:creator>Campillay-Veliz, C. P.</dc:creator>
<dc:creator>Valdebenito-Maturana, B.</dc:creator>
<dc:creator>Garcia-Araya, J.</dc:creator>
<dc:creator>Santander, R. A.</dc:creator>
<dc:creator>Opazo, J.</dc:creator>
<dc:creator>Retamales-Ortega, R.</dc:creator>
<dc:creator>Bocchieri, P.</dc:creator>
<dc:creator>Alarcon, T. A.</dc:creator>
<dc:creator>Plaza, A.</dc:creator>
<dc:creator>Moraga, M.</dc:creator>
<dc:creator>Munoz, C. A.</dc:creator>
<dc:creator>Echeverria, C. A.</dc:creator>
<dc:creator>Dorador,</dc:creator>
<dc:date>2026-10-14</dc:date>
<dc:identifier>doi:10.64898/2026.10.13.26365424</dc:identifier>
<dc:title><![CDATA[A Genome-Wide Association Study in the Chilean admixed population reveals four new loci for COVID-19 severity and susceptibility]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-10-14</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
BackgroundMore than five years after the COVID-19 outbreak, the infection by the SARS-CoV-2 virus should still be considered as a global threat with highly heterogeneous clinical outcomes from asymptomatic to fatal depending on existing genetic and phenotypic inter-individual and inter-population variability. Our objective is to identify risk loci associated with COVID-19 in an admixed Latin American population.

MethodsWe performed a genome-wide association study in the framework of the Chilean C19-GenoNet team, analyzing a cohort of 3,417 individuals recruited from the northernmost to the southernmost regions of the country, who presented variations in the severity of their COVID-19 clinical manifestations.

ResultsOur investigation replicated the extensively reported association of several variants at the 3p21.31 locus with COVID-19 severity and found a suggestive association for a variant within the FOXP4 gene at 6p21.1 with COVID-19 hospitalization. Both associations appear to be shared with other populations. Importantly, our study identified three previously unreported loci associated with COVID-19 severity or hospitalization at 7q21.11, 16p13.12 and 6p25.3, and one additional locus at 4p13 associated with SARS-CoV-2 positivity, a proxy for infection susceptibility.

Conclusionsthese new risk loci may represent population-specific effects in Chilean and, potentially, other Latin American admixed groups. Our study highlights the importance of expanding efforts to study underrepresented and genetically different populations, which may provide new clues on the genetic basis of human diseases and may help to anticipate global responses to emerging viral infections and future pandemics.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.12.26365315v1?rss=1">
<title>
<![CDATA[
Informing risk stratification and vaccine policy via a predictive mathematical model of SARS-COV-2 infection 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.12.26365315v1?rss=1"
</link>
<dc:creator>Chain, B.</dc:creator>
<dc:creator>Callan, C.</dc:creator>
<dc:creator>Scobie, D.</dc:creator>
<dc:creator>Cowley, M.</dc:creator>
<dc:creator>Jang, J.</dc:creator>
<dc:creator>Gupta, R.</dc:creator>
<dc:creator>Turner, C.</dc:creator>
<dc:creator>Rosenheim, J.</dc:creator>
<dc:creator>Thakker, C.</dc:creator>
<dc:creator>Bell, L.</dc:creator>
<dc:creator>Nageswaran, G.</dc:creator>
<dc:creator>Byrne, S.</dc:creator>
<dc:creator>Killingley, B.</dc:creator>
<dc:creator>Boyers, A.</dc:creator>
<dc:creator>Kalinova, M.</dc:creator>
<dc:creator>Catchpole, a.</dc:creator>
<dc:creator>Mann, A.</dc:creator>
<dc:creator>Lindeboom, R.</dc:creator>
<dc:creator>Nikolic, M.</dc:creator>
<dc:creator>Teichmann, S.</dc:creator>
<dc:creator>Wagstaffe, H.</dc:creator>
<dc:creator>Tiffeau-Mayer, A.</dc:creator>
<dc:creator>Chiu, C.</dc:creator>
<dc:creator>Nousadeghi, M.</dc:creator>
<dc:date>2026-10-14</dc:date>
<dc:identifier>doi:10.64898/2026.10.12.26365315</dc:identifier>
<dc:title><![CDATA[Informing risk stratification and vaccine policy via a predictive mathematical model of SARS-COV-2 infection]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-10-14</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
SARS-CoV-2 human challenge studies enabled unprecedented high frequency temporal measurements of immune determinants of viral control. We integrated prior knowledge of SARS-CoV-2 replication, innate, cytotoxic T cell and antibody responses into a dynamic model which captured viral-load kinetics in seronegative volunteers challenged with wildtype virus. The model predicted measured innate and adaptive immune dynamics. Perturbation analyses indicated that innate immunity limits peak viral load, whereas antibodies principally mediate clearance while cytotoxic T cells become critical in antibody deficiency. Pre-existing antibodies suppressed both viral replication and subsequent immune activation- a prediction validated in a second challenge study of seropositive participants infected with the SARS-CoV-2 Delta variant. The model explains how specific immunodeficiencies may increase susceptibility to severe or persistent infection, supporting clinical risk stratification. It suggests that T cell-targeted vaccination strategies may provide limited protection without effective neutralising antibodies, and that attenuated boosting after low-dose exposure requires repeated vaccination to reduce breakthrough infections, informing public health policy.

One Sentence SummaryA mathematical model of SARS-COV-2 infection predicts innate and adaptive immunity, and informs risk stratification and vaccine policy.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.12.26365288v1?rss=1">
<title>
<![CDATA[
The impact of COVID-19 vaccination on long COVID prevention in the Omicron era: An updated systematic review and meta-analysis 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.12.26365288v1?rss=1"
</link>
<dc:creator>Marjenberg, Z.</dc:creator>
<dc:creator>Peluso, M. J.</dc:creator>
<dc:creator>Wynberg, E.</dc:creator>
<dc:creator>Abduljawad, S.</dc:creator>
<dc:date>2026-10-13</dc:date>
<dc:identifier>doi:10.64898/2026.10.12.26365288</dc:identifier>
<dc:title><![CDATA[The impact of COVID-19 vaccination on long COVID prevention in the Omicron era: An updated systematic review and meta-analysis]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-10-13</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
ObjectivesTo evaluate the impact of COVID-19 vaccination on the prevention of long COVID (LC) in the Omicron era through an updated systematic review and meta-analysis.

MethodsWe performed an update of our previously published systematic review and meta-analysis of vaccination and LC risk (searches between 1 January 2022 and 1 March 2024). Databases (Embase, MEDLINE, PubMed, Europe PMC, LILACS, Cochrane COVID-19 Study Register) were searched for studies published between 1 March 2024 and 13 July 2026.

Observational studies assessing the impact of vaccination on the risk of LC four or more weeks after SARS-CoV-2 infection were included. Vaccines were restricted to those centrally authorised in the European Union. Random-effects meta-analyses, restricted to adults, were performed to calculate pooled odds ratios (OR) of LC in three comparisons: vaccinated (any dose) versus unvaccinated; booster vaccination versus unvaccinated; and booster vaccination versus primary course vaccination only.

ResultsNineteen new studies were identified, of which ten were included in the updated meta-analyses alongside eight studies from the original review. The pooled OR of LC in vaccinated adults (any dose) versus unvaccinated was 0.75 (95% confidence interval [CI] 0.67-0.84; 13 studies). ORs were also lower for booster vaccination versus unvaccinated (0.73; 95% CI 0.65-0.82; 6 studies), and booster vaccination versus primary course vaccination (0.63; 95% CI 0.53-0.75; 6 studies). Significant associations between vaccination and lower LC odds were observed in subgroup analyses of mRNA-only vaccination and LC outcomes three or more months after infection.

ConclusionsThis updated review and meta-analysis reinforces our previous finding that vaccination may reduce the burden of LC in the Omicron era, with booster doses potentially providing additional protection. Although evidence in high-risk groups now prioritised for vaccination in most countries remains limited, these findings clearly demonstrate the benefits of vaccination and support current seasonal vaccination strategies.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.12.26365129v1?rss=1">
<title>
<![CDATA[
COVID-19 vaccination and survival of cancer patients in Northwestern Russia: a historical registry-based cohort study 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.12.26365129v1?rss=1"
</link>
<dc:creator>Dyachenko, A. A.</dc:creator>
<dc:creator>Bogdanov, M. A.</dc:creator>
<dc:creator>Bogdanov, D. V.</dc:creator>
<dc:creator>Meldo, A. A.</dc:creator>
<dc:creator>Chernina, V. Y.</dc:creator>
<dc:creator>Gombolevskiy, V. A.</dc:creator>
<dc:creator>Grjibovski, A. M.</dc:creator>
<dc:creator>Valkov, M. Y.</dc:creator>
<dc:date>2026-10-13</dc:date>
<dc:identifier>doi:10.64898/2026.10.12.26365129</dc:identifier>
<dc:title><![CDATA[COVID-19 vaccination and survival of cancer patients in Northwestern Russia: a historical registry-based cohort study]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-10-13</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
BackgroundCancer patients face a significantly elevated risk of severe COVID-19 outcomes. Although vaccination is a cornerstone of prevention, data on vaccination coverage and association with survival among Russian cancer patients remain scarce. We assessed COVID-19 vaccination coverage and its association with overall survival in a population-based cohort of cancer patients in Northwest Russia.

MethodsThis retrospective registry-based cohort study integrated data from the Population-Based Cancer Registry (PBCR) of the Arkhangelsk Region and the Nenets Autonomous Okrug, regional vaccination records, and an artificial intelligence (AI)-based analysis of chest computed tomography (CT) scans. The cohort consisted of 1,144 cancer patients who underwent CT between August 2020 and April 2021. Vaccination status was ascertained via data linkage. Overall survival (OS) was compared between vaccinated and unvaccinated patients using Kaplan-Meier analysis and multivariable Cox proportional hazards regression, adjusted for demographic, clinical, and AI-derived CT biomarkers. To mitigate immortal time bias, the primary analysis used a landmark approach restricted to patients alive on March 1, 2021 (N = 1,136). A sensitivity analysis used a November 1, 2021 landmark (N = 894). Vaccination status was defined as receipt of at least one dose before the landmark date.

ResultsOnly 6.6% (n=76) of patients received at least one dose of a COVID-19 vaccine (Sputnik V or Sputnik Light). Vaccinated patients were more likely to have earlier-stage cancer and were less likely to be receiving active treatment. In the primary landmark analysis, vaccination was associated with a significantly higher 3-year OS (80.3% vs. 45.7%, p < 0.001). In multivariable analysis, vaccination was independently associated with a 60% lower hazard of all-cause mortality (adjusted HR 0.40, 95% CI 0.25-0.64). AI-detected COVID-19 pneumonia on baseline CT was also an independent predictor of poorer survival (adjusted HR 1.32, 95% CI 1.09-1.59). In the sensitivity analysis (November 1, 2021 landmark), the adjusted HR for vaccination was 0.56 (95% CI 0.34-0.92), showing a consistent but attenuated association.

ConclusionThis study reveals critically low COVID-19 vaccination coverage among cancer patients in Northwest Russia. Nevertheless, vaccination was strongly associated with a substantial survival benefit, underscoring its importance as a potentially lifesaving intervention for this vulnerable population.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.09.26365114v1?rss=1">
<title>
<![CDATA[
Hand-Washing Hygiene Knowledge, Attitude and Practice among University Students in the Post-COVID-19 Era: A Case of KCMC University, Moshi, Tanzania 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.09.26365114v1?rss=1"
</link>
<dc:creator>issangya, E. T.</dc:creator>
<dc:creator>Mosha, V. V.</dc:creator>
<dc:creator>Mnzava, D.</dc:creator>
<dc:creator>Mwageni, R.</dc:creator>
<dc:creator>Kajeguka, D. C.</dc:creator>
<dc:date>2026-10-13</dc:date>
<dc:identifier>doi:10.64898/2026.10.09.26365114</dc:identifier>
<dc:title><![CDATA[Hand-Washing Hygiene Knowledge, Attitude and Practice among University Students in the Post-COVID-19 Era: A Case of KCMC University, Moshi, Tanzania]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-10-13</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
BackgroundHand hygiene is a key public health intervention for preventing infectious diseases, including respiratory and gastrointestinal infections. Although the COVID-19 pandemic improved awareness and compliance, sustained adherence remains a challenge, with evidence showing a decline in practice after outbreaks, particularly among young adults in high-contact settings such as universities. Therefore, this study aimed to assess the knowledge, attitudes, and practices of handwashing hygiene among university students at KCMC University, Moshi, Tanzania, in the post-COVID-19 era.

MethodsA cross-sectional study was conducted among 380 students at KCMC University. Data were collected using a pretested structured questionnaire, which captured information on socio-demographic characteristics, knowledge, attitudes, and practices regarding handwashing hygiene. Data were analyzed using descriptive and inferential statistics. Associations between variables were assessed using logistic regression and multivariable analysis, and a p-value of <0.05 was considered statistically significant.

ResultsA total of 380 students participated in the study, with a mean age of 23.5 {+/-} 3.5 years. More than half 209 (55.0%) were aged 18-23 years, while 203 (53.4%) were female. Most participants had access to hand hygiene facilities 338 (88.9%). 338 (88.9%) participants had good knowledge of hand hygiene but attitudes were mostly negative 193 (50.8%), and practices were suboptimal, with 201 (52.9%) showing poor hand hygiene practices. Good hand hygiene knowledge was associated with access to hand hygiene facilities (AOR=2.84, 95% CI: 1.25- 6.42, p=0.012) and formal training on hand hygiene (AOR=3.48, 95% CI: 1.24-9.76, p=0.018). Positive attitudes were associated with being in the fourth year or above (AOR=2.12, 95% CI: 1.16-3.89, p=0.015). Good hand hygiene practices were associated with access to hand hygiene facilities (AOR=2.67, 95% CI: 1.18-6.01, p=0.018) and formal training on hand hygiene (AOR=2.98, 95% CI: 1.19-7.48, p=0.020).

ConclusionAlthough knowledge and awareness of handwashing hygiene were generally high among university students, inconsistencies between knowledge and actual practices were observed in the post-COVID-19 era. Strengthening health education programs and ensuring continuous access to handwashing facilities may improve adherence to proper hand hygiene practices among university students.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.09.26363506v1?rss=1">
<title>
<![CDATA[
Uneven Recovery of Exercise Training in US Adults With Cardiovascular Risk Factors or Disease Following the COVID 19 Pandemic 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.09.26363506v1?rss=1"
</link>
<dc:creator>Oddleifson, D. A.</dc:creator>
<dc:creator>Zu, J.</dc:creator>
<dc:creator>Wadhera, R.</dc:creator>
<dc:date>2026-10-12</dc:date>
<dc:identifier>doi:10.64898/2026.10.09.26363506</dc:identifier>
<dc:title><![CDATA[Uneven Recovery of Exercise Training in US Adults With Cardiovascular Risk Factors or Disease Following the COVID 19 Pandemic]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-10-12</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
IntroductionThe COVID-19 pandemic led to significant disruptions in cardiovascular care and reductions in physical activity, but little is known about how exercise patterns changed after this period. This study assessed changes in weekly aerobic and strength training activity between 2020 and 2022 amongst adults aged 18 years or older who reported one or more cardiovascular diseases or risk factors.

MethodsThis study used National Health Interview Survey data from 2020 and 2022. Adjusted differences for moderate-to-vigorous physical activity (MVPA) were calculated using a linear regression model and for strength sessions using a Poisson regression, adjusting for sex and age. Changes in these outcomes were then stratified by age and sex subgroups.

ResultsThe weighted study population included 182,783,008 (standard error, {+/-}3,334,337) adults in 2020 and 185,388,060 (SE, {+/-}3,285,161) adults in 2022. Between 2020 and 2022, the overall weekly MVPA increased from 244.2 (SE, {+/-}4.5) minutes to 266.3 (SE, {+/-}5.7) minutes (adjusted difference, +22.1 [SE, {+/-}6.92] minutes). There were no statistically significant changes in the number of strength session per week overall or among sex and age subgroups. Across sex and age subgroups, increases in weekly MVPA were entirely concentrated among males and younger adults.

ConclusionThe recovery from pandemic era reductions in aerobic and strength exercise training was uneven amongst demographic subgroups, which aligns with concurrent persistent disruptions in cardiovascular care.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.10.08.757814v1?rss=1">
<title>
<![CDATA[
Non-canonical alternate interactors of SARS CoV-2 Spike protein implicated in placental susceptibilty 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.10.08.757814v1?rss=1"
</link>
<dc:creator>Mandal, S.</dc:creator>
<dc:creator>Majumder, S.</dc:creator>
<dc:creator>Nandy, S. K.</dc:creator>
<dc:creator>Mukherjee, R.</dc:creator>
<dc:creator>Giri, K.</dc:creator>
<dc:creator>Mukhopadhyay, A.</dc:creator>
<dc:date>2026-10-10</dc:date>
<dc:identifier>doi:10.64898/2026.10.08.757814</dc:identifier>
<dc:title><![CDATA[Non-canonical alternate interactors of SARS CoV-2 Spike protein implicated in placental susceptibilty]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-10-10</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Vertical transmission of SARS-CoV-2 is controversial. Owing to the low expression of ACE2 along with TMPRSS2 in placenta, role of secondary receptors becomes significant. In our study we predicted twelve interactors of spike protein expressed in placenta through interactome analysis followed by docking and molecular dynamic simulation. Three interactors of SARS-CoV-2 spike protein were found to be CD147, EGFR and LDLR. Expression at transcriptomic and translational level by real-time PCR and immunohistochemistry respectively was observed in placenta samples obtained from women with COVID exposure risk and compared to control. Elevated protein levels of CD147 (OR=14.667), ACE2 (OR=8.25) and LDLR (OR=1.9) was associated with higher exposure risk. However, the variation in mRNA expression was not statistically significant. Computational study showed that CD147/basigin, EGFR and LDLR stably interact with spike protein outside its primary receptor binding domain. In-vitro binding assay confirmed the physical interaction between spike protein and the placental receptors. In-silico site-directed mutagenesis further identified key potential binding hotspots of spike protein- Tyr28 and Trp64 for CD147, Phe643, Val642, Thr632 for LDLR and Leu8, Phe59, Phe32, Tyr28, Trp64, Trwp152, His245, and Val213 for EGFR. Finally, concluded that CD147, EGFR and LDLR might act as secondary non-canonical cofactors for SARS-CoV-2 spike protein in placenta, thereby increasing its susceptibility and tissue tropism. The study overall gives a better insight into potential placental suscpetibility providing targeted therapeutic opportunities.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.07.26364920v1?rss=1">
<title>
<![CDATA[
Investigating the Causal Impact of COVID-19 on Acute Myocardial Infarction: A Multi-ancestry Mendelian Randomization Study 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.07.26364920v1?rss=1"
</link>
<dc:creator>Zhou, K.</dc:creator>
<dc:creator>Ma, Y.</dc:creator>
<dc:date>2026-10-09</dc:date>
<dc:identifier>doi:10.64898/2026.10.07.26364920</dc:identifier>
<dc:title><![CDATA[Investigating the Causal Impact of COVID-19 on Acute Myocardial Infarction: A Multi-ancestry Mendelian Randomization Study]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-10-09</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Observational studies suggest an association between COVID-19 and acute myocardial infarction (AMI), however, whether this relationship is causal remains unclear. We conducted a multi-ancestry Mendelian randomization (MR) study across European, East Asian, South Asian, and African populations, evaluating three COVID-19 phenotypes: very severe COVID-19, hospitalized COVID-19, and general infection association with AMI. GWAS summary statistics were obtained from the COVID-19 Host Genetics Initiative Round 7 and UK Biobank/Biobank Japan for AMI. Inverse-variance weighted (IVW) MR was the primary method, with fixed-or random-effects models selected according to heterogeneity test. MR-Egger, weighted median and weighted mode were conducted as sensitivity analyses. In European ancestry, genetic liability to very severe COVID-19 and hospitalized COVID-19 was slightly inversely associated with AMI risk, but without statistical significances across sensitivity analyses. Hospitalized COVID-19 showed a suggestive but non-significant inverse association in South Asian ancestry. No significant associations were identified in East Asian or African ancestries. Our findings did not support a robust causal association between COVID-19 susceptibility or severity and AMI risk across ancestries, suggesting that the observed cardiovascular burden may be driven more by acute pathophysiological mechanisms than shared genetic architecture.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.10.07.757202v1?rss=1">
<title>
<![CDATA[
Error correction of SARS-CoV-2 genomic sequences using a phylogenetic prior 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.10.07.757202v1?rss=1"
</link>
<dc:creator>Arniella, M.</dc:creator>
<dc:creator>Pipes, L.</dc:creator>
<dc:creator>Nielsen, R.</dc:creator>
<dc:date>2026-10-09</dc:date>
<dc:identifier>doi:10.64898/2026.10.07.757202</dc:identifier>
<dc:title><![CDATA[Error correction of SARS-CoV-2 genomic sequences using a phylogenetic prior]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-10-09</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Genotype calling of sequencing data has improved over recent years thanks to technological and statistical breakthroughs. One such advance is the use of imputation-based genotyping methods in human genetics. For haploid and mostly non-recombining organisms, a natural equivalent is to leverage phylogenetic signal for imputation-based genotype calling. SARS-CoV-2 is one such case, and the use of improved genotyping methods in this species is particularly pertinent given the well-documented systematic problems with read alignment and assembly in rapidly evolving regions of its genome, motivating the need for statistically principled methods for genotype correction that complement existing community efforts to curate sequencing data. We present a statistical framework to combine phylogenetic prior probabilities with the information from aligned reads, and demonstrate its utility in correcting consensus calls made on short-read, viral sequencing data. We derive phylogenetically-informed posterior probabilities based on genome placement in a reference phylogeny, and read likelihoods calculated from machine-reported base quality scores. We further modify the prior at each site by estimating a maximum-likelihood scaling parameter jointly with reads at all other sites. We find that the phylogenetically-informed base calling method stays highly accurate across simulated depth and error conditions. In real datasets, the method vastly improves call rate while still maintaining similar accuracy as reference-based assembly methods. In problematic genomic regions, the phylogenetically-informed method confers both accuracy and call rate gains. Accuracy and call rate do not stratify with sequencing center and primer scheme used, suggesting broad applicability across sequencing technologies and potentially diverging sequences. Our results in real and simulated data demonstrate that phylogenetically-informed genotyping correction results in more complete sequences, achieving a higher call rate without compromising accuracy. In cases of low mean depth, sparse coverage, or difficult-to-sequence regions that may still retain a low call rate, the method improves the accuracy of genotype calls.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.07.26363238v1?rss=1">
<title>
<![CDATA[
Surveillance of bacterial and fungal infections in hospitalised COVID-19 patients: an ISARIC/WHO CCP-UK and UKHSA linkage study 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.07.26363238v1?rss=1"
</link>
<dc:creator>Davison, C.</dc:creator>
<dc:creator>Mason, E.</dc:creator>
<dc:creator>King, N.</dc:creator>
<dc:creator>Beckett-Hill, G.</dc:creator>
<dc:creator>Elmes, J.</dc:creator>
<dc:creator>Turtle, L.</dc:creator>
<dc:creator>Hope, R.</dc:creator>
<dc:creator>Fairfield, C. J.</dc:creator>
<dc:creator>Drake, T. M.</dc:creator>
<dc:creator>Semple, M. G.</dc:creator>
<dc:creator>Baillie, J. K.</dc:creator>
<dc:creator>Brown, C. S.</dc:creator>
<dc:creator>Ho, A.</dc:creator>
<dc:creator>Gerver, S. M.</dc:creator>
<dc:date>2026-10-08</dc:date>
<dc:identifier>doi:10.64898/2026.10.07.26363238</dc:identifier>
<dc:title><![CDATA[Surveillance of bacterial and fungal infections in hospitalised COVID-19 patients: an ISARIC/WHO CCP-UK and UKHSA linkage study]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-10-08</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
ObjectivesTo characterise COVID-19 inpatients with and without bacterial/fungal preceding, co- and secondary infections, and describe the distribution of organisms associated with COVID-19 and antibiotic use.

MethodsWe linked ISARIC/WHO CCP-UK data from hospitals in England (admissions 01/01/2020-18/10/2021) with UK Health Security Agency infections datasets of COVID-19, and bacterial- and fungal-positive specimens using a multi-step hierarchical algorithm. We retained those aged >18 years and categorised COVID-19-associated infection as preceding (2-28 days prior to SARS-CoV-2 PCR positive date), co-infection ({+/-}1 day) or secondary (2-28 days after).

ResultsDuring the study period, there were 173,947 hospitalised episodes of COVID-19; 5.8% (n=10,017) with a bacterial or fungal preceding, co- or secondary infection. Preceding and co-infections were rare (preceding: 0.7%; co-infection: 1.5%) while secondary infections were more common (3.5%). Escherichia coli (29.6%) and Staphylococcus aureus (15.2%) were the most identified organisms in blood specimens, while S. aureus (22.9%) and Pseudomonas aeruginosa (20.4%) were most common in lower respiratory tract specimens. The 28-day case fatality rate (CFR) remained static (36%) in those with secondary infection, whereas it decreased between early 2020 and mid-2021 in the other infection groups (37% to 27%). Of those with no positive microbiology, 72.8% received antibiotics, though this decreased between January-June 2020 (77.6%) and April-October 2021 (62.6%).

ConclusionBacterial and fungal infections complicated approximately 1-in-17 hospitalised episodes of COVID-19, with CFR of >25%. Antibiotic prescribing was common in those without firm evidence of bacterial infection. We recommend adhering to NICE guidance which discourages empirical antibiotic use for hospitalised COVID-19 patients.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.05.26364531v1?rss=1">
<title>
<![CDATA[
Resting-State Functional Connectivity and Cognitive Performance in Long COVID: A Randomized Controlled Trial 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.05.26364531v1?rss=1"
</link>
<dc:creator>O'Connor, D.</dc:creator>
<dc:creator>Watson, E.</dc:creator>
<dc:creator>Reich, D. L.</dc:creator>
<dc:creator>Carnavali, F.</dc:creator>
<dc:creator>Mcveety, M.</dc:creator>
<dc:creator>Gwalani, P.</dc:creator>
<dc:creator>Wisnivesky, J. P.</dc:creator>
<dc:creator>Becker, J. H.</dc:creator>
<dc:date>2026-10-08</dc:date>
<dc:identifier>doi:10.64898/2026.10.05.26364531</dc:identifier>
<dc:title><![CDATA[Resting-State Functional Connectivity and Cognitive Performance in Long COVID: A Randomized Controlled Trial]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-10-08</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Cognitive impairment is a prevalent, disabling manifestation of Long COVID, but whether cognitive rehabilitation alters neural network organization is unknown. We examined whether a 12-week cognitive rehabilitation intervention modified resting-state connectivity within the central-executive (CEN), default-mode (DMN), and salience (SN) networks, and whether connectivity changes associated with cognitive performance. Participants were adults with prior SARS-CoV-2 infection, persistent Long COVID symptoms ([&ge;]3 months), and objectively confirmed mild-to-moderate cognitive impairment. Of 58 participants randomized, 39 (mean age 46.4; 69% women) completed neuroimaging (19 intervention, 20 control). The 12-week intervention combined virtual cognitive rehabilitation and small-group and individual sessions with computerized cognitive training. No significant group, time, or group-by-time interaction effects were observed for within- or between-network connectivity (all P > 0.22). Exploratory analyses identified nominal associations (P < 0.05) between connectivity changes and cognition; improved processing speed associated with increased CEN-DMN connectivity, greater SN-DMN connectivity associated with worse performance across processing speed, working memory, and executive function. None survived correction for multiple comparisons. Cognitive rehabilitation was not associated with detectable changes in resting-state network connectivity in long COVID-related cognitive impairment. SN-DMN connectivity may represent a marker of reduced network segregation underlying cognitive dysfunction, warranting study in larger, multimodal trials. Trial registration: NCT05498493.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.07.26364942v1?rss=1">
<title>
<![CDATA[
Persistent Fibromyalgia-like symptom presentation in Long COVID-associated chronic musculoskeletal pain: a longitudinal cohort study 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.07.26364942v1?rss=1"
</link>
<dc:creator>Silva-Passadouro, B.</dc:creator>
<dc:creator>Delis, I.</dc:creator>
<dc:creator>Astill, S. L.</dc:creator>
<dc:creator>Brown, C.</dc:creator>
<dc:creator>Casson, A. J.</dc:creator>
<dc:creator>Sivan, M.</dc:creator>
<dc:date>2026-10-08</dc:date>
<dc:identifier>doi:10.64898/2026.10.07.26364942</dc:identifier>
<dc:title><![CDATA[Persistent Fibromyalgia-like symptom presentation in Long COVID-associated chronic musculoskeletal pain: a longitudinal cohort study]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-10-08</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
BackgroundChronic musculoskeletal pain (CMP) is a common and debilitating symptom of Long COVID (LC), which shares several clinical features with Fibromyalgia Syndrome (FMS).

AimsThis longitudinal study investigated whether the symptom overlap between LC-CMP and FMS persists over time, whether patterns differ according to pre-COVID CMP history, and the extent to which neuropathic pain features are present.

MethodsIndividuals with LC completed questionnaires assessing the symptom-based component of the 2010 American College of Rheumatology criteria for FMS and the presence of neuropathic pain features (PainDetect Questionnaire, PDQ) at baseline, 6- and 12-month follow-ups. Participants were grouped according to pre-COVID CMP history. Group differences were analysed using mixed-effects logistic regression.

Results240 individuals completed the baseline assessment at a mean of 2.61 years after LC onset, including 131 (100 females) with new-onset CMP and 94 (87 females) with pre-existing CMP. The prevalence of participants meeting the symptom-based criteria for FMS remained high across follow-up (67.5-78.6%), with 50.0-61.0% of those with complete follow-up data fulfilling criteria at all timepoints. No significant subgroup differences were observed (OR = 0.43, 95% CI [0.14 1.39], p = 0.160). Across follow-up, 22.2-36.1% of participants reported likely neuropathic pain features, with significantly higher odds in the pre-existing CMP group (OR = 3.17, 95% CI [1.22 8.18], p = 0.017).

ConclusionsFMS-like symptoms remain highly prevalent several years after acute COVID-19 and persist over a further 12 months, suggesting that LC-CMP frequently represents a persistent long-term condition with substantial overlap with FMS. These findings support closer integration of LC and chronic pain rehabilitation services and add to the wider literature linking post-infectious processes with FMS-like symptoms.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.10.07.756802v1?rss=1">
<title>
<![CDATA[
Genome-wide within-host evolution during prolonged SARS-CoV-2 infection in a person with advanced HIV infection 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.10.07.756802v1?rss=1"
</link>
<dc:creator>Perlaza, K.</dc:creator>
<dc:creator>Dureja, I.</dc:creator>
<dc:creator>Havlir, D.</dc:creator>
<dc:creator>Jain, V.</dc:creator>
<dc:creator>Whitman, J.</dc:creator>
<dc:creator>Dayao, M.</dc:creator>
<dc:creator>Castillo-Rojas, B.</dc:creator>
<dc:creator>Rosecrans, J.</dc:creator>
<dc:creator>Ott, M.</dc:creator>
<dc:creator>Marquez, C.</dc:creator>
<dc:creator>DeRisi, J. L.</dc:creator>
<dc:creator>Taha, T. Y.</dc:creator>
<dc:date>2026-10-08</dc:date>
<dc:identifier>doi:10.64898/2026.10.07.756802</dc:identifier>
<dc:title><![CDATA[Genome-wide within-host evolution during prolonged SARS-CoV-2 infection in a person with advanced HIV infection]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-10-08</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Within-host evolution during prolonged SARS-CoV-2 infection can be extensive in immunocompromised individuals, but the consequences of mutations that emerge and change in frequency over time remain difficult to predict. We characterized an XBB.1.5.10 infection lasting nearly 90 days in a person with advanced human immunodeficiency virus (HIV) infection. Genome-wide tracking of allele frequencies in samples collected on study days 43, 48, and 70 revealed a Spike N-terminal domain (NTD) deletion spanning residues 138-145 at frequencies of 33%, 80%, and 96%, respectively. A receptor-binding domain (RBD) deletion-insertion spanning residues 373-378 was detected on days 43 and 48 but not on day 70, while nsp12 C464Y was detected at approximately 8% on day 48 and 86% on day 70. We reconstructed representative Spike and non-Spike mutation profiles from the longitudinal samples and tested their effects on cell entry and viral RNA replication. The representative Spike construct for days 43 and 48 increased entry relative to XBB.1.5. Comparison with a matched construct lacking the receptor-binding domain deletion-insertion showed that the deletion-insertion enhanced entry, although it was not detected in the day 70 sample. The day 48 non-Spike profile supported the highest RNA replication among the tested replicons. Together, allele-frequency tracking revealed both transient mutations and mutations detected at progressively higher frequencies across the sampled time points. Functional testing showed that increased entry or RNA replication in vitro did not necessarily predict persistence in vivo.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.10.08.757354v1?rss=1">
<title>
<![CDATA[
Epidemiology and virological characteristics of the emerging SARS-CoV-2 variant PJ.2.1 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.10.08.757354v1?rss=1"
</link>
<dc:creator>Hoffmann, M.</dc:creator>
<dc:creator>Zhang, L.</dc:creator>
<dc:creator>Chen, N.</dc:creator>
<dc:creator>Moor, N.</dc:creator>
<dc:creator>Nehlmeier, I.</dc:creator>
<dc:creator>Graichen, L.</dc:creator>
<dc:creator>Moldenhauer, A.-S.</dc:creator>
<dc:creator>Dopfer-Jablonka, A.</dc:creator>
<dc:creator>Happle, C.</dc:creator>
<dc:creator>Behrens, G. M. N.</dc:creator>
<dc:creator>Poehlmann, S.</dc:creator>
<dc:date>2026-10-08</dc:date>
<dc:identifier>doi:10.64898/2026.10.08.757354</dc:identifier>
<dc:title><![CDATA[Epidemiology and virological characteristics of the emerging SARS-CoV-2 variant PJ.2.1]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-10-08</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
SARS-CoV-2 continues to circulate globally at high levels and to evolve into new variants. Recently, a new saltation variant harbouring a highly mutated spike protein, PJ.2.1, emerged in North America. Here, we provide a brief epidemiological and virological characterization of PJ.2.1 and cocirculating variants. We report that PJ.2.1 is spreading in the USA, Canada, and Spain and mainly infects individuals aged 60 years and older, as do most other variants, with the exception of BA.3.2, which preferentially infects individuals aged 0-9 years. PJ.2.1 was less susceptible to inhibition by an antibody against ACE2 than were the other variants, indicating increased ACE2 binding. In contrast, PJ.2.1 did not show augmented evasion of antibodies from vaccinees who had received the LP.8.1-adapted vaccine compared with most other variants analysed. These results suggest that augmented ACE2 affinity rather than increased antibody evasion might drive the current, rapid spread of PJ.2.1.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.05.26363801v1?rss=1">
<title>
<![CDATA[
Data Reduction in SARS-CoV-2 Amplicon Sequencing: Effects of Read Subsampling and Normalization on Consensus Quality, Lineage Assignment, and Computational Burden 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.05.26363801v1?rss=1"
</link>
<dc:creator>Ortega, Y.</dc:creator>
<dc:creator>Gupta, P.</dc:creator>
<dc:creator>Olinares-Perdomo, O.</dc:creator>
<dc:creator>Oakeson, K. F.</dc:creator>
<dc:creator>Young, E. L.</dc:creator>
<dc:date>2026-10-07</dc:date>
<dc:identifier>doi:10.64898/2026.10.05.26363801</dc:identifier>
<dc:title><![CDATA[Data Reduction in SARS-CoV-2 Amplicon Sequencing: Effects of Read Subsampling and Normalization on Consensus Quality, Lineage Assignment, and Computational Burden]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-10-07</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
BackgroundAmplicon-based next-generation sequencing is a cornerstone of viral genomic surveillance, but it often produces datasets with highly uneven read coverage due to PCR amplification bias. This leads to excessive data generation and substantial computational overhead for downstream bioinformatic analysis.

ResultsWe evaluated the efficacy of two data reduction strategies on 220 SARS-CoV-2 clinical specimens and 12 wastewater samples: random subsampling with SeqKit and read depth normalization with BBNorm. FASTQ files were reduced to target depths from 10X to 10,000X to compare genome coverage, lineage assignment concordance, and computational resource usage. Both strategies markedly reduced total processing time. For clinical isolates, read depth normalization corrected for amplification bias resulting in highly concordant lineage assignments at a target depth of just 200X. Random subsampling preserved inherent bias but produced reliable assignments at depths over 500X. Reducing target depths below 500X in complex wastewater mixtures severely degraded variant deconvolution accuracy and heavily skewed lineage abundance profiles for both methods.

ConclusionBoth random subsampling and read depth normalization successfully reduce computational overhead while preserving key clinical sequencing metrics at appropriate reduction settings. The optimal method depends on the analytical goal, ranging from computationally lightweight random subsampling for rapid lineage assignment, to read depth normalization for generating high-quality consensus sequences. However, aggressive data reduction should be avoided in environmental surveillance, where maintaining a high baseline sequencing depth is critical for accurate mixed-variant deconvolution.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.04.26363389v1?rss=1">
<title>
<![CDATA[
The role of personality traits in COVID-19 vaccination: A socio-cultural and gender-stratified analysis in Japan 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.04.26363389v1?rss=1"
</link>
<dc:creator>Takamatsu, M.</dc:creator>
<dc:creator>Tokiya, M.</dc:creator>
<dc:creator>Hara, M.</dc:creator>
<dc:date>2026-10-07</dc:date>
<dc:identifier>doi:10.64898/2026.10.04.26363389</dc:identifier>
<dc:title><![CDATA[The role of personality traits in COVID-19 vaccination: A socio-cultural and gender-stratified analysis in Japan]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-10-07</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
BackgroundCOVID-19 vaccination uptake is influenced by various sociodemographic and psychological factors. Previous studies have suggested that the relationship between personality traits and vaccination is context-dependent. However, this association has not been investigated in Japan--a unique sociocultural context characterized by historically low vaccine confidence but exceptionally high COVID-19 vaccine uptake. We examined the association between the Big Five personality traits and completion of the primary COVID-19 vaccination series, exploring potential gender-personality interactions.

MethodsA web-based, cross-sectional survey was conducted among 7,210 Japanese adults (aged 20-85 years) in December 2021. Personality was assessed using the Japanese version of the Ten-Item Personality Inventory. Multivariable Poisson generalized estimating equations were used to calculate adjusted prevalence ratios (PRs) and assess gender-personality interactions.

ResultsHigher extraversion and lower openness were significantly associated with vaccination completion across genders. A significant gender-agreeableness interaction was observed: agreeableness (PR = 1.016, 95% CI: 1.008-1.024) was positively associated with vaccination completion among men but not women. A similar, though only marginally significant, interaction pattern was observed for neuroticism (PR = 1.011, 95% CI: 1.004-1.019 among men).

ConclusionsPersonality traits act as modest but meaningful, gender-specific psychological modifiers of vaccination behavior in Japan. Public health campaigns should transition from traditional "one-size-fits-all" messages to personality-tailored and gender-responsive communication strategies to optimize vaccine uptake and bolster psychological resilience in future pandemics.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.04.26364721v1?rss=1">
<title>
<![CDATA[
Variation in social contact levels and changes during the COVID-19 pandemic by occupation and socio-economic status in east Zimbabwe 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.04.26364721v1?rss=1"
</link>
<dc:creator>Ayling, S.</dc:creator>
<dc:creator>Nyamukapa, C.</dc:creator>
<dc:creator>Maswera, R.</dc:creator>
<dc:creator>Moorhouse, L.</dc:creator>
<dc:creator>Morris, R.</dc:creator>
<dc:creator>Moyo, B.</dc:creator>
<dc:creator>Melegaro, A.</dc:creator>
<dc:creator>Mugurungi, O.</dc:creator>
<dc:creator>Fry, H.</dc:creator>
<dc:creator>Wise, S.</dc:creator>
<dc:creator>Harling, G.</dc:creator>
<dc:creator>Gregson, S.</dc:creator>
<dc:date>2026-10-06</dc:date>
<dc:identifier>doi:10.64898/2026.10.04.26364721</dc:identifier>
<dc:title><![CDATA[Variation in social contact levels and changes during the COVID-19 pandemic by occupation and socio-economic status in east Zimbabwe]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-10-06</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
BackgroundCOVID-19 movement restrictions reduced social contact worldwide, curbing viral spread but with unequal economic consequences where social safety nets are limited. Little evidence exists on how these impacts varied by occupation, wealth and age in resource-constrained settings. This paper examined pre-pandemic contact and lockdown-related change.

MethodsThe paper documents analysis of a population-representative survey (N=8,499) in Manicaland, Zimbabwe, during April-May 2021, capturing typical weekday contacts before and during the first COVID-19 lockdown. Negative binomial regression models assessed pre-lockdown contact counts by socio-economic characteristics, overall and by place (home, school, work, transport, entertainment); linear regression assessed predictors of lockdown declines.

ResultsPre-COVID-19, respondents reported a median of 12 daily contacts (interquartile range [IQR] 4-47), with higher counts among manual labourers (incidence rate ratio [IRR] 2.21, 95% confidence interval [CI] 2.00, 2.44), retail and public sector workers (IRR 2.33, 95%CI 2.09, 2.60) and students (IRR 2.59, 95%CI 2.38, 2.82), males, wealthier respondents, under-30s, and urban and agricultural estate residents. Counts were highest in schools. During lockdown, contacts fell across all subgroups to a median of 8 (IQR 4-28). Declines were greatest among those with most pre-COVID-19 contacts: urban (mean -17.5, 95%CI -19.53, -15.37) and agricultural estate residents (-18.1, 95%CI -19.99, - 16.13), students and teachers (-17.7, 95%CI -19.82, -15.59), males and 30-44 year olds. Drops were greatest in schools and on transport.

ConclusionReductions in contact under blanket lockdown varied markedly between subgroups and places in Manicaland, Zimbabwe. Selectively targeting high-contact groups might have achieved similar transmission reductions while limiting economic damage, holding lessons for similar settings.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.04.26364675v1?rss=1">
<title>
<![CDATA[
Effects of XFG-adapted mRNA vaccination on SARS-CoV-2 variant neutralisation 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.04.26364675v1?rss=1"
</link>
<dc:creator>Happle, C.</dc:creator>
<dc:creator>Hoffmann, M.</dc:creator>
<dc:creator>Stankov, M. V.</dc:creator>
<dc:creator>Chen, N.</dc:creator>
<dc:creator>Nehlmeier, I.</dc:creator>
<dc:creator>Graichen, L.</dc:creator>
<dc:creator>Moldenhauer, A.-S.</dc:creator>
<dc:creator>Witte, T.</dc:creator>
<dc:creator>Pöhlmann, S.</dc:creator>
<dc:creator>Dopfer-Jablonka, A.</dc:creator>
<dc:creator>Behrens, G. M.</dc:creator>
<dc:date>2026-10-06</dc:date>
<dc:identifier>doi:10.64898/2026.10.04.26364675</dc:identifier>
<dc:title><![CDATA[Effects of XFG-adapted mRNA vaccination on SARS-CoV-2 variant neutralisation]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-10-06</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
SARS-CoV-2 antigenic evolution continues to challenge strain-matched vaccination. For the 2026-27 season, the European Medicines Agency (EMA) identified XFG as the preferred antigen within the JN.1 family and Comirnaty XFG was authorised in the European Union in July, 2026. We studied 22 participants who received 30 g of mRNA encoding XFG (Comirnaty XFG, BioNTech-Pfizer, Mainz, Germany) in September, 2026 and had paired serum available before vaccination and median 14 days afterwards. Median Wuhan-Hu-1 S1-specific IgG increased from 1600 BAU/mL (IQR 1118-2926) to 2914 BAU/mL (2117-4468), a 1{middle dot}8-fold increase. Median RBD-binding ED50 increased from 116 (51{middle dot}4-212) to 305{middle dot}6 (170{middle dot}8-434{middle dot}6) for LP.8.1 and from 354{middle dot}3 (129{middle dot}2-558{middle dot}2) to 832{middle dot}9 (429-1175) for NB.1.8.1, corresponding to 2{middle dot}6-fold and 2{middle dot}4-fold increases, respectively (all p<0{middle dot}0001). XFG-adapted vaccination increased neutralising activity against each tested variant. The GMT against XFG increased from 180 before vaccination to 894 afterwards (5{middle dot}0-fold), and that against RV.1.3 increased from 121 to 599 (4{middle dot}9-fold). GMTs increased from 117 to 386 for PQ.16.1.1 (3{middle dot}3-fold), from 101 to 316 for XFG.1.1 (3{middle dot}1-fold), from 629 to 1772 for LP.8.1 (2{middle dot}8-fold), from 221 to 611 for NB.1.8.1 (2{middle dot}8-fold), and from 228 to 642 for PJ.2.1 (2{middle dot}8-fold). Neutralisation of BA.3.2.2 increased more modestly, from GMT 78 to 126 (1{middle dot}6-fold; p=0{middle dot}0009). Pre-versus post-vaccination neutralisation titres differed significantly for all variants (p<0{middle dot}001). Despite the broad increase, post-vaccination neutralisation remained heterogeneous. Relative to LP.8.1, GMTs were 2{middle dot}0-fold lower for XFG, 2{middle dot}8-fold lower for PJ.2.1, 2{middle dot}9-fold lower for NB.1.8.1, 3{middle dot}0-fold lower for RV.1.3, 4{middle dot}6-fold lower for PQ.16.1.1, 5{middle dot}6-fold lower for XFG.1.1, and 14{middle dot}1-fold lower for BA.3.2.2. These findings provide early human immunogenicity data after XFG-adapted mRNA vaccination. The largest relative increases were observed for XFG and RV.1.3, whereas LP.8.1 remained the most strongly neutralised variant after Comirnaty XFG vaccination and BA.3.2.2 the least. This pattern suggests broad boosting of cross-reactive humoral immunity without elimination of between-variant differences. The small, extensively pre-immunised cohort, short follow-up, absence of a contemporaneous vaccine-comparator group, and use of a pseudovirus assay limit inference. Our data characterise early antibody binding and neutralisation but do not establish durability or clinical effectiveness.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.09.29.755449v1?rss=1">
<title>
<![CDATA[
SARS-CoV-2 Nucleocapsid Protein forms biomolecular condensates and interacts with ALS-associated RNA binding proteins in vitro 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.09.29.755449v1?rss=1"
</link>
<dc:creator>Clarke, J.-P. W. E.</dc:creator>
<dc:creator>Keating, A.</dc:creator>
<dc:creator>Noches, V.</dc:creator>
<dc:creator>McLellan, C.</dc:creator>
<dc:creator>Dulcis, D.</dc:creator>
<dc:creator>Ravits, J.</dc:creator>
<dc:creator>Strong, M. J.</dc:creator>
<dc:date>2026-10-06</dc:date>
<dc:identifier>doi:10.64898/2026.09.29.755449</dc:identifier>
<dc:title><![CDATA[SARS-CoV-2 Nucleocapsid Protein forms biomolecular condensates and interacts with ALS-associated RNA binding proteins in vitro]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-10-06</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
As we have entered the endemic phase of COVID-19, there is a need to assess the long-term effects of SARS-CoV-2 infection on the trajectory of neurodegenerative disorders. Herein, we investigate whether the SARS-CoV-2 RNA-binding nucleocapsid protein (NCP; N-protein) may influence molecular processes relevant to motor neuron degeneration in amyotrophic lateral sclerosis (ALS). We detected N-protein immunoreactivity in ALS spinal cord motor neurons, including cytoplasmic N-protein-positive puncta that colocalized with cytoplasmic TAR DNA-binding protein 43 (TDP-43). In vitro, optogenetically induced N-protein biomolecular condensates (BMCs) showed reversible, liquid-like behavior and recovered after photobleaching. Using this model, we found that these condensates colocalized with TDP-43 and the RNA-binding proteins G3BP1/2, PABPC1 and TIA1. Condensate formation was associated with TDP-43 cytoplasmic mislocalization, altered TARDBP expression, and altered exon 3 splicing of POLDIP3. The N-terminal portion of N-protein influenced BMC formation, whereas truncated C-terminal proteoforms did not form detectable BMCs or show detectable TDP-43 colocalization in this assay. Extending these observations to a human cell model, we show that optogenetically induced N-protein BMCs colocalize with TDP-43 in human iPSC-derived motor neurons. Collectively, these findings support further investigation into potential molecular links between SARS-CoV-2 exposure and the trajectory of neurodegenerative disease.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.10.06.756756v1?rss=1">
<title>
<![CDATA[
Bilayer-bound structure of SARS-CoV-2 Envelope protein in complex with a host PDZ domain 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.10.06.756756v1?rss=1"
</link>
<dc:creator>Varkey, A. C.</dc:creator>
<dc:creator>Nimerovsky, E.</dc:creator>
<dc:creator>Xue, K.</dc:creator>
<dc:creator>Schwiegk, C.</dc:creator>
<dc:creator>Giller, K.</dc:creator>
<dc:creator>Becker, S.</dc:creator>
<dc:creator>Andreas, L. B.</dc:creator>
<dc:date>2026-10-06</dc:date>
<dc:identifier>doi:10.64898/2026.10.06.756756</dc:identifier>
<dc:title><![CDATA[Bilayer-bound structure of SARS-CoV-2 Envelope protein in complex with a host PDZ domain]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-10-06</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Small multifunctional viral membrane proteins called viroporins are attractive drug targets but are difficult to structurally characterize in a lipid-bilayer environment. We have successfully reconstituted the full-length Envelope (E) protein from SARS-CoV-2 in a lipid-bilayer, co-assembled with a native host factor that binds to E, the PDZ domain 2 of ZO1. We have leveraged the enhancement afforded by dynamic nuclear polarization NMR to determine that the ensemble-averaged oligomer state of E is a pentamer. Complexing the protein with a host PDZ domain did not impact the oligomer state, but resulted in structuring of the last four residues of E, and immobilization of the PDZ domain near the lipid surface. Combined with secondary structure information derived from the chemical shifts, these data were used to model an E protein pentamer together with the PDZ protein dimer. Inclusion of a relevant host factor, as well as a complex lipid bilayer that mimics conditions in the ER-Golgi intermediate compartment, approaches native conditions, and addresses the ongoing controversy regarding the functional oligomer state in an infected cell.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.28.26364140v1?rss=1">
<title>
<![CDATA[
Fewer Boys Were Born After Brazil's Gamma COVID-19 Wave and Pele's Death: A National Time-Series Analysis 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.28.26364140v1?rss=1"
</link>
<dc:creator>Leite, D. F.</dc:creator>
<dc:creator>Masukume, R.</dc:creator>
<dc:creator>Chimberengwa, P. T.</dc:creator>
<dc:creator>Grech, V.</dc:creator>
<dc:creator>Mapanga, W.</dc:creator>
<dc:creator>Masukume, G.</dc:creator>
<dc:creator>Liczbinska, G.</dc:creator>
<dc:date>2026-10-05</dc:date>
<dc:identifier>doi:10.64898/2026.09.28.26364140</dc:identifier>
<dc:title><![CDATA[Fewer Boys Were Born After Brazil's Gamma COVID-19 Wave and Pele's Death: A National Time-Series Analysis]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-10-05</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
The sex ratio at birth (SRB), or secondary sex ratio, is stable, with more boys born alive, but shifts after major events. Acute stress may reduce SRB through disproportionate male fetal loss, while sexual intercourse patterns around conception are associated with offspring sex. We examined whether Brazils April 2021 Gamma-wave mortality peak was followed by an SRB decline within the previously reported stress-sensitive 3-5-month window. We analysed >81 million live births (1997-2024) from Brazils Live Birth Information System (SINASC) using pre-pandemic autoregressive forecasts with 95% prediction intervals (PIs). In July 2021, SRB was 50.951% versus 51.185% expected, below the 95% PI (50.968-51.402%), indicating fewer boys. All five macroregions were below expectation, largest in the North, including Amazonas, where Gamma was first identified. Monte Carlo simulation showed that, under usual SRB patterns, a decline with this timing and consistency across Brazil would occur about once in 200 simulations (probability 0.00467), making July 2021 unusual. In February 2023, SRB was 51.441% versus 51.220% expected, above the 95% PI (51.003-51.438%), indicating more boys, nine months after Brazil ended its COVID-19 emergency, suggesting increased sexual intercourse after pandemic relaxation. In April 2023, SRB was 50.956% versus 51.221% expected, below the 95% PI (51.004-51.439%), indicating fewer boys, four months after Peles death. A comparable UK decline followed Princess Dianas death 4-5 months later. Gamma was prespecified; later observations are hypothesis-generating. These findings highlight SRBs population-level utility and warrant investigation of stress-related and behavioural pathways; ecological design precludes causality.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.01.26364553v1?rss=1">
<title>
<![CDATA[
An interpretable Day-1 machine-learning model for COVID-19 mortality and severity prognosis: development in a Pakistani hospital cohort and external evaluation in Chinese and Italian populations 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.01.26364553v1?rss=1"
</link>
<dc:creator>Jaffer, T.</dc:creator>
<dc:creator>Aslam, S.</dc:creator>
<dc:creator>Javaid, N.</dc:creator>
<dc:creator>Khaliq, A.</dc:creator>
<dc:creator>Tariq, E.</dc:creator>
<dc:creator>Mustafa, T.</dc:creator>
<dc:creator>Zaffar, M. A.</dc:creator>
<dc:creator>Mirza, S.</dc:creator>
<dc:date>2026-10-05</dc:date>
<dc:identifier>doi:10.64898/2026.10.01.26364553</dc:identifier>
<dc:title><![CDATA[An interpretable Day-1 machine-learning model for COVID-19 mortality and severity prognosis: development in a Pakistani hospital cohort and external evaluation in Chinese and Italian populations]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-10-05</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Early risk stratification of COVID-19 patients at admission informs triage and resource allocation, particularly in low- and middle-income settings where intensive-care capacity is constrained. Most published models are not interpretable, rarely externally validated, and developed almost exclusively in high-income cohorts. We developed an interpretable random-forest classifier for three-class COVID-19 severity (Mild: not ventilated, survived; Severe: ventilated, survived; Fatal: died) using only data available within 24 hours of admission in 321 hospitalised PCR-confirmed COVID-19 patients in Pakistan. From 2,278 raw variables we retained 20 predictors by clinical screening and permutation-importance selection, with leakage-controlled multiple imputation by chained equations and SHapley Additive exPlanations (SHAP) for interpretation. A 15-feature variant was evaluated in two independent public cohorts: the Chinese iCTCF cohort (n = 894) and an Italian complete-blood-count cohort (n = 1,218). The development model achieved a macro F1 of 0.55, identifying the Fatal class most reliably (F1 0.67, recall 0.73) and Mild cases least well. SHAP identified a parsimonious set of admission-time predictors (oxygen saturation, lactate dehydrogenase, urea, C-reactive protein, age and radiographic pneumonia), including a raised urea-to-creatinine ratio in fatal cases most consistent with dehydration (median urea 80 vs 50 mg/dL, fatal vs mild; p < 0.001). Externally, the model retained useful discrimination in the Chinese cohort (mortality AUC 0.82 in 719 patients with recorded outcomes; severe-or-worse AUC 0.75; macro F1 0.50) but only modest discrimination in the Italian cohort (AUC 0.62, 95% CI 0.56-0.68), which we treat as a feature-availability stress test rather than a second validation. Cross-cohort SHAP rankings correlated strongly in China (Spearman {rho} = 0.91) and moderately in Italy ({rho} = 0.76), where most laboratory predictors were imputed and carried no information beyond the complete blood count; discrimination tracked how many predictors were actually measured. The admission-time signature converges with established markers of hypoperfusion and inflammation.

Author summaryWhen patients arrive at hospital with COVID-19, risk must be assessed immediately to direct limited resources to those in need, particularly where intensive-care capacity is scarce, as in Pakistan. Most existing computer-based tools come from developed countries, act as "black boxes", and are rarely tested elsewhere. We built a model using first-day admission data from 321 patients at a hospital in Lahore, Pakistan. It identifies patients who later died best, and milder cases least well. The strongest markers were blood oxygen, lactate dehydrogenase, urea, C-reactive protein, age and chest-imaging evidence of pneumonia, together pointing to a coherent picture of pulmonary impairment, inflammation and circulatory stress. In fatal cases urea was markedly raised while creatinine rose only modestly, a pattern that most likely reflects dehydration. We then tested the same model on independent Chinese and Italian cohorts: it transferred well to China but lost accuracy in Italy, where only a basic blood count was available. The findings support an interpretable Day-1 prognostic tool whose useful range is set largely by which laboratory tests are available rather than by geography. Because these markers reflect general inflammation rather than anything unique to COVID-19, the approach may extend to other pneumonias.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.02.26364577v1?rss=1">
<title>
<![CDATA[
Vaccine attitudes and perceptions in a post-COVID Era: what lessons can be learned in Tunisia? 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.02.26364577v1?rss=1"
</link>
<dc:creator>Ben Mansour, N.</dc:creator>
<dc:creator>Benzina, B. F.</dc:creator>
<dc:creator>Fray, S.</dc:creator>
<dc:creator>Hariz, E.</dc:creator>
<dc:creator>Gzara, A.</dc:creator>
<dc:creator>Ben Romdhane, H.</dc:creator>
<dc:creator>Mueller, J.</dc:creator>
<dc:creator>Ben Miled, S.</dc:creator>
<dc:date>2026-10-05</dc:date>
<dc:identifier>doi:10.64898/2026.10.02.26364577</dc:identifier>
<dc:title><![CDATA[Vaccine attitudes and perceptions in a post-COVID Era: what lessons can be learned in Tunisia?]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-10-05</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
IntroductionAlthough the COVID-19 pandemic clearly showed the potential consequences of a world without vaccinations, vaccine hesitancy is likely to be more pronounced in the post-COVID-19 era. The introduction of human papillomavirus (HPV) vaccines in this context is likely to raise particular concerns. In Tunisia, decision-makers have prioritized the introduction of HPV vaccine into the immunization schedule. This study assessed individual barriers and facilitators to HPV vaccine acceptability in Tunisia, with the aim of guiding an effective communication strategy for HPV vaccination campaigns in Tunisia and neighboring countries in a post-pandemic context.

MethodsUsing a qualitative design, we conducted 14 focus groups (FG) with healthcare professionals (HCP) (N=32) and community representatives (CR) (N=89) in five regions of the country. The discussion followed a semi-structured guide designed on the basis of vaccine hesitancy determinants matrix. Transcripts were deductively analyzed according to the "social processes" and "thinking and feeling" of the behavioural and social drivers (BeSD) Framework. Inductive approach was used to analyze participants suggestions for promoting HPV vaccination.

ResultsThe FG analysis demonstrated that the historically strong trust in vaccination in Tunisia has weakened after the COVID-19 pandemic. Mistrust of health system and experts, the pandemic management and vaccine mandates measures had negative influence on the vaccine attitudes in a post pandemic Tunisian context. Persistent concerns about COVID-19 vaccines safety were frequently intertwined with widespread distrust of pharmaceutical companies and their profit motives, perceived as imposing inequitable access and lower-quality vaccines on countries in the Global South. These concerns fueled confusion about vaccines side effects. The weakening of immunity was recurring, as well as memory issues, impacts on fertility, and sudden deaths. Regarding information, our research revealed that although digital platforms were perceived as widely used, a significant part of the population interviewed considered public TV channel, as the most reliable source of health information.

ConclusionsEmphasizing how the pandemic has shaped individual and collective perceptions and attitudes toward vaccination, our findings underline the importance of leveraging lessons learned from the pandemic to develop a context tailored and coherent communication strategy for successful HPV vaccine implementation.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.10.05.756735v1?rss=1">
<title>
<![CDATA[
Bivalent CK2 Inhibition as a Potent Strategy Against SARS-CoV-2 and Other Coronaviruses 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.10.05.756735v1?rss=1"
</link>
<dc:creator>Salomon Lopez Molina, D.</dc:creator>
<dc:creator>Ahnou, N.</dc:creator>
<dc:creator>Brillet, R.</dc:creator>
<dc:creator>Delcros, J.-G.</dc:creator>
<dc:creator>Softic, L.</dc:creator>
<dc:creator>Jimenez Araya, B.</dc:creator>
<dc:creator>Duval, M.</dc:creator>
<dc:creator>Veruete, M.</dc:creator>
<dc:creator>Bancet, A.</dc:creator>
<dc:creator>Grenier, D.</dc:creator>
<dc:creator>Mularoni, A.</dc:creator>
<dc:creator>Pawlotsky, J.-M.</dc:creator>
<dc:creator>Krimm, I.</dc:creator>
<dc:creator>Ahmed-Belkacem, A.</dc:creator>
<dc:date>2026-10-05</dc:date>
<dc:identifier>doi:10.64898/2026.10.05.756735</dc:identifier>
<dc:title><![CDATA[Bivalent CK2 Inhibition as a Potent Strategy Against SARS-CoV-2 and Other Coronaviruses]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-10-05</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Protein kinase CK2 (CK2), a ubiquitously expressed serine/threonine kinase, has emerged as a key host factor exploited by several viruses, including Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we investigate the role of CK2 subunits in SARS-CoV-2 replication and evaluate the antiviral potential and broad-spectrum anti-coronavirus activity of two CK2 inhibitors: the previously described ATP-competitive inhibitor CX-4945 and a newly developed, highly selective bivalent inhibitor, AB668. The siRNA-mediated knockdown of CK2 subunits significantly reduced SARS-CoV-2 replication, highlighting its essential role in the viral lifecycle. Co-immunoprecipitation assays revealed that the SARS-CoV-2 nucleoprotein interacts with CK2. Furthermore, bio-layer interferometry assays demonstrated that the nucleoprotein specifically binds to the tetrameric CK2 holoenzyme (CK22{beta}2) but not to individual CK2 or CK2{beta} subunits. Pharmacological inhibition of CK2 with AB668 exhibited potent antiviral activity, significantly reducing viral replication by targeting a pre-replicative or RNA-replicative step of the viral life cycle. Importantly, AB668 displayed broad-spectrum antiviral activity, effectively inhibiting both HCoV-OC43 ({beta}-CoV) and HCoV-229E (-CoV). In summary, our findings establish CK2 as a critical host factor for SARS-CoV-2 replication and identify AB668 as a promising candidate for broad-spectrum antiviral therapy. With its high selectivity, minimized off-target effects, and efficacy against multiple coronaviruses, AB668 represents a valuable chemobiological and therapeutic tool.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.10.02.756193v1?rss=1">
<title>
<![CDATA[
C-terminal domain of SARS CoV 2 nucleocapsid protein binds transcriptional regulatory sequence RNA with high affinity and forms higher-order assemblies 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.10.02.756193v1?rss=1"
</link>
<dc:creator>Gupta, P.</dc:creator>
<dc:creator>Singh, M.</dc:creator>
<dc:date>2026-10-05</dc:date>
<dc:identifier>doi:10.64898/2026.10.02.756193</dc:identifier>
<dc:title><![CDATA[C-terminal domain of SARS CoV 2 nucleocapsid protein binds transcriptional regulatory sequence RNA with high affinity and forms higher-order assemblies]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-10-05</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
The SARS-CoV-2 nucleocapsid (N) protein is a 419-amino-acid modular protein essential for viral RNA replication, genome packaging, and host-cell modulation. It contains two structured domains, the N-terminal RNA-binding domain (NTD) and C-terminal dimerization domain (CTD), separated and flanked by three intrinsically disordered regions. Although the CTD mediates N-protein dimerization and contributes to RNA binding, the molecular basis of its interaction with RNA remains poorly understood. Here, we characterized CTD binding to transcriptional regulatory sequence (TRS) RNAs from the SARS-CoV-2 genome using NMR spectroscopy, isothermal titration calorimetry, size-exclusion chromatography, and in vitro phase-separation assays. The CTD bound structured stem-loop TRS RNA with higher affinity than the canonical RNA-binding NTD. NMR chemical-shift perturbation experiments indicated formation of higher-order molecular assemblies upon titration of the CTD with longer, structured stem-loop TRS RNA, consistent with size-exclusion chromatography results. The CTD also underwent RNA-induced phase separation in vitro, with stem-loop TRS RNA promoting markedly more robust condensation than single-stranded RNA sequences. Together, these findings establish the CTD as a high-affinity, structure-selective RNA-binding domain with a preference for stem-loop TRS RNA. The results further show that CTD-TRS interactions promote higher-order assembly and phase separation, providing mechanistic insight into N-protein-mediated viral genome packaging and nucleocapsid assembly.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.10.05.756635v1?rss=1">
<title>
<![CDATA[
HNRNPM promotes protein synthesis via an interaction with stem-loop 5 in the SARS-CoV-2 5'-UTR 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.10.05.756635v1?rss=1"
</link>
<dc:creator>Golagha, J.</dc:creator>
<dc:creator>Wieja, M.</dc:creator>
<dc:creator>Biedenkopf, N.</dc:creator>
<dc:creator>Weigand, J. E.</dc:creator>
<dc:date>2026-10-05</dc:date>
<dc:identifier>doi:10.64898/2026.10.05.756635</dc:identifier>
<dc:title><![CDATA[HNRNPM promotes protein synthesis via an interaction with stem-loop 5 in the SARS-CoV-2 5'-UTR]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-10-05</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
The 5'-untranslated region (5'-UTR) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is highly structured and comprises five conserved stem-loops that serve as cis-acting regulatory elements. During infection, host proteins are recruited to these elements and regulate multiple steps during the viral life cycle. Stem-loop 5 (SL5) is highly conserved among different alpha- and betacoronaviruses and includes the start codon of non-structural protein 1 (nsp1). However, the function of SL5 in viral replication and its interacting proteins remain to be determined. Here, we identified heterogeneous nuclear ribonucleoprotein M (HNRNPM) as a host protein functionally interacting with SL5. HNRNPM translocates into the cytoplasm during SARS-CoV-2 infection and promotes protein synthesis from the viral 5'-UTR. Mutations in the lower stem of SL5 impair HNRNPM binding and reduce protein synthesis. Notably, the interaction between HNRNPM and SL5 is conserved among different alpha- and betacoronaviruses. Our findings indicate that HNRNPM is an important host factor that regulates viral translation to promote SARS-CoV-2 replication.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.09.28.755090v1?rss=1">
<title>
<![CDATA[
Male and female mice achieve equivalent protection against heterologous SARS-CoV-2 infection through divergent immune mechanisms 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.09.28.755090v1?rss=1"
</link>
<dc:creator>Kenney, D.</dc:creator>
<dc:creator>Matsuo, M.</dc:creator>
<dc:creator>Pantelias, A.</dc:creator>
<dc:creator>Leger, J.</dc:creator>
<dc:creator>Kaplan, A.</dc:creator>
<dc:creator>Cerbo, F.</dc:creator>
<dc:creator>Chen, D.-Y.</dc:creator>
<dc:creator>Adams, S.</dc:creator>
<dc:creator>Unali, G.</dc:creator>
<dc:creator>Wallace, D.</dc:creator>
<dc:creator>Saeed, M.</dc:creator>
<dc:creator>Belkina, A.</dc:creator>
<dc:creator>Harly, C.</dc:creator>
<dc:creator>Douam, F.</dc:creator>
<dc:date>2026-10-03</dc:date>
<dc:identifier>doi:10.64898/2026.09.28.755090</dc:identifier>
<dc:title><![CDATA[Male and female mice achieve equivalent protection against heterologous SARS-CoV-2 infection through divergent immune mechanisms]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-10-03</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Biological sex is a major determinant of antiviral immunity, yet how it shapes lung-resident antiviral immunity remains poorly understood. We report that prior mild SARS-CoV-2 BA.1 infection protects mice from lethal heterologous Delta challenge through distinct sex-biased immune mechanisms. Although heterologous protection is clinically equivalent between sexes, T- and B-cell depletions before BA.1 exposure abrogate protection only in males. Depletion with anti-CD4, but not anti-CD8, abolishes protection in both sexes, but co-depletion with anti-CD4/anti-CD8 partially restores protection in females only. Further, females exhibit enhanced IFN-gamma-associated myeloid inflammation upon secondary Delta infection. Using lymphoid-deficient mice that display female-biased resistance to Delta infection, IFN-gamma treatment provides partial protection to naive males against Delta. Female resistance is lost after previous BA.1 exposure, highlighting the importance of lymphoid-mediated inflammatory regulation. Together, equivalent antiviral protection against heterologous respiratory viral infection is governed by sexually dimorphic mechanisms, with significant implications for designing mucosal vaccines and immunotherapies.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.25.26364013v1?rss=1">
<title>
<![CDATA[
The Effects of a Digital Exercise Therapy Application for Patients with Shoulder and Knee Pain During the COVID-19 Pandemic 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.25.26364013v1?rss=1"
</link>
<dc:creator>McLaughlin, K. H.</dc:creator>
<dc:creator>Gruner, M.</dc:creator>
<dc:creator>Ahmadian, N.</dc:creator>
<dc:creator>Patch, T.</dc:creator>
<dc:creator>Zakria, B.</dc:creator>
<dc:creator>Skolasky, R. L.</dc:creator>
<dc:date>2026-10-01</dc:date>
<dc:identifier>doi:10.64898/2026.09.25.26364013</dc:identifier>
<dc:title><![CDATA[The Effects of a Digital Exercise Therapy Application for Patients with Shoulder and Knee Pain During the COVID-19 Pandemic]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-10-01</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
ObjectiveTo examine changes in function and pain interference among patients utilizing a digital exercise therapy application (DETA) for knee and shoulder pain.

MethodsWe conducted a retrospective analysis of data from patients utilizing a DETA for non-operative knee and shoulder pain. Primary outcomes for the study were 8-week changes in physical function, measured using the PROMIS-Physical Function (knee pain) and PROMIS-Upper Extremity Function (shoulder pain); and pain interference, measured using the PROMIS-Pain Interference. Data on patient characteristics was used to examine outcomes among specific patient subgroups.

ResultsWe observed a 3.5 point (SD: 7.8) increase in function and a 3.9 point (SD: 7.5) decrease in pain interference overall (p<0.001), with changes in function and pain interference surpassing the minimal clinically important difference for patients with knee and shoulder pain. Patients with knee pain experienced greater improvements in function than those with shoulder pain (p=0.02), as did patients who report moderate-high levels of exertion during exercise compared to those reporting low levels of exertion (p=0.05). We saw greater reductions in pain interference among those with higher education (p=0.03), those with more acute symptoms (p=0.01) and those reporting moderate-high levels of exercise exertion (p=0.02).

ConclusionWe observed a clinically meaningful improvement in pain interference and function among patients utilizing a DETA for knee and shoulder pain. Patients with knee pain, higher levels of education, more acute symptoms, and those who reported higher levels of exertion with exercise experienced the greatest changes in function and pain.

Impact StatementThis study indicates that self-guided interventions, such as those delivered through a DETA, may be beneficial for patients with knee and shoulder pain. These results may also inform the development of patient profiles that can be used to identify patients most appropriate to receive care through a mobile application.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.24.26363490v1?rss=1">
<title>
<![CDATA[
Functional connectivity correlates of post-acute covid 19 cognitive and neuropsychiatric complications 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.24.26363490v1?rss=1"
</link>
<dc:creator>Auwal, A. M.</dc:creator>
<dc:creator>Keller, S.</dc:creator>
<dc:creator>Bullmore, E.</dc:creator>
<dc:creator>Ellul, M.</dc:creator>
<dc:creator>Michael, B. D.</dc:creator>
<dc:date>2026-10-01</dc:date>
<dc:identifier>doi:10.64898/2026.09.24.26363490</dc:identifier>
<dc:title><![CDATA[Functional connectivity correlates of post-acute covid 19 cognitive and neuropsychiatric complications]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-10-01</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
BackgroundThe neuropsychiatric sequelae (cognitive deficits, anxiety and depression) post-COVID-19 exist as part of the spectrum of the multisystemic long COVID. People with these symptoms have been shown to have worse functional outcomes. Hence, this significantly impacts the economy, primarily due to productivity losses. Yet, the precise underlying pathogenesis remains unknown, as do any diagnostic or prognostic biomarkers.

AimThis study aims to identify functionally impacted brain regions in those with post-COVID-19 neurological sequelae and to evaluate how alterations in brain function relate to acute serum inflammatory mediators and brain injury biomarkers.

MethodsThe study will utilise data from the COVID-19 Clinical Neuroscience Study (CNS), a large UK multicentre study conducted during the pandemic. This sub-study will be a secondary analysis of the COVID-19 CNS, a prospective observational study that compared COVID-19-positive participants with negative controls. Participants had an MRI, blood tested for acute serum inflammatory mediators and brain injury biomarkers, and neuropsychiatric assessment (cognitron test, PHQ-9 and GAD-7) post-acutely and at follow-up. The DPABI (Data Processing & Analysis for Brain Imaging) toolbox will be used for pre-processing and analysis of the neuroimaging data (resting state functional MRI) to obtain regional homogeneity (ReHo). The association between ReHO and neuropsychiatric symptoms, acute inflammatory mediators and brain injury biomarkers will be explored. Regression models would be used to determine the risk and protective factors for developing these symptoms.

ConclusionIt is anticipated that the study will provide new insights into the functional basis of post-acute COVID-19 neuropsychiatric manifestations and identify new diagnostic biomarkers.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.09.30.755793v1?rss=1">
<title>
<![CDATA[
Predicting viral host range for reverse zoonosis surveillance 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.09.30.755793v1?rss=1"
</link>
<dc:creator>Irvine, E. B.</dc:creator>
<dc:creator>Bikias, T.</dc:creator>
<dc:creator>Schifferli, T.</dc:creator>
<dc:creator>Plath, L.</dc:creator>
<dc:creator>Han, J.</dc:creator>
<dc:creator>Chen, N.</dc:creator>
<dc:creator>Sahin, B.</dc:creator>
<dc:creator>Frei, L.</dc:creator>
<dc:creator>Taft, J. M.</dc:creator>
<dc:creator>Reddy, S. T.</dc:creator>
<dc:date>2026-10-01</dc:date>
<dc:identifier>doi:10.64898/2026.09.30.755793</dc:identifier>
<dc:title><![CDATA[Predicting viral host range for reverse zoonosis surveillance]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-10-01</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Zoonotic transmission of viruses has triggered major outbreaks throughout history. However, human-to-animal transmission, or reverse zoonotic transmission, also represents an underappreciated public health threat. Reverse zoonoses can establish novel animal reservoirs that fuel viral evolution and enable eventual spillback into humans, underscoring the importance of defining viral host range. Current approaches for host range prediction are limited. Experimental methods are retrospective and rely on brute-force testing in a small number of models, whereas computational approaches often lack experimental grounding. Here, we present a platform that integrates high-throughput experimental screening with deep learning to predict viral host range from sequence. We screened a yeast-displayed SARS-CoV-2 receptor-binding domain library against 15 ACE2 orthologs from diverse species, and deep sequenced the ACE2-binding and non-binding populations to generate an atlas of 8.8 million unique RBD:ACE2 interaction measurements. These data were used to train a transformer-based deep learning model that predicts RBD:ACE2 compatibility across animal species from sequence alone, and generalizes in a zero-shot manner to ACE2 orthologs not observed during training. Critically, the model pairs each prediction with a distance-based uncertainty estimate, allowing hundreds of candidate species to be triaged by both predicted host compatibility and confidence. This framework enables the rapid prioritization of animal species for SARS-CoV-2 surveillance and provides a general strategy for anticipating viral host range.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.09.30.755498v1?rss=1">
<title>
<![CDATA[
Mechanism of spike opening in a mammalian gammacoronavirus 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.09.30.755498v1?rss=1"
</link>
<dc:creator>Clarke, J. D.</dc:creator>
<dc:creator>Grabias, M.</dc:creator>
<dc:creator>Di Maio, A.</dc:creator>
<dc:creator>Phlora, H.</dc:creator>
<dc:creator>Vasiljevic, S.</dc:creator>
<dc:creator>Burnap, S. A.</dc:creator>
<dc:creator>Tripathy, R.</dc:creator>
<dc:creator>Chai, W.</dc:creator>
<dc:creator>Struwe, W. B.</dc:creator>
<dc:creator>Benton, D. J.</dc:creator>
<dc:creator>Liu, Y.</dc:creator>
<dc:creator>Gamblin, S. J.</dc:creator>
<dc:creator>Wrobel, A. G.</dc:creator>
<dc:date>2026-10-01</dc:date>
<dc:identifier>doi:10.64898/2026.09.30.755498</dc:identifier>
<dc:title><![CDATA[Mechanism of spike opening in a mammalian gammacoronavirus]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-10-01</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Coronavirus spike proteins mediate receptor binding and fusion and are key determinants of viral host range. To bind protein receptors, some CoV spikes undergo conformational changes termed opening, which expose the receptor-binding surface. Yet, the prerequisites and mechanism of spike opening remain poorly understood, especially outside of beta-CoVs, and many CoV spikes have been observed only in the closed conformation. The receptor specificities of gamma-CoVs, for which birds are natural hosts, await in-depth characterisation and their spikes have not been observed to open. Here, we report structures of the spike from an unusual mammalian gamma-CoV isolated from a beluga whale (BwCoV), in closed and open conformations, the latter with two S1B domains erect. BwCoV spike opening is associated with changes throughout S1 that resemble those observed in beta-CoV spikes and similarly propagate into destabilisation of the fusogenic S2 core. Furthermore, the BwCoV-S structure contains an additional density likely corresponding to a fatty acid, consistent with lipid binding stabilising the closed conformation through a pocket distinct from that identified for beta-CoVs. These structural insights reveal conserved principles regulating spike dynamics across coronavirus genera and support lipid binding as a potential modulatory mechanism of spike opening.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.09.29.755432v1?rss=1">
<title>
<![CDATA[
Sex-specific differences in ADAR editing patterns in response to SARS-CoV-2 infections 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.09.29.755432v1?rss=1"
</link>
<dc:creator>Nair, A. M.</dc:creator>
<dc:creator>Piontkivska, H.</dc:creator>
<dc:date>2026-09-30</dc:date>
<dc:identifier>doi:10.64898/2026.09.29.755432</dc:identifier>
<dc:title><![CDATA[Sex-specific differences in ADAR editing patterns in response to SARS-CoV-2 infections]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-30</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Sex-specific differences in COVID-19 outcomes are well documented, with male sex being a key risk factor for severe disease. Multiple factors, including differences in the expression of Interferons (IFNs) and Interferon stimulated genes (ISGs) between the sexes have been identified as contributing to these differences. Adenosine-to-inosine (A-to-I) RNA editing, mediated by ADAR enzymes, is an important component of antiviral innate immune signaling. While previous studies, including us, have identified altered expression and activity of ADARs in response to SARS-CoV-2 infection, it remains unknown whether sex-specific differences in expression and activity of ADARs exist during infection with SARS-CoV-2. We address this question by analyzing a publicly available whole blood RNA sequencing dataset from males and females, matched for age and comorbidity status across pre-, mid-, and post-infection stages of SARS-CoV-2 infection. Our results show distinct patterns of ADAR expression between the sexes across different stages of infection, with significant differences in the expression of ADAR and ADAR2 in pre- and mid- infection that were not observed post-viral clearance. Interestingly, expression of predominantly neural isoform ADAR3 was significantly different and higher in females, mid-infection. Furthermore, these differences in ADAR expression were likely amplified downstream with significant differences in the global editing levels. Correlation analysis revealed that the relationship between ADAR expression and global editing activity differed by sex and stage of infection, indicating that ADAR editing is dynamically regulated and is influenced by factors other than ADAR transcript abundance. Noteworthy, sex-specific differences in ADAR editing were observed within genes that escape X-chromosome inactivation (XCI), a gene set enriched in immune related functions and known to be involved in sex-specific outcomes to viral infections. ADAR editing within these genes differed at baseline and changed across stages of infection in a manner independent of gene expression. Altogether, our findings establish ADAR editing as an additional layer of immune regulation that may be contributing, in part, to the differential clinical manifestations of COVID-19 observed between males and females.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.25.26364053v1?rss=1">
<title>
<![CDATA[
Spatiotemporal clustering of tuberculosis notifications in Nepal during the COVID-19 pandemic and subsequent recovery: A national space-time scan analysis, 2019-2024 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.25.26364053v1?rss=1"
</link>
<dc:creator>Bisht, N.</dc:creator>
<dc:creator>Bhatt, R.</dc:creator>
<dc:creator>Rijal, P.</dc:creator>
<dc:creator>Gupta, R. K.</dc:creator>
<dc:creator>Bisht, R.</dc:creator>
<dc:creator>Yadav, H.</dc:creator>
<dc:creator>Singh, S.</dc:creator>
<dc:creator>Kalwar, D. K.</dc:creator>
<dc:creator>Adhikari, C.</dc:creator>
<dc:date>2026-09-29</dc:date>
<dc:identifier>doi:10.64898/2026.09.25.26364053</dc:identifier>
<dc:title><![CDATA[Spatiotemporal clustering of tuberculosis notifications in Nepal during the COVID-19 pandemic and subsequent recovery: A national space-time scan analysis, 2019-2024]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-29</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
The COVID-19 pandemic substantially disrupted tuberculosis (TB) prevention, diagnosis, and treatment services worldwide. Despite increased TB notifications in Nepal during the post-pandemic recovery period, the geographic distribution and temporal clustering of notifications remain poorly understood. This study examined the spatial and temporal patterns of TB notifications across Nepal during the COVID-19 recovery period. We conducted a nationwide retrospective ecological analysis of district-level TB notifications across all 77 districts of Nepal from FY 2019/20 to FY 2023/24. Space-time, purely spatial, and purely temporal scan statistics were performed using a discrete Poisson model in SaTScan. Statistical significance was assessed using Monte Carlo simulation with 999 replications. A total of 172,155 TB cases were notified during the study period. TB notification rates increased by 51%, from 92 to 139 per 100,000 population between FY 2019/20 and FY 2023/24. Four statistically significant high-notification space-time clusters were identified (all p < 0.001). The primary cluster included Kathmandu, Lalitpur, Bhaktapur, Makwanpur, Bara, and Parsa districts during FY 2021/22-FY 2023/24 (RR = 1.60). Additional clusters were identified in western Nepal, the eastern Terai, and Rupandehi district. Purely temporal analysis showed a nationwide increase in notifications during FY 2022/23-FY 2023/24 (RR = 1.26, p = 0.001). TB notifications increased substantially during Nepals post-pandemic recovery period, with marked geographic and temporal heterogeneity. Integrating spatial and temporal surveillance may help identify areas requiring geographically targeted TB control strategies.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.28.26364044v1?rss=1">
<title>
<![CDATA[
Antiviral Antibody Fc Dysfunction Is Linked to Increased IgG1 Fucosylation in Long COVID 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.28.26364044v1?rss=1"
</link>
<dc:creator>Ukey, R.</dc:creator>
<dc:creator>Michailidis, I. E.</dc:creator>
<dc:creator>Greenberg, P.</dc:creator>
<dc:creator>Andrews, T.</dc:creator>
<dc:creator>Jung, S. Y.</dc:creator>
<dc:creator>Zheng, H.</dc:creator>
<dc:creator>Honnen, W.</dc:creator>
<dc:creator>Pinter, A.</dc:creator>
<dc:creator>Kleinman, L. C.</dc:creator>
<dc:creator>Bruiners, N.</dc:creator>
<dc:creator>gennaro, m. l.</dc:creator>
<dc:date>2026-09-29</dc:date>
<dc:identifier>doi:10.64898/2026.09.28.26364044</dc:identifier>
<dc:title><![CDATA[Antiviral Antibody Fc Dysfunction Is Linked to Increased IgG1 Fucosylation in Long COVID]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-29</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
BackgroundPersistent SARS-CoV-2 antigen is a leading hypothesis for post-acute sequelae of SARS-CoV-2 infection (PASC), commonly known as Long COVID. Impaired Fc-mediated antiviral antibody function could contribute to inefficient clearance of infected cells and viral antigen despite preserved antibody levels. Therefore, we tested whether PASC is associated with altered Fc{gamma} receptor-mediated antibody function and differences in IgG1 Fc fucosylation, a major regulator of Fc effector function.

MethodsSerum samples from RECOVER-Adult participants with prior SARS-CoV-2 infection (99 PASC, 139 non-PASC) were analyzed for anti-SARS-CoV-2 spike receptor-binding domain (RBD) IgG and subclasses, Fc{gamma}RIIIa- and Fc{gamma}RIIa-mediated reporter activity as surrogate measures of antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), anti-RBD IgG1 Fc glycosylation, and circulating fucose-modifying enzymes.

ResultsDespite higher anti-RBD IgG and IgG1 abundance, PASC sera showed lower ADCC- and ADCP-associated Fc{gamma}R reporter activity, including after normalization for antibody abundance. Anti-RBD IgG1 showed greater fucosylation in PASC samples (30 PASC, 34 non-PASC). Serum FUCA2 was lower in PASC samples (24 PASC, 34 non-PASC), whereas FUCA1 and soluble CD16a levels did not differ between the two groups.

ConclusionPASC is associated with impaired antiviral IgG Fc function, increased IgG1 Fc fucosylation, and reduced circulating FUCA2, identifying a glycoimmune axis that may contribute to impaired Fc-dependent antigen clearance and represents a potentially targetable pathway in Long COVID.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.26.26364084v1?rss=1">
<title>
<![CDATA[
Incorporating county-level NO2 data into a metapopulation model: a case study of the first COVID-19 wave in Oklahoma 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.26.26364084v1?rss=1"
</link>
<dc:creator>Das, H. K.</dc:creator>
<dc:creator>Stephens, P.</dc:creator>
<dc:creator>Martins Stolerman, L.</dc:creator>
<dc:date>2026-09-28</dc:date>
<dc:identifier>doi:10.64898/2026.09.26.26364084</dc:identifier>
<dc:title><![CDATA[Incorporating county-level NO2 data into a metapopulation model: a case study of the first COVID-19 wave in Oklahoma]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-28</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Nitrogen dioxide (NO2) is a widespread air pollutant associated with the risk and prevalence of various respiratory infectious diseases. Epidemiological studies have reported associations between NO2 exposure and COVID-19 incidence, and biological evidence indicates that NO2 exposure increases vulnerability to infection. Motivated by these findings and by the scarcity of mechanistic epidemic models that incorporate air pollutant data, here we introduce an NO2- and mobility-informed metapopulation model and study the first COVID-19 wave in Oklahoma. County-level NO2 concentrations enter the infection rates through a first-order parameterization, alongside high-resolution mobility patterns capturing heterogeneous inter-county connectivity. Using numerical simulations, we demonstrate that higher environmental sensitivity produces earlier and more synchronized outbreaks across counties, while lower sensitivity yields delayed, asynchronous trajectories. When fitted to county-level COVID-19 incidence data, our model outperformed the classic SIR model (fitted independently in each county) in over 75% of counties in Oklahoma across all standard error metrics. The improvements were even more pronounced in forecasting tasks across epidemic stages, with county-level win rates against the SIR model of 59.74% (surge), 87.01% (peak), 80.52% (post-peak), and 88.31% (decline) by nRMSE. To isolate the contribution of NO2, we compared our model against a mobility-only model with NO2 removed and homogeneous infection rates across counties. The NO2 term improved county-level forecasts during the surge (94.81% of counties by nRMSE), post-peak (88.31%), and peak (62.34%) stages, though not during the early and decline stages, suggesting that NO2 information can generate better forecasts than mobility alone during periods of high incidence. Our results demonstrate that environmental exposure can enter the transmission structure of a mechanistic epidemic model directly and that doing so yields measurable forecasting gains.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.09.21.753329v1?rss=1">
<title>
<![CDATA[
Mechanism of molecular recognition revealed through dynamic drug binding pathways to SARS-CoV-2 main protease 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.09.21.753329v1?rss=1"
</link>
<dc:creator>Santos Perez, D.</dc:creator>
<dc:creator>Arhin, G.</dc:creator>
<dc:creator>Fu, Y.</dc:creator>
<dc:creator>McCarty, S.</dc:creator>
<dc:creator>Lin, S.-H.</dc:creator>
<dc:creator>Sztain, T.</dc:creator>
<dc:date>2026-09-28</dc:date>
<dc:identifier>doi:10.64898/2026.09.21.753329</dc:identifier>
<dc:title><![CDATA[Mechanism of molecular recognition revealed through dynamic drug binding pathways to SARS-CoV-2 main protease]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-28</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Characterization of drug-binding pathways remains experimentally limited by transient intermediates and computationally challenging due to long timescales intractable for conventional molecular dynamics. To address these challenges, we combined solution NMR titrations with weighted ensemble (WE) enhanced sampling simulations to resolve atomistic pathways of nirmatrelvir binding to the SARS-CoV-2 main protease. NMR titration revealed residue-dependent heterogeneity spanning fast, intermediate, and slow exchange regimes. WE simulations complement the NMR by providing insights into unassigned residues and adding time-resolved and three-dimensional structural context. We map key interactions along two distinct binding pathways, provide dynamic explanations for residues involved in resistance, and capture unique backbone conformations compared to those sampled in unbound or bound states. Our comprehensive binding model is consistent with a combined conformational selection and induced fit mechanism in which early transient contacts are made with residues E47 and L50 and allosteric motions are centered around residue V204 of the distal domain. This synergistic application of WE and titration NMR enables a more comprehensive characterization of drug binding than either method alone, providing an integrated framework that may have broader applicability to defining structure-kinetic relationships and guiding design of next-generation inhibitors.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.09.23.753140v1?rss=1">
<title>
<![CDATA[
Proteolytic control of the SARS-CoV-2 furin cleavage site defines the phenotypic evolution from the pandemic to endemic state 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.09.23.753140v1?rss=1"
</link>
<dc:creator>Aggarwal, A.</dc:creator>
<dc:creator>Ognenovska, S.</dc:creator>
<dc:creator>Ison, T.</dc:creator>
<dc:creator>Fichter, C.</dc:creator>
<dc:creator>Milogiannakis, V.</dc:creator>
<dc:creator>Afzal, M.</dc:creator>
<dc:creator>Ospina-Stella, A.</dc:creator>
<dc:creator>Asarnow, D.</dc:creator>
<dc:creator>Morgan, A. L.</dc:creator>
<dc:creator>Waters, S.</dc:creator>
<dc:creator>Boecking, T.</dc:creator>
<dc:creator>Ng, B.</dc:creator>
<dc:creator>Esneau, C.</dc:creator>
<dc:creator>Bartlett, N.</dc:creator>
<dc:creator>Naik, A.</dc:creator>
<dc:creator>poehlmann, S.</dc:creator>
<dc:creator>Hoffmann, M.</dc:creator>
<dc:creator>Broer, S.</dc:creator>
<dc:creator>Broer, A.</dc:creator>
<dc:creator>Johansen, M. D.</dc:creator>
<dc:creator>Brink, R.</dc:creator>
<dc:creator>burrell, L. M.</dc:creator>
<dc:creator>patel, S. K.</dc:creator>
<dc:creator>Ellis, S.</dc:creator>
<dc:creator>wehrhahn, M.</dc:creator>
<dc:creator>Ginn, A.</dc:creator>
<dc:creator>Martinez, E.</dc:creator>
<dc:creator>Churchill, M. J.</dc:creator>
<dc:creator>Angelovich, T. A.</dc:creator>
<dc:creator>Rawlinson, W.</dc:creator>
<dc:creator>Yeang, M.</dc:creator>
<dc:creator>Walker, G.</dc:creator>
<dc:creator>Foster, C.</dc:creator>
<dc:creator>Kok, J.</dc:creator>
<dc:creator>Sintchenko, V.</dc:creator>
<dc:creator>Rocket, R.</dc:creator>
<dc:creator>Asquith, W.</dc:creator>
<dc:creator>Parry, R.</dc:creator>
<dc:creator>Sng, J. D.</dc:creator>
<dc:creator>Neely, G.</dc:creator>
<dc:creator>Moreno, C.</dc:creator>
<dc:creator>Spence, M.</dc:creator>
<dc:creator>Jackson, C.</dc:creator>
<dc:creator>Loo, L.</dc:creator>
<dc:creator>Park, Y.-J.</dc:creator>
<dc:creator>Gibson, C.</dc:creator>
<dc:creator>Merz, B.</dc:creator>
<dc:creator>Stewart, C.</dc:creator>
<dc:creator>Kelleher, A. D.</dc:creator>
<dc:creator>Brilot, F.</dc:creator>
<dc:creator>Khromykh, A. A.</dc:creator>
<dc:creator>Veesler, D.</dc:creator>
<dc:creator>Menachery, V. D.</dc:creator>
<dc:creator>Turville, S. G.</dc:creator>
<dc:date>2026-09-24</dc:date>
<dc:identifier>doi:10.64898/2026.09.23.753140</dc:identifier>
<dc:title><![CDATA[Proteolytic control of the SARS-CoV-2 furin cleavage site defines the phenotypic evolution from the pandemic to endemic state]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-24</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
The successive emergence of SARS-CoV-2 variants with altered tissue tropism has progressively decoupled transmissibility from lower respiratory tract pathogenicity. Omicron lineages transmit exceptionally well whilst limiting severe lung disease. Here, we demonstrate that this phenotype has evolved through two temporally distinct tissue-specific proteolytic controls at the Spike (S) furin cleavage site (FCS). At the virion level, cell-type-dependent furin-mediated FCS hyper-cleavage depletes S in lung but not nasal epithelial cells. At the infected cell membrane during cell-cell spread, TMPRSS2 mediates S FCS cleavage but is negatively regulated in the presence of ACE2. Tissue-specific solute carriers SLC6A19 and SLC6A20 sequester ACE2, thereby relieving inhibition of TMPRSS2 and enabling S FCS cleavage during cell-cell spread. Critically, whilst all SARS-CoV-2 lineages benefit from this latter pathway, Omicron variants have evolved exclusive dependence on it, a strategic consolidation that focuses S proteolytic activation to TMPRSS2 alone. The combined outcomes of S protein regulation across viral and cell membranes reveal how tissue-specific proteolytic optimisation drives Omicron's transmission fitness advantage in the upper respiratory tract but at the cost of heavy attenuation in the lower respiratory tract.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.09.22.753561v1?rss=1">
<title>
<![CDATA[
Predicting single mutation effects on binding affinity at protein-protein interfaces based on MMPBSA calculations 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.09.22.753561v1?rss=1"
</link>
<dc:creator>Noske, J.</dc:creator>
<dc:creator>Janzen, M.</dc:creator>
<dc:creator>Lepoivre, T.</dc:creator>
<dc:creator>Höcker, B.</dc:creator>
<dc:date>2026-09-24</dc:date>
<dc:identifier>doi:10.64898/2026.09.22.753561</dc:identifier>
<dc:title><![CDATA[Predicting single mutation effects on binding affinity at protein-protein interfaces based on MMPBSA calculations]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-24</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Accurate prediction of mutation-induced changes in protein-protein affinity remains a central challenge in computational biophysics and protein engineering. Here we present a physics-based scoring method for predicting the effects of single amino acid substitutions on protein-protein and protein-peptide binding affinity. The method is based on MMPBSA energy calculations and implemented in a user-friendly, publicly available workflow (https://github.com/Hoecker-Lab/mmpbsa_scoring). To derive the scoring function, MMPBSA energy terms were fitted using a large and diverse dataset of experimentally measured binding affinity changes upon point mutation. The terms were then evaluated on independent systems. Specifically, we assessed the ability to predict mutational effects at the interface of SARS-CoV-2 spike protein with its cellular receptor, as well as computationally predicted Armadillo-repeat protein-peptide complexes. The approach performs well across diverse targets and shows promising predictive performance on both experimentally determined and computationally predicted structures. It matches or exceeds the accuracy of established physics-based protein design software and state-of-the-art deep learning-based scoring functions when applied to data outside their training domain. The method provides a computationally efficient and interpretable framework for prioritizing interface mutations in protein engineering and binding affinity optimization.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.09.23.753684v1?rss=1">
<title>
<![CDATA[
Deciphering Mechanistic Signatures in Drug-Drug Interactions with Dual Topology Graphs 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.09.23.753684v1?rss=1"
</link>
<dc:creator>Ma, W.</dc:creator>
<dc:creator>Bi, X.</dc:creator>
<dc:creator>Jiang, H.</dc:creator>
<dc:creator>Lu, W.</dc:creator>
<dc:creator>Nie, J.</dc:creator>
<dc:creator>Lin, S.</dc:creator>
<dc:creator>Lin, J.</dc:creator>
<dc:creator>Wei, Z.</dc:creator>
<dc:creator>Zhang, H.</dc:creator>
<dc:creator>Zhang, S.</dc:creator>
<dc:date>2026-09-24</dc:date>
<dc:identifier>doi:10.64898/2026.09.23.753684</dc:identifier>
<dc:title><![CDATA[Deciphering Mechanistic Signatures in Drug-Drug Interactions with Dual Topology Graphs]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-24</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Drug-drug interactions (DDIs) represent a critical challenge in drug development and clinical practice, as they can lead to severe adverse effects, including toxicity and reduced therapeutic efficacy. Deep learning methods have shown promise in large-scale, rapid DDI prediction; however, current approaches suffer from significant limitations in providing mechanistic insights into these interactions. Here, we propose DualTopoDDI, a dual-topology-enhanced interpretable deep learning model for DDI prediction. We applied DualTopoDDI to predict 9.2 billion potential interactions among approved drugs, achieving 97.99% high-confidence predictions. The model demonstrates molecular-level interpretability, identifying key substructures responsible for drug actions in terms of both atom-centric and bond-centric views. DualTopoDDI also excels in elucidating particular DDI toxicity mechanisms, which is validated by its successful explanation of the controversial cardiac toxicity in two COVID-19 drug combination regimens at the time. Evaluations across 11 benchmark datasets demonstrates that DualTopoDDI not only achieves state-of-the-art performance but also showcases robust generalizability and good interpretability. Overall, DualTopoDDI offers a powerful, interpretable tool for understanding and predicting drug-drug interactions, providing critical insights for drug safety and design.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.09.23.753110v1?rss=1">
<title>
<![CDATA[
Detection and characterisation of alpha- and betacoronaviruses in rodents and bats from Germany, France, Belgium and Ireland 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.09.23.753110v1?rss=1"
</link>
<dc:creator>Sgarabotto, E.</dc:creator>
<dc:creator>Venkat, V.</dc:creator>
<dc:creator>Altan, E.</dc:creator>
<dc:creator>Gyzels, D.</dc:creator>
<dc:creator>Erdin, M.</dc:creator>
<dc:creator>Lehtinen, V.</dc:creator>
<dc:creator>Niamsap, T.</dc:creator>
<dc:creator>Greilich, S.</dc:creator>
<dc:creator>Valta, A.</dc:creator>
<dc:creator>Galan, M.</dc:creator>
<dc:creator>Firozpoor, J.</dc:creator>
<dc:creator>Eccard, J. A.</dc:creator>
<dc:creator>Jacob, J.</dc:creator>
<dc:creator>Imholt, C.</dc:creator>
<dc:creator>Sluydts, V.</dc:creator>
<dc:creator>Colombo, V.</dc:creator>
<dc:creator>Leirs, H.</dc:creator>
<dc:creator>McManus, A.</dc:creator>
<dc:creator>Stuart, P.</dc:creator>
<dc:creator>Gryseels, S.</dc:creator>
<dc:creator>De Bruyn, L.</dc:creator>
<dc:creator>Voigt, C. C.</dc:creator>
<dc:creator>Hoffmeister, U.</dc:creator>
<dc:creator>Alburkat, H.</dc:creator>
<dc:creator>Bourret, V.</dc:creator>
<dc:creator>Smura, T.</dc:creator>
<dc:creator>Castel, G.</dc:creator>
<dc:creator>Charbonnel, N.</dc:creator>
<dc:creator>Sironen, T.</dc:creator>
<dc:creator>Dutra, L. A. L.</dc:creator>
<dc:date>2026-09-24</dc:date>
<dc:identifier>doi:10.64898/2026.09.23.753110</dc:identifier>
<dc:title><![CDATA[Detection and characterisation of alpha- and betacoronaviruses in rodents and bats from Germany, France, Belgium and Ireland]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-24</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Recent zoonotic coronavirus outbreaks have sparked an interest in understanding coronaviruses circulating in animal reservoirs. While bats are recognised as major reservoirs for these viruses, coronaviruses have also been detected in a wide range of terrestrial small mammals, particularly rodents. However, coronavirus diversity in these mammals, specifically in Europe, is still poorly characterised. In this study, we detected and characterised coronaviruses in terrestrial small mammals and bats from Belgium, France, Germany, and Ireland. We screened tissue samples from rodents and shrews and environmental bat guano using pan-coronavirus real-time and conventional PCRs, with positive results confirmed by sanger sequencing. Among 2667 bat and 1152 terrestrial mammal samples, we detected 59 positive samples, 36 from bats and 23 from rodents, from which we recovered 60 coronavirus sequences, spanning both Alphacoronavirus and Betacoronavirus lineages. Through next generation sequencing we identified one Pipistrellus pygmaeus bat guano sample carrying two distinct alphacoronaviruses, representing Nyctacovirus and Pedacovirus subgenera. Among rodents, most coronavirus-positive samples originated from a zoo in Belgium, where several CoV lineages co-circulated. The identified rodent coronaviruses clustered among previously described rodent-associated lineages, some of which also include human and other mammal-derived coronavirus sequences. Consistent with previous studies, we found sarbecoviruses in horseshoe bats (particularly Rhinolophus ferrumequinum and R. hipposideros) and merbecoviruses in Plecotus auritus bats, and these viruses are distantly related to the human coronaviruses of the respective families. Similar to bat coronaviruses, some rodent coronaviruses strains seemed to be association with specific rodent species. In conclusion, our study enhances the understanding of coronaviruses in rodents and bats, revealing potential hotspots for these viruses and their implication for human and animal health. These findings underscore the necessity for continued surveillance of coronaviruses in wildlife reservoirs to mitigate future zoonotic spillover risks.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.09.21.753243v1?rss=1">
<title>
<![CDATA[
Early Steps in Pathogen-induced TTR-amyloid-formation 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.09.21.753243v1?rss=1"
</link>
<dc:creator>Premathilaka, M. B.</dc:creator>
<dc:creator>Hansmann, U. H. E.</dc:creator>
<dc:date>2026-09-24</dc:date>
<dc:identifier>doi:10.64898/2026.09.21.753243</dc:identifier>
<dc:title><![CDATA[Early Steps in Pathogen-induced TTR-amyloid-formation]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-24</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Motivated by correlations between SARS-COV-2 infections and transthyretin (TTR) amyloidosis we use molecular dynamics simulations to study whether three protein fragments from the SARS-CoV-2 virus can initiate dissociation of the transthyretin (TTR) homotetramer as the first step on the pathway to TTR amyloidosis. We find that the peptides reduce the frequency of transient hydrogen bonds at the monomer-monomer interfaces, decreasing in this way the stability of the TTR tetramer.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.09.23.753728v1?rss=1">
<title>
<![CDATA[
Multi-attribute characterisation of mRNA via MazF endoribonuclease and LC-MS workflows 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.09.23.753728v1?rss=1"
</link>
<dc:creator>Welbourne, E. P.</dc:creator>
<dc:creator>Owen, G. R.</dc:creator>
<dc:creator>Wright, L. P.</dc:creator>
<dc:creator>Trabulo, S.</dc:creator>
<dc:creator>Kis, Z.</dc:creator>
<dc:creator>Dickman, M. J.</dc:creator>
<dc:date>2026-09-24</dc:date>
<dc:identifier>doi:10.64898/2026.09.23.753728</dc:identifier>
<dc:title><![CDATA[Multi-attribute characterisation of mRNA via MazF endoribonuclease and LC-MS workflows]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-24</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
The rapid expansion of mRNA-based medicines has driven demand for robust, high-resolution analytical methods capable of characterising critical quality attributes including sequence identity, 5[prime] capping efficiency, and poly(A) tail length and heterogeneity. Here, we present two complementary liquid chromatography-mass spectrometry based workflows for mRNA characterisation, both based on site-specific digestion with the endoribonuclease MazF from Escherichia coli. A middle-up approach, optimised via specific 5[prime]-ACA cleavage enables rapid characterisation via oligoribonucleotide mass mapping providing complete sequence coverage and simultaneous assessment of 5[prime]-capping efficiency and 3[prime]-poly(A) tail length and heterogeneity. This workflow was successfully applied to three different mRNA constructs, NLuc, eGFP and FLuc mRNAs, achieving sequence coverages of 100%, 87%, and 74%, respectively. A complementary bottom-up approach, employing less specific 5[prime]-ACX cleavage enables tandem mass spectrometry-based sequencing of shorter oligoribonucleotides and detailed characterisation via mRNA sequence mapping. Applied to SARS-CoV-2 Spike Protein mRNA, this method yielded 50% sequence coverage based on unique oligoribonucleotides with MazF alone, extended to 90% by combining MazF, partial RNase T1, and partial RNase U2 digests. Together, these workflows provide a flexible, orthogonal platform for both high-throughput quality assessment and in-depth primary sequence characterisation of mRNA vaccines and therapeutics.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.09.22.753304v1?rss=1">
<title>
<![CDATA[
Mutational screening reveals a cluster of residues within the SARS-CoV-2 nsp1 N-terminus that confers RNA-targeting selectivity 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.09.22.753304v1?rss=1"
</link>
<dc:creator>Guillen, J. V.</dc:creator>
<dc:creator>Tokamov, S. A.</dc:creator>
<dc:creator>Glaunsinger, B. A.</dc:creator>
<dc:date>2026-09-23</dc:date>
<dc:identifier>doi:10.64898/2026.09.22.753304</dc:identifier>
<dc:title><![CDATA[Mutational screening reveals a cluster of residues within the SARS-CoV-2 nsp1 N-terminus that confers RNA-targeting selectivity]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-23</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
The SARS-CoV-2 nsp1 protein is a virulence factor that broadly inhibits cellular gene expression. Although cellular mRNAs are translationally inhibited by nsp1 and subsequently degraded, viral transcripts possess a 5' leader sequence (CoV2L) that enables them to escape nsp1-mediated repression. Both transcript targeting selectivity and mRNA decay require coordination by the nsp1 N-terminal domain (NTD) through an unknown mechanism. Here, we generated an alanine-scanning library of mutations encompassing all residues in the nsp1 NTD to gain a deeper understanding of how this domain coordinates nsp1 function. We screened this library for the ability to repress mRNA bearing a host- or CoV2L-derived 5' untranslated region, revealing two predominant clusters of residues required for target selectivity. These largely comprised adjacent surface-exposed beta-sheets on the NTD, whose deletion rendered CoV2L-containing mRNA susceptible to repression and prevented nsp1-induced mRNA decay. This work provides residue-level information on the role of the NTD in distinguishing among mRNA targets and further links nsp1 target selectivity to mRNA decay.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.09.21.751853v1?rss=1">
<title>
<![CDATA[
A knockout screening platform for interferon-stimulated genes in respiratory cells identifies LY6E as a dominant antiviral effector against coronaviruses 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.09.21.751853v1?rss=1"
</link>
<dc:creator>Stoddard, C. I.</dc:creator>
<dc:creator>Litchford, M. L.</dc:creator>
<dc:creator>Sung, K.</dc:creator>
<dc:creator>Hutcheson, R. L.</dc:creator>
<dc:creator>Marceau, J.</dc:creator>
<dc:creator>Johnson, T.</dc:creator>
<dc:creator>Ota, A.</dc:creator>
<dc:creator>Baumgarten, N. E.</dc:creator>
<dc:creator>Gale, M.</dc:creator>
<dc:creator>Overbaugh, J.</dc:creator>
<dc:date>2026-09-23</dc:date>
<dc:identifier>doi:10.64898/2026.09.21.751853</dc:identifier>
<dc:title><![CDATA[A knockout screening platform for interferon-stimulated genes in respiratory cells identifies LY6E as a dominant antiviral effector against coronaviruses]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-23</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Human coronaviruses (HCoVs) cause pathogenic outcomes ranging from mild illness to severe respiratory disease. Determining how respiratory cells coordinate an early antiviral response is necessary to understand successful control of HCoV replication. The Type I Interferon (IFN) response is a major component of innate viral immunity. IFN signaling leads to the upregulation of hundreds of interferon-stimulated genes (ISGs) that can have antiviral activity, though the individual ISGs that are responsible for restricting mildly pathogenic HCoVs in the respiratory epithelium are not clear. Here, we developed a targeted CRISPR-Cas9 knockout sgRNA library (termed the respISG library), focusing on ISGs that are upregulated across a panel of respiratory cells, to screen for innate host factors that restrict the mildly pathogenic human coronavirus, HCoV-OC43. We executed cell death-based screens in immortalized human small airway epithelial cells and identified lymphocyte antigen 6E (LY6E) as a top hit. We confirmed LY6E activity in validation studies and found it regulates entry of various SARS-CoV-2 Spike-pseudotyped lentiviruses. In addition to demonstrating a key role for LY6E in blocking a variety of HCoVs in small airway epithelial cells, this study establishes a loss-of-function CRISPR-Cas9 screening platform for identification of HCoV antiviral ISGs in respiratory cells.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.09.19.752820v1?rss=1">
<title>
<![CDATA[
Bronchial epithelial IB3-1 cells exposed to the anti-SARS-CoV2 BNT162b2 vaccine: induction of apoptosis is partially reversed by Aged Garlic Extract (AGE) and its bioactive components S-allyl-Cysteine and S1-propenyl-l-Cysteine 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.09.19.752820v1?rss=1"
</link>
<dc:creator>di Padua, F.</dc:creator>
<dc:creator>Marzaro, G.</dc:creator>
<dc:creator>Agostinelli, E.</dc:creator>
<dc:creator>Gambari, R.</dc:creator>
<dc:creator>Finotti, A.</dc:creator>
<dc:date>2026-09-21</dc:date>
<dc:identifier>doi:10.64898/2026.09.19.752820</dc:identifier>
<dc:title><![CDATA[Bronchial epithelial IB3-1 cells exposed to the anti-SARS-CoV2 BNT162b2 vaccine: induction of apoptosis is partially reversed by Aged Garlic Extract (AGE) and its bioactive components S-allyl-Cysteine and S1-propenyl-l-Cysteine]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-21</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
The Spike protein (S-protein) of the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV2) exhibits important and negative effects on human cells. Accordingly, the adverse effects of COVID-19 mRNA vaccines could be due to the presence of circulating spike and need to be mitigated. One of the biological activities of the Spike protein (and, indirectly, of the Spike-producing vaccines) is the high induction of apoptosis and pro-inflammatory gene expression in different cellular systems. We have recently demonstrated that Aged Garlic Extract (AGE) and its components S-allyl-Cysteine (SAC) and S1-propenyl-I-Cysteine (S1PC) are potent inhibitors of the expression of pro-inflammatory genes induced by treatment of the bronchial epithelial IB3-1 cells with the Spike RNA-based BNT162b2 vaccine. The main purpose of the present study was to determine (a) whether treatment of the IB3-1 bronchial epithelia cells with the BNT162b2 vaccine is associated with activation of the apoptotic pathway and (b) whether AGE, SAC and S1PC have any effect of therapeutic relevance on this experimental model system. We have exposed IB3-1 cells to increasing amounts of the BNT162b2 vaccine and, after 3 days of culture, apoptosis was assessed using the Annex V and the Caspase 3/7 apoptosis assays. The results obtained demonstrated highly significant increase of the percentage of apoptotic cells after treatment of IB3-1 cells with the BNT162b2 vaccine. The percentage of apoptotic cells was found to be significantly reduced in cell populations treated with the BNT162b2 vaccine in the presence of AGE, SAC and S1PC. The main conclusion of the results of our study is that Aged Garlic Extracts, and its components S-allyl-Cysteine and S1-propenyl-l-Cysteine are able to mitigate the pro-apoptotic effects of the Spike-producing BNT162b2 vaccine using the bronchial epithelial IB3-1 cell line as experimental model system. The efficacy of the reversion of BNT162b2 induced apoptosis suggests that AGE, SAC and S1PC should be considered for the development of protocols aimed at counteracting apoptosis induced by the Spike mRNA-based COVID-19 vaccines. This might be of potential clinical relevance, since one of the biological adverse effects of Spike protein (and, indirectly, of the Spike-producing vaccines) is the high induction of apoptosis in different cellular systems.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.09.19.752823v1?rss=1">
<title>
<![CDATA[
Localized SARS-CoV-2 Infection Triggers a Tissue-Wide Antiviral Response and Functional Impairment of Olfactory Sensory Neurons 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.09.19.752823v1?rss=1"
</link>
<dc:creator>Liu, J.</dc:creator>
<dc:creator>Akhtar, M. S.</dc:creator>
<dc:creator>Liu, H.</dc:creator>
<dc:creator>Kim, Y.</dc:creator>
<dc:creator>Ramirez, B. M.</dc:creator>
<dc:creator>Weidner, A. L.</dc:creator>
<dc:creator>Chan, A.</dc:creator>
<dc:creator>Collins, M.</dc:creator>
<dc:creator>Rothenburg, S.</dc:creator>
<dc:creator>Coffey, L. L.</dc:creator>
<dc:creator>Gong, Q.</dc:creator>
<dc:date>2026-09-21</dc:date>
<dc:identifier>doi:10.64898/2026.09.19.752823</dc:identifier>
<dc:title><![CDATA[Localized SARS-CoV-2 Infection Triggers a Tissue-Wide Antiviral Response and Functional Impairment of Olfactory Sensory Neurons]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-21</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Olfactory dysfunction is a hallmark of COVID-19, yet the mechanisms by which severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causes widespread sensory impairment remain incompletely understood. We compared the olfactory epithelial tropism of multiple SARS-CoV-2 variants in a mouse model and observed that Alpha and Beta variants exhibited the greatest infectivity for the olfactory epithelium (OE), whereas Omicron rarely infected this tissue despite comparable pulmonary viral titers. We further defined the effects of SARS-CoV-2 on olfactory sensory neurons (OSNs) using immunohistochemistry, single-cell RNA sequencing, spatial gene expression characterization, and functional odor stimulation. The localized infection of sustentacular cells triggered a tissue-wide interferon-stimulated antiviral response that extended beyond infected regions for Alpha and Beta but was largely absent following Omicron infection. Mature OSNs transiently adopted an interferon-responsive state before exhibiting persistent downregulation of odorant signal transduction, mitochondrial, and activity-dependent gene pathways. Consistent with these transcriptional changes, odor stimulation failed to elicit normal activity-dependent gene expression during SARS-CoV-2 infection, indicating impaired neuronal function without widespread neuronal loss. Progressive accumulation of macrophages further indicated sustained inflammatory remodeling of the OE. Together, these findings demonstrate that SARS-CoV-2 infection initiates tissue-wide antiviral signaling in the OE that persistently disrupts OSN function, providing a mechanistic framework for COVID-19-associated anosmia.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.09.17.752210v1?rss=1">
<title>
<![CDATA[
SARS-CoV-2 maturation driven by a mechano-active nucleocapsid-RNA condensate 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.09.17.752210v1?rss=1"
</link>
<dc:creator>Ravindran, R.</dc:creator>
<dc:creator>Guerin, B.</dc:creator>
<dc:creator>Mahmood, A.</dc:creator>
<dc:creator>Leung, S. S. W.</dc:creator>
<dc:creator>Wahba, H. M.</dc:creator>
<dc:creator>Dagenais, P.</dc:creator>
<dc:creator>Baid, K.</dc:creator>
<dc:creator>Shrivastava, S.</dc:creator>
<dc:creator>Bhuinya, A. B.</dc:creator>
<dc:creator>Williams, S.</dc:creator>
<dc:creator>Sandolache, A.</dc:creator>
<dc:creator>Legault, P.</dc:creator>
<dc:creator>Omichinski, J. G.</dc:creator>
<dc:creator>Banerjee, A.</dc:creator>
<dc:creator>Wiseman, P. W.</dc:creator>
<dc:creator>Hendricks, A. G.</dc:creator>
<dc:creator>Michnick, S. W.</dc:creator>
<dc:date>2026-09-18</dc:date>
<dc:identifier>doi:10.64898/2026.09.17.752210</dc:identifier>
<dc:title><![CDATA[SARS-CoV-2 maturation driven by a mechano-active nucleocapsid-RNA condensate]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-18</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
The nucleocapsid (N) protein, the core component of the SARS-CoV-2 virus, binds to the 30-kb viral genomic RNA (vgRNA) to form ribonucleoprotein assemblies that are packaged into ~100 nm membrane-enclosed virions. In addition to viral assembly, the N protein performs other functions, including roles in viral mRNA transcription, replication, and immune regulation, making it a key target for developing diagnostics and vaccines. Recent studies show that N protein and RNA undergo phase separation to form a biomolecular condensate that constitutes the viral core. However, how this condensate becomes selectively enveloped by a membrane remains unclear. Here, using a minimal reconstituted system, we demonstrate that N protein-vgRNA condensates are spontaneously enveloped by lipid bilayer membranes, whereas condensates formed by N protein alone or with genomic RNA fragments fail to undergo envelopment and instead adhere to or weakly deform membranes. We show that RNA length tunes the material properties of N protein condensates, with vgRNA imparting enhanced elasticity. We propose a physical model for SARS-CoV-2 maturation in which adhesion between the membrane and the N protein-vgRNA condensate drives membrane bending, while condensate elasticity preserves core geometry. These results identify RNA-dependent material properties as an underlying physical principle for selective SARS-CoV-2 maturation.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.09.16.751725v1?rss=1">
<title>
<![CDATA[
CX3CR1+ microglia/macrophages, activated T cells, and IFN-γ-driven stimulation confer age-dependent protective immunity in young-adult mice following β-coronavirus infection. 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.09.16.751725v1?rss=1"
</link>
<dc:creator>Ghosh, S.</dc:creator>
<dc:creator>Hazra, B.</dc:creator>
<dc:creator>Das Sarma, S.</dc:creator>
<dc:creator>Chakravarty, D.</dc:creator>
<dc:creator>DasSarma, J.</dc:creator>
<dc:date>2026-09-18</dc:date>
<dc:identifier>doi:10.64898/2026.09.16.751725</dc:identifier>
<dc:title><![CDATA[CX3CR1+ microglia/macrophages, activated T cells, and IFN-γ-driven stimulation confer age-dependent protective immunity in young-adult mice following β-coronavirus infection.]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-18</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Age-dependent variation in the immune response is a critical determinant of host susceptibility, disease severity, and long-term sequelae in coronavirus infections, a principle strikingly demonstrated by the COVID-19 pandemic caused by SARS-CoV-2. Although primarily pneumotropic, coronaviruses carry significant neurotropic potential, driving neurological complications whose severity is profoundly determined by host age. Elderly individuals and often children suffer disproportionately severe disease, whereas young adults relatively mount protective responses; yet the cellular and molecular determinants of this age-dependent neuroprotection remain poorly characterized. Using juvenile and young-adult C57BL/6 mice intracranially inoculated with {beta}-coronavirus MHV-RSA59, a murine equivalent of human coronaviruses, we examined immune dynamics at days 5 (innate-acute), 7 (innate-to-adaptive transition), and 30 (chronic) post-infection. Young-adult mice exhibited only occasional demyelination, in stark contrast to the extensive demyelination observed across all spinal cord levels in juveniles. This differential outcome was attributable to enhanced age-dependent immune maturation, characterized by efficient T cell-microglia/macrophage crosstalk enabling effective viral control by day 7 post-infection. Young adults displayed greater glial activation, heightened cytokine release, CX3CR1+ microglia activation, and augmented CNS trafficking of CX3CR1+ and MHC II+ monocytes/macrophages, IFN-{gamma}+ CD4+/CD8+ T cells, and CXCR3+ effector T cells relative to juveniles. Reduced naive T cell frequencies and elevated effector/central memory T cell populations in cervical lymph nodes further indicate a robust adaptive memory response conferring long-term protection. Additionally, greater regulatory T cell accumulation in young adults facilitates timely suppression of excessive neuroinflammation as viral burden subsides. Together, these findings define the age-dependent immune landscape that underpins neuroprotection in {beta}-coronavirus infection.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.09.16.752245v1?rss=1">
<title>
<![CDATA[
A diffusion model of viral evolution predicts mutation fitness and evolutionary trajectories 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.09.16.752245v1?rss=1"
</link>
<dc:creator>Wu, J.</dc:creator>
<dc:creator>Ding, X.</dc:creator>
<dc:creator>Wu, A.</dc:creator>
<dc:date>2026-09-18</dc:date>
<dc:identifier>doi:10.64898/2026.09.16.752245</dc:identifier>
<dc:title><![CDATA[A diffusion model of viral evolution predicts mutation fitness and evolutionary trajectories]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-18</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Viral evolution arises from random mutations and natural selection, yet computational approaches rarely model these two forces in a unified way. We present Viral Evolution Simulator (VES), a diffusion model-based framework that mirrors this duality by design: forward noise injection simulates stochastic mutation, and reverse denoising recapitulates selective filtering. Trained solely on viral protein sequences, VES predicts mutational fitness without functional data, measuring fitness as the reconstruction difficulty of a mutated sequence relative to its wild-type counterpart. Across immune escape, receptor binding, and deep mutational scanning datasets, VES outperforms state-of-the-art generative models, achieving a 31.78% error reduction over the best baseline in immune escape mutation fitting evaluation. When trained on sequences collected before June 2024 and evaluated against H1N1 strains that later emerged, VES assigned high scores to 16 of 20 mutations that subsequently showed the sharpest frequency shifts. Extending to avian influenza H5, the framework reveals a dynamic interplay between antigenic escape and human-type receptor binding. Both functions dropped sharply in 2021, followed by a sustained rise in receptor affinity that could connect to recent epidemiological trends. VES offers a generalizable, sequence-only foundation for tracing evolutionary trajectories and prioritizing mutations for surveillance and experimental validation, pointing toward where functional efforts might matter most.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.09.16.751817v1?rss=1">
<title>
<![CDATA[
Progressive Post-Acute Gut Microbiome Disruption Following SARS-CoV-2 Infection in Mice 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.09.16.751817v1?rss=1"
</link>
<dc:creator>Mann-Nuttel, R.</dc:creator>
<dc:creator>Ogando, N. S.</dc:creator>
<dc:creator>Armbruster, M.</dc:creator>
<dc:creator>Mandal, S.</dc:creator>
<dc:creator>Ospondpant, D.</dc:creator>
<dc:creator>Elaish, M.</dc:creator>
<dc:creator>Hobman, T. C.</dc:creator>
<dc:creator>Power, C.</dc:creator>
<dc:creator>Forsythe, P.</dc:creator>
<dc:date>2026-09-18</dc:date>
<dc:identifier>doi:10.64898/2026.09.16.751817</dc:identifier>
<dc:title><![CDATA[Progressive Post-Acute Gut Microbiome Disruption Following SARS-CoV-2 Infection in Mice]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-18</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
SARS-CoV-2 infection is increasingly recognized to produce long-lasting physiological disturbances that extend beyond the acute phase. The gut microbiome has emerged as a potential contributor to post-infection outcomes, yet the longitudinal progression of microbial disruption following infection remains poorly defined. Here, we used a mouse model of SARS-CoV-2 infection to characterize gut microbiome dynamics at 7 (late acute phase), 14 (early recovery), and 21 (post-COVID condition, PCC) days post-infection (dpi). Viral RNA was detected in the lungs through 21 dpi. Longitudinal microbiome profiling revealed a two-phase restructuring marked by early shifts in Bacillota and Bacteroidota abundance, followed by pronounced post-acute dysbiosis characterized by reduced diversity, expansion of Bacillota, and near-complete loss of Bacteroidota. Functional pathway predictions showed progressive metabolic remodeling, including disruptions in nucleotide turnover, fermentation, and vitamin-related pathways. Together, these findings demonstrate that SARS-CoV-2 infection drives progressive and sustained alterations in gut microbial composition and function after the transition from acute infection through recovery into PCC.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.09.16.752249v1?rss=1">
<title>
<![CDATA[
Mapping First In Vivo Ebolavirus Infection Events 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.09.16.752249v1?rss=1"
</link>
<dc:creator>Barry, M.</dc:creator>
<dc:creator>Liu, J.</dc:creator>
<dc:creator>Zell, B.</dc:creator>
<dc:creator>Wang, L.</dc:creator>
<dc:date>2026-09-18</dc:date>
<dc:identifier>doi:10.64898/2026.09.16.752249</dc:identifier>
<dc:title><![CDATA[Mapping First In Vivo Ebolavirus Infection Events]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-18</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Orthoebolaviruses, including Ebola virus (EBOV) and Bundibugyo virus (BDBV), cause sporadic outbreaks and devastating hemorrhagic infections in humans. A significant challenge that impedes the study of filoviruses is that the infectious virus can only be handled in biosafety level 4 (BSL4) facilities due to their extreme virulence. Life cycle modeling systems that use minigenomes and transcription/replication-competent virus-like particles (trVLPs) are powerful tools for studying these virus biology and to explore antiviral therapies under BSL2 conditions. To date, these powerful tools have only been utilized in vitro in cell culture systems. In this work, we demonstrate the use of EBOV trVLPs in vivo. We report the fine specificity of first infection events in a model of EBOV injection in the skin. Cre recombinase expressing monocistronic EBOV trVLPs were packaged and used to inject Cre reporter mice intradermally (ID). Initial infection events were monitored in living animals by luciferase imaging and then by flow cytometry to track cell-specific expression of Cre-activated GFP. By this approach, EBOV trVLPs were shown to directly infect T cells, monocytes, dendritic cells (DCs) with notably high first infections of skin-resident Langerhans cells (LCs) in the skin barrier and its draining lymph node. EBOV trVLPs were next tested as an in vivo tool to assess antiviral therapies by testing the ability of an EBOV vaccine to reduce trVLP luciferase levels after infection in the skin. This work demonstrates first in vivo use of EBOV trVLPs and provides proof of concept for their use as an in vivo BSL2 model to more rapidly develop antiviral agents and vaccines.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.09.15.751712v1?rss=1">
<title>
<![CDATA[
The COVID-19 RNA vaccine SpikevaxTM transfects human umbilical endothelial cells and induces Spike protein production, inflammation and leukocyte adhesion 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.09.15.751712v1?rss=1"
</link>
<dc:creator>Cosentino, M.</dc:creator>
<dc:creator>Ferrari, M.</dc:creator>
<dc:creator>Schiavone, N.</dc:creator>
<dc:creator>Rasini, E.</dc:creator>
<dc:creator>Luini, A.</dc:creator>
<dc:creator>Legnaro, M.</dc:creator>
<dc:creator>Federico, M.</dc:creator>
<dc:creator>Marino, F.</dc:creator>
<dc:creator>Frajese, G.</dc:creator>
<dc:date>2026-09-18</dc:date>
<dc:identifier>doi:10.64898/2026.09.15.751712</dc:identifier>
<dc:title><![CDATA[The COVID-19 RNA vaccine SpikevaxTM transfects human umbilical endothelial cells and induces Spike protein production, inflammation and leukocyte adhesion]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-18</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Endothelial cell dysfunction plays a key role in the pathogenesis of severe and critical COVID-19, leading to a multi-systemic inflammatory disease, and results from the direct interaction of the SARS-CoV-2 Spike proteins with endothelial cells. COVID-19 RNA vaccines encode a recombinant SARS-CoV-2 Spike protein which undergoes systemic biodistribution. No information is however so far available on the direct effects of COVID-19 RNA vaccines on human endothelial cells. In the present study, we exposed cultured human umbilical venous endothelial cells (HUVEC) to the COVID-19 RNA vaccine SpikevaxTM (Moderna, Inc.), and thereafter we measured the expression of the Spike protein, of the proinflammatory cytokines interleukin (IL)-6 and tumor necrosis factor (TNF)-, of the adhesion molecules intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1), as well as the attachment of human leukocytes to HUVEC layers. We also assessed the effects of SpikevaxTM on HUVEC viability. Exposure of HUVEC to the COVID-19 RNA vaccine SpikevaxTM resulted in effective cell transfection, and subsequent production of the Spike protein, which was expressed in the cells and secreted in the culture medium. Spike protein production was accompanied by increased gene expression of IL-6 and TNF- and of ICAM-1 and VCAM-1, as well as by increased attachment of leukocytes to HUVEC monolayers. Exposure to the COVID-19 RNA vaccine SpikevaxTM did not affect HUVEC viability. Our results provide a mechanistic explanation to post-COVID-19 RNA vaccination pathologies resulting from endothelial dysfunction, such as during atherosclerosis, autoimmune inflammation, and systemic inflammatory conditions.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.09.17.752411v1?rss=1">
<title>
<![CDATA[
Post-selection inference in testing for phenotypic differences with scRNA-Seq 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.09.17.752411v1?rss=1"
</link>
<dc:creator>Sanchez, N.</dc:creator>
<dc:creator>Etourneau, L.</dc:creator>
<dc:creator>Purdom, E.</dc:creator>
<dc:date>2026-09-18</dc:date>
<dc:identifier>doi:10.64898/2026.09.17.752411</dc:identifier>
<dc:title><![CDATA[Post-selection inference in testing for phenotypic differences with scRNA-Seq]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-18</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
For the purpose of differential expression (DE) analysis in single-cell RNA-sequencing (scRNA-Seq), phenotype differences between samples are often tested within specific cell types. Cell types are regularly imputed by clustering the same gene expression data which is later used for phenotype testing. This creates the potential for a "double-dipping" or post-selection inference problem resulting in inflated rates of false discoveries. While this selection bias is known to inflate significance in cell-type marker identification, its effect on sample-level phenotype testing, e.g. in patient cohorts, has never been explored despite the growing preponderance of this type of analysis. To address this, we perform an extensive simulation study and demonstrate that naive clustering on uncorrected embeddings can severely inflate the False Discovery Rate (FDR) in the presence of strong phenotypic differences. However, we further show that applying batch-correction methods to remove phenotypic effects prior to clustering resolves the FDR inflation with no obvious loss of power. Finally, we provide measures of phenotypic imbalance that can be applied to real datasets which closely track the false discovery proportion and thus can be used to as part of data exploration to gauge the risk of post-selection inflation of p-values in a particular dataset.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.09.16.752071v1?rss=1">
<title>
<![CDATA[
An Artificial Intelligence Model for Longitudinal Assessment of TCR Repertoires in SARS-CoV-2 Vaccine Recipients 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.09.16.752071v1?rss=1"
</link>
<dc:creator>Wang, Z.</dc:creator>
<dc:creator>Zhao, Y.</dc:creator>
<dc:creator>Xiao, X.</dc:creator>
<dc:creator>He, B.</dc:creator>
<dc:creator>Sun, Y.</dc:creator>
<dc:creator>Xiong, S.</dc:creator>
<dc:creator>Qin, C.</dc:creator>
<dc:creator>Zhou, Z.</dc:creator>
<dc:creator>Chang, L.</dc:creator>
<dc:creator>Bai, J.</dc:creator>
<dc:creator>Zhao, W.</dc:creator>
<dc:creator>Liang, W.</dc:creator>
<dc:creator>Yao, J.</dc:creator>
<dc:date>2026-09-18</dc:date>
<dc:identifier>doi:10.64898/2026.09.16.752071</dc:identifier>
<dc:title><![CDATA[An Artificial Intelligence Model for Longitudinal Assessment of TCR Repertoires in SARS-CoV-2 Vaccine Recipients]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-18</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
T cells play a crucial role in reducing disease severity during SARS-CoV-2 infection and in shaping long-term immune memory. However, the precise molecular immune responses, particularly involving T-cell receptor (TCR) repertoire changes after full vaccination, and the use of TCR analysis to evaluate vaccine efficacy, remain incompletely understood. In this study, we developed the DeepAir-Cov19 model (AUC=0.94), a large language model tailored to identify SARS-CoV-2-specific TCRs, and observed significant differences in the TCR profiles between antibody-negative and antibody-positive populations before and after vaccination, indicating that the immune status of pre-vaccine recipients can directly assess the efficacy of vaccination. Notably, SARS-CoV-2-specific TCRs expanded to peak levels after the second dose and remained detectable in most subjects up to 10 months post-vaccination. Meanwhile, we also identified three specific V genes, 20 V-J combinations, and 3 epitopes associated with these responses. Finally, by leveraging vaccine-specific TCRs as novel biomarkers, we developed a vaccine efficacy model that predicts antibody levels with a mean AUC of 0.96. These findings underscore the accuracy of the large model in predicting SARS-CoV-2-specific TCRs and reveal a strong correlation between SARS-CoV-2-specific TCR responses and antibody levels. This highlights the complementary and synergistic roles of T cells and antibodies in providing vaccine-mediated protection. Our results offer valuable insights into the longitudinal dynamics of SARS-CoV-2-specific TCRs and illustrate the potential for developing potency evaluation models based on these TCR insights.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.09.17.752370v1?rss=1">
<title>
<![CDATA[
Accelerated discovery of thermostable vaccines using data-efficient AI 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.09.17.752370v1?rss=1"
</link>
<dc:creator>Tian, J.</dc:creator>
<dc:creator>Tran, K. T. M.</dc:creator>
<dc:creator>Pogostin, B. H.</dc:creator>
<dc:creator>Sheridan, O.</dc:creator>
<dc:creator>Mursalova, S.</dc:creator>
<dc:creator>Lee, A. H.</dc:creator>
<dc:creator>Liu, S.</dc:creator>
<dc:creator>Hamkins, J.</dc:creator>
<dc:creator>Antov, D.</dc:creator>
<dc:creator>Power, A. L.</dc:creator>
<dc:creator>Dash, Z. S.</dc:creator>
<dc:creator>Yun, D.</dc:creator>
<dc:creator>Konakovic Lukovic, M.</dc:creator>
<dc:creator>Langer, R.</dc:creator>
<dc:creator>Jaklenec, A.</dc:creator>
<dc:date>2026-09-18</dc:date>
<dc:identifier>doi:10.64898/2026.09.17.752370</dc:identifier>
<dc:title><![CDATA[Accelerated discovery of thermostable vaccines using data-efficient AI]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-18</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
The inherent instability of mRNA- lipid nanoparticles (LNPs) necessitates ultra-cold storage, creating significant barriers for global distribution and limiting their broader application in advanced delivery systems. Solid-state, water-free formulations offer a promising solution by enhancing thermostability and enabling integration into emerging delivery modalities such as microneedle (MN) patches. Prior efforts to stabilize mRNA-LNPs have been constrained by narrow formulation scope and low-throughput screening methods. Here, we introduce AGENT (Algorithm-Guided Experimental design for lipid Nanoparticle Thermostabilization), an AI-driven framework that couples high-throughput experimentation with Bayesian optimization to rapidly identify thermostable mRNA-LNP formulations. Manual exploration of the formulation space required months of screening and yielded suboptimal candidates. In contrast, AGENT extracted maximal information from sparse experimental datasets, enabling efficient formulation optimization in only six iterations completed within one month. Using AGENT, we stabilized mRNA vaccines with diverse LNPs, including those in clinical use, into solid state formulations that retained 100% bioactivity after storage at 37 degree C for over two months. The thermostable vaccines induced antigen-specific IgG and germinal center B cell responses that were non-inferior to those elicited by freshly prepared soluble vaccines. The solid-state formulations were further incorporated into dissolvable MN patches and administered to rodents and nonhuman primates, yielding comparable neutralizing antibody titers compared to conventional intramuscular delivery of fresh vaccines. To our knowledge, this study presents the first demonstration of AI-driven design of thermostable RNA vaccines, offering a scalable, cold-chain-free solution for global immunization. By addressing both stability and delivery challenges, AGENT provides a potentially transformative platform for developing accessible next-generation therapeutics.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.09.16.751791v1?rss=1">
<title>
<![CDATA[
Hantaan virus polymerase has an in vitro Terminal Nucleotidyl Transferase activity that is conserved across the Bunyaviricetes class 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.09.16.751791v1?rss=1"
</link>
<dc:creator>Barata-Garcia, S.</dc:creator>
<dc:creator>Durieux Trouilleton, Q.</dc:creator>
<dc:creator>Debarnot, C.</dc:creator>
<dc:creator>MALET, H.</dc:creator>
<dc:creator>Reguera, J.</dc:creator>
<dc:date>2026-09-18</dc:date>
<dc:identifier>doi:10.64898/2026.09.16.751791</dc:identifier>
<dc:title><![CDATA[Hantaan virus polymerase has an in vitro Terminal Nucleotidyl Transferase activity that is conserved across the Bunyaviricetes class]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-18</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Bunyaviricetes is a class of segmented negative strand RNA viruses (sNSV) that includes causative agents of severe zoonotic diseases resulting in hemorrhagic fever in humans and livestock. Hantaan virus (HTNV), family Hantaviridae, is an example of life-threatening bunyavirus transmitted by rodents which leads to Hantavirus hemorrhagic fever with renal syndrome in humans. Infection relies on the replication and transcription of their tripartite genomes through multifunctional RNA-dependent RNA polymerases (RdRp) in the context of ribonucleoproteins (RNPs) made of one viral RNA fragment, one RdRp and multiple copies of viral nucleoproteins. The RdRp, also known as L protein, performs replication by de novo initiation through a prime-and-realign mechanism while transcription initiates through a cap snatching mechanism, that engages a cap-binding domain and an endonuclease (EN) domain present in the L protein C and N terminal regions, respectively. In this work we show that HTNV L protein has a terminal nucleotidyl transferase (TNTase) activity over double-stranded RNA substrates (dsRNA) in vitro. We show that the TNTase activity is also present in other bunyaviral L proteins by comparing HTNV L protein activity with La Crosse (LACV, family Orthobunyaviridae) and Crimean Congo Hemorrhagic Fever Virus (CCHFV, family Nairoviridae) L proteins. Our results show that TNTase activity appears to be a general feature of Bunyaviruses and report the differences on substrate and nucleotide specificity for each family of virus.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.09.15.751875v1?rss=1">
<title>
<![CDATA[
Transmission of mutated SARS-CoV-2 variants is favored by relatively prolonged infections due to delayed immunity 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.09.15.751875v1?rss=1"
</link>
<dc:creator>Owens, K.</dc:creator>
<dc:creator>Radecki, P.</dc:creator>
<dc:creator>Tempia, S.</dc:creator>
<dc:creator>von Gottberg, A.</dc:creator>
<dc:creator>Cohen, C.</dc:creator>
<dc:creator>Boritz, E.</dc:creator>
<dc:creator>Schiffer, J. T.</dc:creator>
<dc:creator>Reeves, D. B.</dc:creator>
<dc:date>2026-09-18</dc:date>
<dc:identifier>doi:10.64898/2026.09.15.751875</dc:identifier>
<dc:title><![CDATA[Transmission of mutated SARS-CoV-2 variants is favored by relatively prolonged infections due to delayed immunity]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-18</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
SARS-CoV-2 evolution enhanced viral fitness and immune evasion, extending the COVID-19 pandemic and resulting in millions of excess deaths. Viral diversity is generated within infected individuals, yet the timing and interplay of viral and immunological forces that drive transmissible evolution are incompletely understood. We developed a multi-scale within host phylodynamic (WiPhy) model of SARS-CoV-2 infection which couples viral replication, innate and acquired immune responses, and viral mutation. We then validated the model against quantitative viral and phylodynamic metrics. Model output predicts that typical acute infections rapidly generate genetic diversity due to accumulation of minor variants which in most cases do not achieve sufficient concentrations for transmission. Delayed innate immune responses correlate with higher peak viral load and diversification, allowing higher transmission risk of the founder virus or with a novel variant that is equally or less fit. In contrast, the risk of transmitting a fitter variant is highest during the ~10% of infections in which viral loads remain sufficiently high for transmission after 10-14 days. In these cases, non-sustained innate and/or weak acquired immune responses allow sufficient time for selection of a variant with one or more fitness enhancing non-synonymous mutations. Across a simulated cohort of ~1500 individuals, 5% of transmission risk came from variants with enhanced fitness from nonsynonymous mutations, and 13% of simulated infections accounted for 90% of fitter variant transmission risk. Our results highlight how the timing and interplay of viral and immunological forces within a host create bottlenecks that severely limit between host evolution.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.09.15.751278v1?rss=1">
<title>
<![CDATA[
Durability and diversity of human upper airway T cell memory 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.09.15.751278v1?rss=1"
</link>
<dc:creator>Ramirez, S. I.</dc:creator>
<dc:creator>Faraji, F.</dc:creator>
<dc:creator>Lopez, P. G.</dc:creator>
<dc:creator>Garin-Ortega, L.</dc:creator>
<dc:creator>Hern, N. A.</dc:creator>
<dc:creator>Eisenman, O.</dc:creator>
<dc:creator>Azhan, A.</dc:creator>
<dc:creator>Frazier, A.</dc:creator>
<dc:creator>Phillips, E. J.</dc:creator>
<dc:creator>Mallal, S.</dc:creator>
<dc:creator>Sette, A.</dc:creator>
<dc:creator>Dileepan, T.</dc:creator>
<dc:creator>Jenkins, M. K.</dc:creator>
<dc:creator>Crotty, S.</dc:creator>
<dc:date>2026-09-18</dc:date>
<dc:identifier>doi:10.64898/2026.09.15.751278</dc:identifier>
<dc:title><![CDATA[Durability and diversity of human upper airway T cell memory]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-18</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
T cells are major contributors to protective immunity against pathogens and cancers. Immune memory is a central feature of protective adaptive immunity, and mucosal barrier tissues are major sites of pathogen invasion. Yet, fundamental gaps remain in our knowledge of human T cell immune memory durability in mucosal barrier sites. Here, we employed minimally invasive nasal swab sampling to directly detect, and longitudinally assess, human antigen-specific T cells in two upper airway tissue sites (~ 900 samples) and peripheral blood. Antigen-specific memory CD8 and CD4 T cells were detected in upper airway tissue of > 95% of individuals. Both memory CD8 and CD4 T cells were sustained in both mucosal epithelial and mucosal lymphoid tissue over the course of 18+ months, with monthly sampling, and no clear evidence of decline. Virus-specific upper airway CD8 and CD4 T cells were predominantly resident memory T cells (TRM) throughout the 18+ month period of observation. These findings can inform future T cell vaccines and therapeutics.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.09.14.751198v1?rss=1">
<title>
<![CDATA[
3D Spatial Interactomics Maps the Dynamics of NF-κB Multiprotein Signalosomes in Single Cells 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.09.14.751198v1?rss=1"
</link>
<dc:creator>Zhang, N.</dc:creator>
<dc:creator>Leese-Thompson, C.</dc:creator>
<dc:creator>Ozuna, H.</dc:creator>
<dc:creator>Peng, B.</dc:creator>
<dc:creator>Sirigireddy, S.</dc:creator>
<dc:creator>Nambiar, D.</dc:creator>
<dc:creator>Ramanan, L.</dc:creator>
<dc:creator>Tirouvanziam, R.</dc:creator>
<dc:creator>Kopp, B.</dc:creator>
<dc:creator>Coskun, A. F.</dc:creator>
<dc:date>2026-09-17</dc:date>
<dc:identifier>doi:10.64898/2026.09.14.751198</dc:identifier>
<dc:title><![CDATA[3D Spatial Interactomics Maps the Dynamics of NF-κB Multiprotein Signalosomes in Single Cells]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-17</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
NF{kappa}B signaling drives inflammatory responses by rapidly assembling membrane-proximal multiprotein supercomplexes, yet how these assemblies are organized in space and time within the 3D interior of a single cell has remained uncharacterized. We addressed this by profiling endogenous NF{kappa}B protein-protein interactions with an intelligent sequential proximity ligation assay (iseqPLA), read out by spinning disk confocal microscopy and 3D reconstruction. Each detected protein-protein proximity event is represented by a rolling-circle amplification product, and we treat clusters of co-localized puncta as a measure of supercomplex spatial organization. Across NIH-3T3 mouse fibroblasts, cystic fibrosis (CF) patient-derived macrophage co-cultures with IMR-90 human fibroblasts, and an independent set of healthy- and CF-donor monocyte-fibroblast co-cultures profiled by 3D iseqPLA, we tracked supercomplex dissociation, p65 nuclear translocation, and negative-feedback engagement across cytokine time courses. Three findings emerge: 3D volumetric quantification reduces the variance in nuclear-to-cytoplasmic ratio measurements relative to 2D projections, the choice of extracellular matrix coating shapes the fraction of NF{kappa}B-responsive cells, and CF airway-conditioned macrophages amplify paracrine NF{kappa}B signaling in neighboring fibroblasts in a CF model. A single-cell Generative Pretrained Transformer (scGPT) foundation model, fine-tuned on curated transcriptomic datasets, further places our NF{kappa}B gene panel within an inflammation-relevant feature space. Together, these results establish a 3D spatial interactomics workflow for dissecting supercomplex dynamics in health and disease.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.09.14.751616v1?rss=1">
<title>
<![CDATA[
The selection for cidofovir-resistant mutant vaccinia viruses is inhibited by coinfecting cidofovir-sensitive wildtypes 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.09.14.751616v1?rss=1"
</link>
<dc:creator>Lee, S. Z.</dc:creator>
<dc:creator>Lin, Y.-C.</dc:creator>
<dc:creator>Evans, D. H.</dc:creator>
<dc:creator>Noyce, R. S.</dc:creator>
<dc:date>2026-09-17</dc:date>
<dc:identifier>doi:10.64898/2026.09.14.751616</dc:identifier>
<dc:title><![CDATA[The selection for cidofovir-resistant mutant vaccinia viruses is inhibited by coinfecting cidofovir-sensitive wildtypes]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-17</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Recent years have seen two outbreaks of zoonotic mpox, highlighting the need for additional therapies to treat these infections and curb the spread of the virus. However, there are only two antiviral drugs available for treating mpox, and drug resistance is a potential threat to intervention. Here we investigate how drug resistance emerges in a population of viruses where the sensitive wildtype strain vastly outnumbers the drug-resistant mutant. Using cidofovir treatment and resistance as a model system during vaccinia virus infection, we found that cidofovir-resistant poxviruses rapidly outcompete cidofovir-sensitive viruses when the two strains replicate in complete isolation. However, when the two strains infect the same cell, the drug-resistant virus lost its competitive advantage over the sensitive strain. We found that when the two viruses replicate in separate cells treated with cidofovir, the resistant strain displays faster genome replication kinetics compared to the sensitive strain. However, when the two viruses replicate in the same drug-treated cell, the strains replicated at the same rate. This showed that the drug-resistance trait was functionally shared between the two genetically-distinct strains, allowing the sensitive strain to parasitize the growth advantage of the resistant strain and preventing the rapid outgrowth of the resistant strain. These observations suggest that poxvirus coinfections negatively affect the selection for a rare trait like cidofovir-resistance. Considering that poxviruses actively prevent superinfection, we hypothesize that superinfection exclusion could maintain fitness in a population and facilitate the outgrowth of rare, advantageous traits in poxvirus populations.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.09.11.750839v1?rss=1">
<title>
<![CDATA[
Risk factors and immunological characteristics of SARS-CoV-2 RNA re-positivity in convalescent COVID-19 Patients: A retrospective study 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.09.11.750839v1?rss=1"
</link>
<dc:creator>Li, L.</dc:creator>
<dc:creator>Zhang, X.</dc:creator>
<dc:creator>Fan, J.</dc:creator>
<dc:creator>Fan, J.</dc:creator>
<dc:creator>Du, J.</dc:creator>
<dc:creator>Yan, H.</dc:creator>
<dc:creator>Dai, E.</dc:creator>
<dc:creator>Gao, H.</dc:creator>
<dc:creator>Feng, A.</dc:creator>
<dc:date>2026-09-17</dc:date>
<dc:identifier>doi:10.64898/2026.09.11.750839</dc:identifier>
<dc:title><![CDATA[Risk factors and immunological characteristics of SARS-CoV-2 RNA re-positivity in convalescent COVID-19 Patients: A retrospective study]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-17</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Purpose: To investigate the incidence, clinical features, and risk factors for SARS-CoV-2 nucleic acid re-positivity in recovered COVID-19 patients. Methods: We enrolled 441 convalescent COVID-19 patients from the rehabilitation ward of the Fifth Hospital of Shijiazhuang between January and April 2021. Based on nucleic acid test results, patients were categorized into repositive (n = 69) and non-repositive (n = 372) groups. Demographic, clinical, laboratory, and imaging data were compared between groups. Logistic regression was used to identify factors associated with re-positivity. Results: The overall re-positivity rate was 15.65%. Compared with the non-repositive group, the repositive group presented with a significantly higher proportion of moderate disease severity (72.46% vs. 50.54%) and a lower proportion of patients under 14 years old (7.25% vs. 23.66%). Additionally, multi-lobar involvement ([&ge;] 3 lobes) during the acute phase was more common in the repositive group (43.48% vs. 26.61%), with all differences being statistically significant (P < 0.001). Laboratory analysis revealed that repositive patients had significantly lower lymphocyte and eosinophil counts, as well as reduced albumin (ALB), aspartate aminotransferase/alanine aminotransferase (AST/ALT) ratio, and albumin/globulin (A/G) ratio. Furthermore, circulating CD3+, CD4+, and CD8+ T-cell counts were markedly decreased. In contrast, the neutrophil-to-lymphocyte ratio (NLR), immunoglobulin M (IgM), immunoglobulin A (IgA), and neutralizing antibody (NAb) levels were significantly elevated in re-positive patients (all P < 0.05). Multivariate logistic regression analysis identified the CD8+ as independent risk factors for re-positivity. Conclusion: In convalescent patients, SARS-CoV-2 RNA re-positivity correlates with distinct clinical and immunological characteristics. The CD8+ T-cell level is an independent predictor, highlighting that dysregulated immune and inflammatory responses contribute to delayed viral clearance.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.15.26361876v1?rss=1">
<title>
<![CDATA[
Cost-Effectiveness of Ensitrelvir for COVID-19 Post-Exposure Prophylaxis Among High-Risk Household Contacts in Japan: A Model-Based Cost-Utility Analysis 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.15.26361876v1?rss=1"
</link>
<dc:creator>Taniguchi, T.</dc:creator>
<dc:creator>Yahaba, M.</dc:creator>
<dc:creator>Yoshikawa, H.</dc:creator>
<dc:creator>Igari, H.</dc:creator>
<dc:creator>Sato, D.</dc:creator>
<dc:date>2026-09-16</dc:date>
<dc:identifier>doi:10.64898/2026.09.15.26361876</dc:identifier>
<dc:title><![CDATA[Cost-Effectiveness of Ensitrelvir for COVID-19 Post-Exposure Prophylaxis Among High-Risk Household Contacts in Japan: A Model-Based Cost-Utility Analysis]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-16</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
BackgroundEnsitrelvir reduced symptomatic COVID-19 after household exposure in the SCORPIO-PEP trial, but its economic value as post-exposure prophylaxis is unknown.

ObjectiveTo estimate the cost-effectiveness of ensitrelvir post-exposure prophylaxis for high-risk household contacts in Japan.

MethodsWe developed a decision-analytic cost-utility model from the Japanese public healthcare payer perspective. Trial risks of symptomatic COVID-19 through day 10 were linked to Japanese evidence on hospitalization, mortality, costs, quality of life, and life expectancy. Because the trial observed no COVID-19-related hospitalization or death, downstream outcomes were modeled only through prevention of symptomatic disease. We performed deterministic, probabilistic, structural, subgroup, and threshold analyses.

ResultsEnsitrelvir increased costs by JPY 54,945 and gained 0.003267 QALYs per exposed contact, yielding an ICER of JPY 16.82 million/QALY. None of 10,000 simulations was cost-effective at JPY 5 million/QALY. Applying the overall-trial relative risk to the high-risk baseline yielded JPY 19.24 million/QALY. Restricting post-acute utility loss to 6 months, halving it, or excluding it yielded ICERs of JPY 23.62 million, JPY 26.76 million, and JPY 65.51 million/QALY, respectively. The drug acquisition-cost threshold was JPY 11,021 per course.

ConclusionsAt current Japanese costs, ensitrelvir post-exposure prophylaxis for high-risk household contacts was unlikely to be cost-effective at JPY 5 million/QALY. This conclusion remained unfavorable under conservative efficacy, post-acute utility, hospitalization-attribution, and mortality assumptions. Severe-outcome benefits remain model-based extrapolations rather than trial-observed effects.

Key Points for Decision MakersO_LIThe pivotal post-exposure prophylaxis trial showed a substantial reduction in symptomatic COVID-19, but no COVID-19-related hospitalization or death occurred; modeled severe-outcome benefits therefore depend on external Japanese evidence.
C_LIO_LIAt current Japanese drug and delivery costs, the base-case ICER was JPY 16.82 million per QALY. The probability of cost-effectiveness was 0% at JPY 5 million per QALY and 2.28% at JPY 10 million per QALY.
C_LIO_LIThe acquisition-cost threshold was approximately JPY 11,000 per course. Conservative efficacy and post-acute utility scenarios remained above JPY 19 million and JPY 23 million per QALY, respectively.
C_LI
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.09.13.750764v1?rss=1">
<title>
<![CDATA[
Structural basis of diverse antibody recognition of conserved coronavirus spike S2 epitopes that contribute to protective immunity 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.09.13.750764v1?rss=1"
</link>
<dc:creator>Rubio, A. A.</dc:creator>
<dc:creator>Crivelli, V.</dc:creator>
<dc:creator>Hönig, V.</dc:creator>
<dc:creator>Cizkova, M.</dc:creator>
<dc:creator>Cervantes Rincon, T.</dc:creator>
<dc:creator>Abernathy, M. E.</dc:creator>
<dc:creator>Parada, M. K.</dc:creator>
<dc:creator>Vahdat, D.</dc:creator>
<dc:creator>Lee, Y. E.</dc:creator>
<dc:creator>Eso, M.</dc:creator>
<dc:creator>Cantergiani, J.</dc:creator>
<dc:creator>Moro, S. G.</dc:creator>
<dc:creator>Jarrossay, D.</dc:creator>
<dc:creator>Guerra, C.</dc:creator>
<dc:creator>Cena, B.</dc:creator>
<dc:creator>Minculescu, M.</dc:creator>
<dc:creator>Gradauskaite, V.</dc:creator>
<dc:creator>Biggiogero, M.</dc:creator>
<dc:creator>Calvaruso, V.</dc:creator>
<dc:creator>Pellanda, A. F.</dc:creator>
<dc:creator>Cavalli, A.</dc:creator>
<dc:creator>Garzoni, C.</dc:creator>
<dc:creator>Palus, M.</dc:creator>
<dc:creator>Robbiani, D. F.</dc:creator>
<dc:creator>Barnes, C. O.</dc:creator>
<dc:date>2026-09-16</dc:date>
<dc:identifier>doi:10.64898/2026.09.13.750764</dc:identifier>
<dc:title><![CDATA[Structural basis of diverse antibody recognition of conserved coronavirus spike S2 epitopes that contribute to protective immunity]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-16</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Conserved epitopes within the coronavirus spike S2 domain elicit broadly reactive antibodies, yet many characterized responses show limited neutralizing and variable protective activity, leaving their contribution to antiviral immunity unclear. Building on our previous mapping of evolutionarily conserved spike coldspots, we isolated human monoclonal antibodies targeting four conserved epitopes in the spike S2 domain: the internal fusion peptide (iFP), the central helix (CH), the connector domain (CD), and a membrane-proximal epitope in the heptad repeat 2 that we term the lower stalk (LS). A crystal structure of an LS-directed antibody defined a previously unresolved mode of antibody recognition of this membrane-proximal epitope, while cryogenic electron microscopy (cryo-EM) structures revealed that genetically diverse CH-specific antibodies use distinct binding modes to converge on conserved features of the prefusion S2 apex. Despite minimal neutralizing activity, CH- and LS-directed antibodies exhibited distinct antiviral functions. LS-directed antibodies mediated Fc{gamma} receptor-dependent effector activity in vitro, whereas the broadly reactive CH-directed antibody ch.007 lacked detectable antibody-dependent cellular cytotoxicity (ADCC) or cellular phagocytosis (ADCP) activity yet protected mice from lethal SARS-CoV-2 MA10 challenge, with protection abrogated by Fc{gamma} receptor-silencing mutations. Together, these findings expand the genetic, structural and functional landscape of human antibody responses to conserved coronavirus S2 epitopes and demonstrate that CH-directed antibodies can contribute to protective immunity through Fc-dependent mechanisms not predicted by in vitro neutralization or conventional in vitro Fc effector assays.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.14.26362989v1?rss=1">
<title>
<![CDATA[
Effectiveness of 2025 bi-annual COVID-19 vaccination campaigns against hospitalisation in England 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.14.26362989v1?rss=1"
</link>
<dc:creator>Abdul Aziz, N.</dc:creator>
<dc:creator>Allen, A.</dc:creator>
<dc:creator>Andrews, N.</dc:creator>
<dc:date>2026-09-15</dc:date>
<dc:identifier>doi:10.64898/2026.09.14.26362989</dc:identifier>
<dc:title><![CDATA[Effectiveness of 2025 bi-annual COVID-19 vaccination campaigns against hospitalisation in England]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-15</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
BackgroundIn 2025, COVID-19 vaccination programmes in England targeted adults aged [&ge;]75 years and immunosuppressed individuals, with JN.1-based vaccines offered in spring and KP.2-based vaccines offered in autumn. This study evaluated vaccine effectiveness (VE) against COVID-19 hospitalisation following these campaigns and assessed VE in immunosuppressed populations.

MethodsVE against COVID-19 hospitalisation in adults aged [&ge;]75 years following the 2025 spring JN.1 and autumn KP.2 vaccination campaigns was estimated using a test-negative case-control design. Logistic regression was used to calculate VE among eligible hospitalised individuals, adjusting for covariates. Manufacturer-specific analyses were performed for the spring 2025 campaign. VE in immunosuppressed and non-immunosuppressed adults aged [&ge;]75 years was assessed by pooling estimates from the autumn 2024 and spring and autumn 2025 campaigns using fixed-effects meta-analysis.

ResultsSpring 2025 JN.1 vaccines conferred moderate protection, peaking at 55% (95%CI: 45-62%) within 5-9 weeks and declining to 17% (95%CI: -18-42%) from 35 weeks onwards. Autumn 2025 KP.2 VE peaked at 48% (95%CI: 34-59%) at 5-9 weeks, with follow-up needed to assess long-term protection. No significant differences were observed between manufacturers in the spring campaign. VE following autumn KP.2 vaccination was lower among individuals who received a spring JN.1 vaccine. When assessed across three campaigns, there was some evidence that VE was lower in individuals with immunosuppression than those without.

ConclusionThe 2025 COVID-19 vaccination programmes in England provided moderate protection against COVID-19 hospitalisation in adults aged [&ge;]75 years, with protection waning over time. The findings support the continued benefit of seasonal vaccination in high-risk groups, including immunosuppressed individuals.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.14.26363077v1?rss=1">
<title>
<![CDATA[
Separating the effects of immune waning and viral evolution on COVID-19 vaccine effectiveness reveals improved effectiveness of updated vaccines 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.14.26363077v1?rss=1"
</link>
<dc:creator>Jin, W.</dc:creator>
<dc:creator>Mitchell, A.</dc:creator>
<dc:creator>Stadler, E.</dc:creator>
<dc:creator>Foster, C. S. P.</dc:creator>
<dc:creator>Schlub, T. E.</dc:creator>
<dc:creator>Davenport, M. P.</dc:creator>
<dc:creator>Cromer, D. P.</dc:creator>
<dc:date>2026-09-15</dc:date>
<dc:identifier>doi:10.64898/2026.09.14.26363077</dc:identifier>
<dc:title><![CDATA[Separating the effects of immune waning and viral evolution on COVID-19 vaccine effectiveness reveals improved effectiveness of updated vaccines]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-15</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
The continued evolution of SARS-CoV-2 has led to regular updates of the COVID-19 vaccine immunogen. However, the exact benefits of these updates for vaccine effectiveness in a real world context are difficult to evaluate. We performed a comprehensive meta-analysis of booster vaccine effectiveness in studies identified through the ViewHub systematic review. We integrated evidence from 44 studies reporting on effectiveness of mRNA booster vaccines containing XBB.1.5, JN.1 and KP.2 immunogens to assess the combined impact of booster immunogen, time since vaccination and calendar time at which a study was conducted. We estimate that the relative risk of severe disease increases by 9% [95%CI 7.4-10.5] each month following booster administration, likely due to antibody waning, and by an additional 2.4% [95%CI 1.2-3.6] for each calendar month, likely due to antigenic drift. Our findings show that COVID-19 booster vaccine effectiveness declines both with time after vaccination as well as calendar time since the vaccine immunogen emerged. This reinforces the need for regularly and timely vaccine immunogen updates.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.09.12.751050v1?rss=1">
<title>
<![CDATA[
Host soluble inositol phosphate signaling promotes coronavirus replication 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.09.12.751050v1?rss=1"
</link>
<dc:creator>Shats, I.</dc:creator>
<dc:creator>Wang, H.</dc:creator>
<dc:creator>Zhou, Y.</dc:creator>
<dc:creator>Gu, C.</dc:creator>
<dc:creator>Carr, A.</dc:creator>
<dc:creator>Guardia, C. M.</dc:creator>
<dc:creator>Shears, S.</dc:creator>
<dc:creator>Stanley, R. E.</dc:creator>
<dc:creator>Zhang, Q.</dc:creator>
<dc:creator>Blind, R.</dc:creator>
<dc:creator>Wang, X.</dc:creator>
<dc:creator>Li, X.</dc:creator>
<dc:date>2026-09-15</dc:date>
<dc:identifier>doi:10.64898/2026.09.12.751050</dc:identifier>
<dc:title><![CDATA[Host soluble inositol phosphate signaling promotes coronavirus replication]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-15</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Coronaviruses rely extensively on host pathways for replication, making host-directed therapies an attractive strategy for broad-spectrum antivirals with reduced risk of viral resistance. Here we identify the host soluble inositol phosphate pathway as a previously unrecognized dependency for coronavirus infection. Genetic or pharmacologic inhibition of several kinases in this pathway markedly suppresses replication of both alpha- and betacoronaviruses, while increasing pathway activity promotes viral replication. We developed UNC7844, a potent multi-target inhibitor of these kinases, which reduces coronavirus replication by more than four orders of magnitude in cultured cells and suppresses coronavirus infection in mice. Mechanistically, UNC7844 suppresses inositol (pyro)phosphates production, disrupts phosphoinositide homeostasis, and impairs late endosomal dynamics, blocking early post-entry steps required for viral genome release and replication. Together, our findings establish the soluble inositol (pyro)phosphate pathway as an important regulator of coronavirus infection and highlight its inhibition as a promising host-directed antiviral strategy.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.09.12.750390v1?rss=1">
<title>
<![CDATA[
A rational design strategy and validation for protease-resistant fusion-inhibitor antiviral peptides 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.09.12.750390v1?rss=1"
</link>
<dc:creator>Yang, K.</dc:creator>
<dc:creator>Wang, C.</dc:creator>
<dc:creator>Topi, F.</dc:creator>
<dc:creator>Muratcioglu, S.</dc:creator>
<dc:creator>Kant, R.</dc:creator>
<dc:creator>Strandin, T.</dc:creator>
<dc:creator>Bong, Y. T.</dc:creator>
<dc:creator>Kareinen, L.</dc:creator>
<dc:creator>Mäki, S.</dc:creator>
<dc:creator>Saber, S. H.</dc:creator>
<dc:creator>Binder, T.</dc:creator>
<dc:creator>Sironen, T.</dc:creator>
<dc:creator>Subramanian, S.</dc:creator>
<dc:creator>White, K. I.</dc:creator>
<dc:creator>Pfuetzner, R.</dc:creator>
<dc:creator>Esquivies, L.</dc:creator>
<dc:creator>Vapalahti, O.</dc:creator>
<dc:creator>Joensuu, M.</dc:creator>
<dc:creator>Kuriyan, J.</dc:creator>
<dc:creator>Hepojoki, J.</dc:creator>
<dc:creator>Balistreri, G.</dc:creator>
<dc:creator>Brunger, A. T.</dc:creator>
<dc:date>2026-09-15</dc:date>
<dc:identifier>doi:10.64898/2026.09.12.750390</dc:identifier>
<dc:title><![CDATA[A rational design strategy and validation for protease-resistant fusion-inhibitor antiviral peptides]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-15</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Peptide-based fusion inhibitors are promising pharmaceuticals in the fight against enveloped viruses relying on membrane fusion for host infection. However, peptide therapeutic applications have long been hindered by their poor stability in vivo. Here, we discovered that peptide inhibitors with the wildtype sequence of the heptad repeat 2 (HR2) domain of the SARS-CoV-2 spike protein are efficiently cleaved by Transmembrane Protease, Serine 2 (TMPRSS2), a key protease involved in the SARS-CoV-2 virus-cell fusion pathway. We then identified the corresponding cleavage sites and designed three protease-resistant peptides using ranking based on deep mutational scanning and natural occurrence. The three candidates all exhibit inhibitory activity in a cell-cell fusion assay. A high-resolution cryo-EM structure of the top candidate, HR2-NHN, bound to its HR1 target reveals the molecular basis for its potent activity. The top candidate of the cell-based screening assay significantly improved efficacy relative to the wildtype peptide when administered 12 h before infection in both an authentic virus-cell infection assay and a mouse assay. More broadly, our results suggest that the design strategies for protease-resistant peptides could be applied to a broad spectrum of other enveloped viruses and pave the way for the development of safe, prophylactic antivirals that can be administered before exposure.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.09.11.750491v1?rss=1">
<title>
<![CDATA[
Multi-omics reveals a monocyte-macrophage-fibroblast axis in post-COVID-19 fibroinflammatory lung remodelling 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.09.11.750491v1?rss=1"
</link>
<dc:creator>Mehta, P.</dc:creator>
<dc:creator>Mawer, C. M. A.</dc:creator>
<dc:creator>Beattie, G.</dc:creator>
<dc:creator>Smith, D. J. F.</dc:creator>
<dc:creator>Nikola, F.</dc:creator>
<dc:creator>Selway-Clarke, H.</dc:creator>
<dc:creator>Zhao, A. Y.</dc:creator>
<dc:creator>Adams, T. S.</dc:creator>
<dc:creator>Kunzemann-Martinez, A.</dc:creator>
<dc:creator>Stanel, S. C.</dc:creator>
<dc:creator>Worlock, K. B.</dc:creator>
<dc:creator>Yoshida, M.</dc:creator>
<dc:creator>Walters, R.</dc:creator>
<dc:creator>Goldsworthy, S.</dc:creator>
<dc:creator>Uddin, I.</dc:creator>
<dc:creator>Barnes, J. L.</dc:creator>
<dc:creator>Rockett, G. J.</dc:creator>
<dc:creator>Nikolic, M. Z.</dc:creator>
<dc:creator>Piazza, P.</dc:creator>
<dc:creator>Plate, M.</dc:creator>
<dc:creator>Stewart, I.</dc:creator>
<dc:creator>Porter, J. C.</dc:creator>
<dc:creator>Nair, A.</dc:creator>
<dc:creator>Jacob, J.</dc:creator>
<dc:creator>Yan, X.</dc:creator>
<dc:creator>Kaminski, N.</dc:creator>
<dc:creator>Alhendi, A. S. N.</dc:creator>
<dc:creator>Chambers, R. C.</dc:creator>
<dc:date>2026-09-14</dc:date>
<dc:identifier>doi:10.64898/2026.09.11.750491</dc:identifier>
<dc:title><![CDATA[Multi-omics reveals a monocyte-macrophage-fibroblast axis in post-COVID-19 fibroinflammatory lung remodelling]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-14</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Post-COVID-19 residual lung abnormalities (RLA) are associated with persistent respiratory symptoms and radiological changes, yet the underlying mechanisms remain unclear. We performed integrated multi-omic profiling of paired bronchoalveolar lavage and blood samples from patients with post-COVID-19 RLA and healthy controls, combining single-cell RNA sequencing, CITE-seq, single-cell T cell receptor sequencing, bronchoalveolar lavage fluid proteomics and functional fibroblast assays. In post-COVID-19 RLA lungs, we identified an increased abundance of profibrotic SPP1hi monocyte-derived alveolar macrophages, arising from an expanded circulating HLA-DRlowCD163+PDE4Dhi classical monocyte progenitor population, supporting a blood-lung myeloid axis. Cell-cell communication modelling positioned macrophages as central hubs of immune-stromal crosstalk, promoting monocyte recruitment with profibrotic priming, and fibroblast activation. Proteomic analysis of bronchoalveolar lavage fluid from post-COVID-19 RLA and idiopathic pulmonary fibrosis, compared with healthy controls, revealed shared and distinct signatures. These alveolar proteins in post-COVID-19 RLA were predominantly attributed to myeloid cells and predicted to engage fibroblast receptors. Bronchoalveolar lavage fluid induced fibroblast proliferation, differentiation and collagen deposition in vitro, with proliferation attenuated by the antifibrotic drug nintedanib. We also identified compartment-specific lymphoid dysregulation, including depletion of mucosal-associated invariant T (MAIT) cells in both the lung and blood, decreased natural killer (NK) cells with oligoclonal T cell expansion in the lung, and expansion of regulatory and cytotoxic T cells in the blood. These findings support a persistent monocyte-macrophage-fibroblast axis linking immune dysregulation to fibroproliferative remodelling after COVID-19 and highlights candidate therapeutic targets for post-viral lung fibrosis. We provide a publicly available atlas (on publication).
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.09.10.750645v1?rss=1">
<title>
<![CDATA[
Antibody evasion and receptor binding of SARS-CoV-2 RW.1.1 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.09.10.750645v1?rss=1"
</link>
<dc:creator>Daniel, K.</dc:creator>
<dc:creator>Hong, H.</dc:creator>
<dc:creator>Huang, C.-Y.</dc:creator>
<dc:creator>Gordon, A.</dc:creator>
<dc:creator>Guo, Y.</dc:creator>
<dc:creator>Ho, D. D.</dc:creator>
<dc:creator>Mellis, I. A.</dc:creator>
<dc:date>2026-09-14</dc:date>
<dc:identifier>doi:10.64898/2026.09.10.750645</dc:identifier>
<dc:title><![CDATA[Antibody evasion and receptor binding of SARS-CoV-2 RW.1.1]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-14</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
The continued evolution of SARS-CoV-2 is shaped by changes in antibody evasion and receptor engagement that influence viral fitness. RW.1.1, an emerging descendant of XFJ carrying five additional spike substitutions, has recently increased in frequency in North America. Here, we characterized the serum antibody evasion, monoclonal antibody sensitivity, and ACE2 receptor engagement of RW.1.1. Pseudovirus neutralization assays using sera from adults showed that RW.1.1 was not more resistant to serum neutralization than currently circulating variants, with neutralizing titers comparable to XFG, BA.3.2.2, and NB.1.8.1 in the tested cohort. Neutralization of RW.1.1 also did not differ significantly among adults, children, and infants and toddlers. Despite the absence of increased overall serum antibody resistance, monoclonal antibody neutralization assays revealed substantial resistance to several RBD class 1 antibodies and increased resistance to a subset of class 1/4 antibodies. Moreover, RW.1.1 exhibited reduced ACE2 receptor engagement compared with XFG, which itself has reduced receptor engagement relative to earlier JN.1 subvariants. Thus, RW.1.1 has continued to expand despite a further reduction in receptor engagement and without a substantial increase in overall serum antibody evasion. These findings suggest that the fitness of emerging SARS-CoV-2 variants may depend not only on the magnitude of antibody evasion but also on the specific components of the polyclonal antibody response that are evaded, highlighting the increasingly complex interplay between population immunity and receptor engagement in shaping SARS-CoV-2 evolution.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.09.11.750997v1?rss=1">
<title>
<![CDATA[
Breathlessness catastrophising after COVID-19 involves both interoceptive and visceromotor connectivity 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.09.11.750997v1?rss=1"
</link>
<dc:creator>Qiu, L.</dc:creator>
<dc:creator>Raman, B.</dc:creator>
<dc:creator>Cassar, M.</dc:creator>
<dc:creator>Fraser, E.</dc:creator>
<dc:creator>Atkinson, L. Z.</dc:creator>
<dc:creator>Clare, S.</dc:creator>
<dc:creator>Clarke, W. T.</dc:creator>
<dc:creator>Neubauer, S.</dc:creator>
<dc:creator>Davies, H. E.</dc:creator>
<dc:creator>Harrison, N. A.</dc:creator>
<dc:creator>Evans, C. J.</dc:creator>
<dc:creator>Ezra, M.</dc:creator>
<dc:creator>Pattinson, K. T. S.</dc:creator>
<dc:date>2026-09-14</dc:date>
<dc:identifier>doi:10.64898/2026.09.11.750997</dc:identifier>
<dc:title><![CDATA[Breathlessness catastrophising after COVID-19 involves both interoceptive and visceromotor connectivity]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-14</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Persistent breathlessness is common after COVID-19, yet its severity typically correlates weakly with objective clinical measures. This discordance is often attributed to perceptual inference amplified by anxiety. Because breathing involves a closed perception-action loop, breathlessness may also reflect alterations in interoceptive and visceromotor pathways. We acquired 7-tesla resting-state functional MRI in 53 post-COVID patients with varying breathlessness and estimated functional connectivity across 18 pre-defined interoceptive and visceromotor regions. Linear regression identified two connections associated with breathlessness catastrophising: reduced dorsal periaqueductal grey-posterior insula (dPAG-PoI1) and increased basolateral amygdala-dorsal anterior cingulate (BLA-dACC) connectivity. The dPAG-PoI1 association was stronger in patients who had required mechanical ventilation, whereas the BLA-dACC association was attenuated at higher generalised anxiety. These findings are consistent with two potentially separable contributions to symptom burden: weakened interoceptive signalling between brainstem and sensory cortex, and heightened visceromotor influence of threat processing on autonomic control, rather than anxiety-driven misperception alone.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.09.10.750728v1?rss=1">
<title>
<![CDATA[
Real-time accessible phylogenetics for every highly sampled virus 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.09.10.750728v1?rss=1"
</link>
<dc:creator>Hinrichs, A. S.</dc:creator>
<dc:creator>Karim, L. M.</dc:creator>
<dc:creator>Turakhia, Y.</dc:creator>
<dc:creator>Sanderson, T.</dc:creator>
<dc:creator>Corbett-Detig, R.</dc:creator>
<dc:date>2026-09-11</dc:date>
<dc:identifier>doi:10.64898/2026.09.10.750728</dc:identifier>
<dc:title><![CDATA[Real-time accessible phylogenetics for every highly sampled virus]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-11</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
The scale of viral genome sequencing has outpaced the phylogenetic tools traditionally used to analyze it, as highlighted by the COVID-19 pandemic. We present viral_usher, a unified framework for scalable viral phylogenetics built on UShER. viral_usher is a containerized command-line tool that constructs mutation-annotated trees directly from public sequence repositories with minimal user input, building phylogenies of tens of thousands of genomes in minutes. Applying it across the International Nucleotide Sequence Database Collaboration, we assembled viral_usher_trees, a repository of 446 phylogenies spanning 163 well-sequenced viral species, rebuilt automatically monthly as new genomes are deposited. We extended Taxonium from a tree viewer into a web platform supporting in-browser phylogenetic placement and de novo tree construction, so that users can upload sequences and contextualize them within global phylogenies without local computational infrastructure. Because every tree is built by the same procedure, the repository enables comparative analyses across the breadth of viral diversity. We demonstrate the utility of this resource by asking what factors shape viral mutation spectra. We found that replication machinery, captured as Baltimore class, explains 46% of the variance across 162 viral genomes, while host taxon and envelope status together explain under 5%. These resources provide an extensible platform for real-time genomic epidemiology and for comparative evolutionary analysis across viral pathogens. Resources and code are freely available at https://taxonium.org/, https://github.com/lilymaryam/spectrum_analysis, https://github.com/AngieHinrichs/viral_usher_trees, and https://github.com/AngieHinrichs/viral_usher.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.09.10.750593v1?rss=1">
<title>
<![CDATA[
Hantavirus mutagenesis is impacted by mutagens and host antiviral proteins 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.09.10.750593v1?rss=1"
</link>
<dc:creator>Ruis, C.</dc:creator>
<dc:creator>Parkhill, J.</dc:creator>
<dc:creator>Floto, R. A.</dc:creator>
<dc:date>2026-09-11</dc:date>
<dc:identifier>doi:10.64898/2026.09.10.750593</dc:identifier>
<dc:title><![CDATA[Hantavirus mutagenesis is impacted by mutagens and host antiviral proteins]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-11</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Hantaviruses are emerging zoonotic viruses that infect humans with high fatality rates. We currently have a poor understanding of the processes that contribute to hantavirus mutagenesis and therefore the potential for viral adaptation. To understand the drivers of mutations in hantaviruses, we calculated and compared mutational spectra across 14 divergent hantavirus species. We found that mutagens that are conserved across host species have a major impact on hantaviruses mutagenesis, contributing to at least six of the 12 possible mutation types. We found differences in mutational signatures across hantaviruses, some of which may be due to variation in host mutagen levels that are known to influence somatic mutations. However, we could find no evidence for differential mutational signatures between viruses associated with distinct diseases in humans and no evidence of tissue tropism differences between reservoir hosts. Using a novel method to quantify the impact of ZAP-mediated selection, we found that ZAP greatly influences mutational patterns in transition mutation types across hantaviruses. We also find evidence that APOBEC family proteins drive mutagenesis in all hantaviruses, with the likely exception of Nova virus. Our results therefore provide strong support that mutagens and host antiviral proteins are major contributors to hantavirus mutagenesis, thereby generating the genetic diversity necessary for viral adaptation.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.08.26362558v1?rss=1">
<title>
<![CDATA[
A comparison of two forecasting models for COVID-19 hospitalizations using wastewater concentration data 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.08.26362558v1?rss=1"
</link>
<dc:creator>Keyel, A.</dc:creator>
<dc:creator>Hill, D. T.</dc:creator>
<dc:creator>Johnson, K. E.</dc:creator>
<dc:creator>Lang, D.</dc:creator>
<dc:creator>Rosenberg, E. S.</dc:creator>
<dc:creator>Bush, K.</dc:creator>
<dc:creator>Larsen, D. A.</dc:creator>
<dc:date>2026-09-10</dc:date>
<dc:identifier>doi:10.64898/2026.09.08.26362558</dc:identifier>
<dc:title><![CDATA[A comparison of two forecasting models for COVID-19 hospitalizations using wastewater concentration data]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-10</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Wastewater surveillance has become a prominent part of public health efforts to track circulating pathogens and has been incorporated into disease forecasting models. We compared two recent wastewater forecasting models for forecasting COVID-19 hospitalizations using SARS-CoV-2 concentrations in wastewater: a generalized linear mixed model (GLMM) and a Bayesian mechanistic model known as wwinference. We retrospectively produced 1-week ahead forecasts using these two conceptually different models across 10 regions in New York state, from September 2022 - mid-April 2024. We compared the performance of forecasts produced from the two models fit with wastewater and clinical data to a version of each model fit to only clinical data. Models were scored against observations using Continuous Ranked Probability Scores for each forecast (n = 363 forecasts). Of the two models, the GLMM showed improved forecast performance across space and time when evaluated on a natural scale compared to the wwinference model, but no significant difference in forecast performance was found on a log-scale, which evaluates the relative rather than absolute error. Consequently, either model could be used to forecast COVID-19 hospitalizations. Including wastewater concentrations in these models at these spatial and temporal scales did not provide additional forecasting benefit beyond just clinical data. The performance of a wastewater-only model relative to simple null models; however, demonstrates that there is a clear forecasting signal present in wastewater, thus we think the lack of change is likely due to the strong signal from the clinical measures included in the model at this spatial and temporal scale.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.06.26362161v1?rss=1">
<title>
<![CDATA[
Mental health before, during, and after COVID-19 (through 2025) in boys, girls, and gender-diverse youth 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.06.26362161v1?rss=1"
</link>
<dc:creator>Kiviruusu, O.</dc:creator>
<dc:creator>Therman, S.</dc:creator>
<dc:creator>Lehtonen, J.</dc:creator>
<dc:creator>Ystrom, E.</dc:creator>
<dc:creator>Butwicka, A.</dc:creator>
<dc:creator>Halldorsdottir, T.</dc:creator>
<dc:creator>Ask, H.</dc:creator>
<dc:creator>Suvisaari, J.</dc:creator>
<dc:date>2026-09-10</dc:date>
<dc:identifier>doi:10.64898/2026.09.06.26362161</dc:identifier>
<dc:title><![CDATA[Mental health before, during, and after COVID-19 (through 2025) in boys, girls, and gender-diverse youth]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-10</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
BackgroundAdolescent mental health after the COVID-19 pandemic has been a major public health concern. Studies covering the post-pandemic period remain scarce and rarely include gender-diverse youth. We examined trends in mental health among cisgender, transgender, and nonbinary youth during the pandemic and through 2025.

MethodsParticipants (N=636,201) were adolescents in grades 8-11 from the Finnish School Health Promotion study between 2019 and 2025, a repeated cross-sectional classroom survey.

Validated questionnaires were used to assess clinical levels of depressive, generalized anxiety and social anxiety symptoms, as well as mental well-being.

ResultsIn 2025 there were 81,145 (48.6%) cisgender girls, 1137 (0.7%) transgender boys, 78,898 (47.2%) cisgender boys, 449 (0.3%) transgender girls, and 4658 (2.8%) nonbinary youth. Clinically significant depressive and generalized anxiety symptoms remained more prevalent in 2025 (reference) compared with pre-pandemic levels across all groups (ORs for 2019, 0.48-0.86; p<0.01). Compared with other groups, symptoms were most prevalent among transgender boys and nonbinary youth. Among cisgender youth, generalized anxiety symptoms increased across the post-pandemic period (ORs for 2021 and 2023, 0.81-0.95; p<0.0001). Nonbinary youth were the only group to show a recovery pattern in depressive, generalized anxiety, and social anxiety symptoms (ORs for 2021, 1.36-1.52; p<0.0001) and demonstrated improved mental well-being after the pandemic (beta for 2021, -0.68; p<0.0001).

ConclusionsThe results indicate that the elevated levels of mental health problems among adolescents associated with the COVID-19 pandemic have not subsided. They also reveal persistent disparities by gender identity and call for targeted policy action.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.09.26362611v1?rss=1">
<title>
<![CDATA[
Pre-Infection Mental Health, but Not Brain Volumetry, Predicts Risk of Post-COVID Condition: A Population-Based Cohort Study in the German National Cohort (NAKO) 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.09.26362611v1?rss=1"
</link>
<dc:creator>Flint, C.</dc:creator>
<dc:creator>Spreckelsen, C.</dc:creator>
<dc:creator>Otto, C.</dc:creator>
<dc:creator>Mikolajczyk, R.</dc:creator>
<dc:creator>Frost, J.</dc:creator>
<dc:creator>Claass, L. V.</dc:creator>
<dc:creator>Fasshauer, J. M.</dc:creator>
<dc:creator>Scholz, M.</dc:creator>
<dc:creator>Buschmann, L.</dc:creator>
<dc:creator>Rübsamen, N.</dc:creator>
<dc:creator>Wright, M. N.</dc:creator>
<dc:creator>Burk, L.</dc:creator>
<dc:creator>Bamberg, F.</dc:creator>
<dc:creator>Schlett, C. L.</dc:creator>
<dc:creator>Niendorf, T.</dc:creator>
<dc:creator>Forsting, M.</dc:creator>
<dc:creator>Li, Y.</dc:creator>
<dc:creator>Steindorf, K.</dc:creator>
<dc:creator>Karrasch, S.</dc:creator>
<dc:creator>Leitzmann, M.</dc:creator>
<dc:creator>Haug, S.</dc:creator>
<dc:creator>Bärnighausen, T. W.</dc:creator>
<dc:creator>Schmidt, B.</dc:creator>
<dc:creator>Harries, M.</dc:creator>
<dc:creator>Melhorn, V.</dc:creator>
<dc:creator>Krist, L.</dc:creator>
<dc:creator>Keil, T.</dc:creator>
<dc:creator>Peters, A.</dc:creator>
<dc:creator>Opel, N.</dc:creator>
<dc:date>2026-09-10</dc:date>
<dc:identifier>doi:10.64898/2026.09.09.26362611</dc:identifier>
<dc:title><![CDATA[Pre-Infection Mental Health, but Not Brain Volumetry, Predicts Risk of Post-COVID Condition: A Population-Based Cohort Study in the German National Cohort (NAKO)]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-10</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
BackgroundPost-COVID Condition (PCC) affected 10-30% of individuals after SARS-CoV-2 infection, and pre-infection predictors of who goes on to develop it are not well established. We compared pre-infection structural brain variation and baseline psychiatric phenotype as candidate predictors of PCC within a common multi-modal framework in the German National Cohort (NAKO). Both are candidate "first hits" under the second-hit hypothesis, which motivates the comparison; this is a prediction study, not a test of that hypothesis.

MethodsIn 8,464 SARS-CoV-2-infected NAKO neuroimaging participants, of whom 2,304 (27.2%) met PCC criteria (weighted post-COVID syndrome (PCS) score > 10.75) and the rest were symptom-free controls, ten pre-infection modalities (T1-weighted volumetric brain MRI across six parcellations, baseline mental health (PHQ-9, GAD-7), demographics, and seven further biomedical and socioeconomic domains) entered a stacked ensemble with 10 x 5 nested cross-validation (primary metric: the area under the precision-recall curve, PR-AUC). Pre-specified analyses assessed transportability to a non-imaging cohort and robustness to the mental-health symptom trajectory and to unmeasured confounding. SARS-CoV-2 infection status and the PCC outcome were ascertained by self-report; no clinically confirmed diagnoses were available.

ResultsBaseline mental health, assessed 3-8 years before infection, was the strongest predictor (38.0% of feature importance; standalone ROC-AUC = 0.640), whereas all six brain-MRI parcellations performed at or near chance (ROC-AUC 0.496-0.516). The multi-modal model achieved moderate, well-calibrated discrimination (ROC-AUC = 0.665, 95% CI 0.653-0.677; PR-AUC = 0.413, 0.392-0.434; ECE = 0.013). A four-modality non-imaging version, applied without retraining to NAKO participants without MRI, retained discrimination (ROC-AUC = 0.660, 0.654-0.665), meeting all three pre-specified equivalence criteria, the calibration intercept narrowly. The baseline mental-health odds ratio was 2.06 (1.83-2.32; E-value 2.66) and essentially unchanged under an alternative control definition (2.07); adjusting for the full mental-health symptom trajectory reduced it to a conservative lower bound of 1.38 (1.20-1.58) that remained independently significant. Baseline mental health did not predict objectively measured hyposmia in participants screened before their infection (0.89) while predicting self-reported smell loss in the same participants (1.92).

ConclusionsBaseline mental health years before infection is the strongest pre-infection predictor of PCC among the infected, and the association held across the pre-specified sensitivity analyses. Whether it acts specifically on COVID-19 sequelae is a separate question this design cannot answer, and the indirect evidence points away from specificity: the association is undiminished after mild infection but absent among the hospitalized, and baseline mental health predicts current mental-health symptom load slightly less strongly in infected than in non-infected participants. The volumetric structural candidate is not supported: prepandemic T1-weighted volumetry carried no predictive signal in this single neuroimaging cohort. Risk stratification may benefit from incorporating baseline psychiatric phenotype; whether treating it reduces PCC incidence requires interventional study.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.08.26362589v1?rss=1">
<title>
<![CDATA[
Clinico-Epidemiological Characteristics, Hospital Care Interventions, and Clinical Outcomes of Patients with SARS-CoV-2 in Nepal: The Mediating Role of Age 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.08.26362589v1?rss=1"
</link>
<dc:creator>Neupane, M. S.</dc:creator>
<dc:creator>Hassan, H. C.</dc:creator>
<dc:creator>Uranw, S.</dc:creator>
<dc:creator>Mehta, R. K.</dc:creator>
<dc:date>2026-09-10</dc:date>
<dc:identifier>doi:10.64898/2026.09.08.26362589</dc:identifier>
<dc:title><![CDATA[Clinico-Epidemiological Characteristics, Hospital Care Interventions, and Clinical Outcomes of Patients with SARS-CoV-2 in Nepal: The Mediating Role of Age]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-10</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Coronavirus disease 2019 (COVID-19) outcomes among hospitalized patients are influenced by demographic characteristics, clinical presentation, and requirements for hospital-based care. Age is an important determinant of COVID-19 outcomes; however, its statistical role in the relationships between hospital-care interventions and survival has received limited attention in resource-constrained settings. This prospective observational analytical study assessed clinico- epidemiological characteristics, hospital-care interventions, clinical outcomes, and the mediating role of patient age group among adults hospitalized with SARS-CoV-2 infection in Nepal. A total of 348 adults with laboratory-confirmed SARS-CoV-2 infection were consecutively recruited at a tertiary care teaching hospital from March 30, 2022 to June 30, 2023 and followed until discharge or in-hospital death. Associations with survival were examined using Chi-square/Fishers exact tests and multivariable binary logistic regression. Mediation analyses were performed using Hayes PROCESS Macro version 4.2, Model 4, with 5,000 bias-corrected bootstrap samples. Of 348 participants, 277 (79.6%) survived and 71 (20.4%) died. Older adults constituted 41.1% of participants. Hypertension (29.3%) and diabetes mellitus (23.0%) were the most common comorbidities, while fever (81.0%), cough (75.9%), and dyspnea (48.0%) were the predominant symptoms. Age group and dyspnea remained independently associated with hospital survival in multivariable analysis. Steroid therapy, oxygen therapy, and respiratory support were significantly associated with survival in unadjusted analyses. Age group partially statistically mediated the steroid therapy-survival relationship (indirect effect = -0.1371; 95% bootstrap CI: -0.3053 to -0.0154), while the direct effect remained significant (c' = -2.8670; p = 0.0049). No significant age-mediated indirect effects were observed for oxygen therapy or respiratory support. These findings highlight the importance of age and respiratory presentation in hospital outcomes and suggest age-related heterogeneity in the steroid therapy-survival relationship. The mediation finding should be interpreted as statistical rather than causal because age precedes treatment exposure.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.07.26362439v1?rss=1">
<title>
<![CDATA[
Risk of acute gastroenteritis following COVID-19 exposure: a retrospective population-based analysis conducted in England 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.07.26362439v1?rss=1"
</link>
<dc:creator>Hawkings, M. J.</dc:creator>
<dc:creator>Hughes, D. M.</dc:creator>
<dc:creator>Elliot, A. J.</dc:creator>
<dc:creator>Buchan, I. E.</dc:creator>
<dc:creator>Hungerford, D.</dc:creator>
<dc:date>2026-09-09</dc:date>
<dc:identifier>doi:10.64898/2026.09.07.26362439</dc:identifier>
<dc:title><![CDATA[Risk of acute gastroenteritis following COVID-19 exposure: a retrospective population-based analysis conducted in England]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-09</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
BackgroundSevere COVID-19 is associated with immune dysregulation, microbiome disruption, and increased vulnerability to secondary infections. However, the longer-term risk of acute gastroenteritis (AGE) following COVID-19 remains poorly studied. We compared AGE incidence among community-managed and hospitalised COVID-19 patients with test-negative controls and hospitalised sepsis patients.

MethodsWe conducted a retrospective cohort study using electronic healthcare data. Patients with a recorded SARS-CoV-2 PCR test between 01 March 2020 and 01 March 2022 were allocated to test-negative, community COVID-19, or hospitalised COVID-19 cohorts. A hospitalised sepsis cohort was assembled for an age-, sex- and time-matched analysis. AGE incidence rates were calculated for the two years before enrolment and during follow-up. Negative binomial regression and conditional Poisson models estimated incidence rate ratios (IRRs) adjusting for demographic and clinical covariates.

ResultsAmong 788 103 patients, AGE incidence in the pre-pandemic period was higher among individuals later hospitalised with COVID-19 or sepsis compared with community cases. During follow-up, AGE incidence was slightly lower in community COVID-19 cases than test-negative controls (adjusted IRR 0{middle dot}88 [95% CI 0{middle dot}85-0{middle dot}92]), but substantially higher among hospitalised COVID-19 patients (IRR 5{middle dot}80 [95% CI: 5{middle dot}38-6{middle dot}25]). Matched analyses confirmed increased AGE rates compared with community controls (IRR 4{middle dot}63 [95% CI: 4{middle dot}15-5{middle dot}17]) and hospitalised sepsis controls (IRR 1{middle dot}41 [95% CI 1{middle dot}21-1{middle dot}64]).

ConclusionsCOVID-19 hospitalisation is associated with a marked increase in AGE risk after discharge, exceeding that associated with sepsis hospitalisation. By contrast, lower AGE rates in community COVID-19 cases likely reflect baseline differences rather than protective effects of infection. Overall, these findings demonstrate heightened post-discharge vulnerability to gastrointestinal illness after COVID-19 hospitalisation and support the need for improved follow-up and surveillance strategies.

FundingNational Institute for Health Research
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.09.08.749933v1?rss=1">
<title>
<![CDATA[
PhenoMapR: scalable mapping of sample phenotypes to single-cell, spatial, and bulk transcriptomics data 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.09.08.749933v1?rss=1"
</link>
<dc:creator>Benard, B. A.</dc:creator>
<dc:creator>Lalgudi, C. K.</dc:creator>
<dc:creator>Azizi, A.</dc:creator>
<dc:creator>Gentles, A. J.</dc:creator>
<dc:date>2026-09-09</dc:date>
<dc:identifier>doi:10.64898/2026.09.08.749933</dc:identifier>
<dc:title><![CDATA[PhenoMapR: scalable mapping of sample phenotypes to single-cell, spatial, and bulk transcriptomics data]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-09</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Single-cell and spatial transcriptomic studies often lack sufficient sample size to compute robust statistical associations between a sample-level phenotype and cell types or spatial locations. In contrast, lower resolution methods such as bulk gene expression profiling have been applied at scale in large, annotated datasets, providing reliable signatures for phenotype associations. We introduce PhenoMapR, a semi-supervised method designed to integrate the phenotypic rigor of large-scale bulk expression studies with the cellular and spatial granularity of single-cell and spatial transcriptomics. PhenoMapR achieves this by deriving and mapping bulk gene expression signatures onto cells and spatial locations in a computationally efficient and scalable manner. The framework is broadly applicable across biological contexts, supporting the mapping of binary, continuous, and survival phenotypes derived from bulk expression studies across transcriptomic data modalities. This enables the identification of biologically-relevant cellular populations and spatial niches for experimental validation and therapeutic intervention.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.03.26362130v1?rss=1">
<title>
<![CDATA[
The impact of COVID-19 pandemic on health service utilization among patients with chronic non-communicable diseases in Ghana 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.03.26362130v1?rss=1"
</link>
<dc:creator>Tannor, E. K.</dc:creator>
<dc:creator>Newton, S.</dc:creator>
<dc:creator>Busse, R.</dc:creator>
<dc:creator>Gatorwu, S.</dc:creator>
<dc:creator>Safo, J. K.</dc:creator>
<dc:creator>Adjei, R.</dc:creator>
<dc:creator>Amuasi, J.</dc:creator>
<dc:creator>Quentin, W.</dc:creator>
<dc:date>2026-09-08</dc:date>
<dc:identifier>doi:10.64898/2026.09.03.26362130</dc:identifier>
<dc:title><![CDATA[The impact of COVID-19 pandemic on health service utilization among patients with chronic non-communicable diseases in Ghana]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-08</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
BackgroundThe COVID-19 pandemic significantly disrupted health systems globally and in sub-Saharan Africa (SSA) leading to reduction of health service utilization (HSU). Patients with non- communicable diseases (NCDs) had increased morbidity and mortality during the COVID-19 pandemic. We sought to determine the changes and impact of the COVID-19 pandemic on HSU among patients with NCDs comparing an epicentre to a non-epicentre region in Ghana.

MethodsWe conducted a cross-sectional observational study of patients with NCD in the Ashanti and Northern regions in Ghana from 14th April 2024 to 31st July 2024. We distributed questionnaires to patients with NCD in selected facilities in the Northern and Ashanti regions of Ghana. The Andersens Behavioural Model was used as the conceptual framework to determine the factors affecting HSU. Multiple logistic regression was used to identify independent variables predicting reduction in HSU. P value of less than 0.05 was considered statistically significant.

ResultsThe study included 844 participants with NCDs equally sampled in the Ashanti and Northern regions of Ghana. The mean age of respondents was 61.4{+/-}11.6 years with 569(67%) females. Almost half 367 (43.5%) of all respondents reported COVID-19 led to a decrease in their HSU and over a third of respondents, 303(35.9%) missed their hospital appointments. The proportion of respondents reporting a decrease in HSU was significantly higher in the Northern region 276 (65.4%) than the Ashanti region 91 (21.6%), [p<0.001]. Reduction in HSU was associated with increasing age (aOR=0.97, 0.96 - 0.99, p<0.001), Northern region residence (aOR=9.60 CI 6.43 - 14.32, p<0.001), higher household income (aOR=1.36 CI 1.15-1.60, p<0.001), longer duration of NCD (aOR=1.03, CI 1.01 - 1.06, p=0.033) and possession of valid NHIS card (aOR=7.43, CI 2.44 - 22.57, p <0.001).

ConclusionThe COVID-19 pandemic led to reduction in HSU in Ghana. There was a significant reduction in NCDs in a non-epicentre region (Northern region) compared to the Ashanti region which was an epicenter region. Hence patients in non-epicentres should also be prioritized in pandemic situations.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.02.26362122v1?rss=1">
<title>
<![CDATA[
Early human capital, the COVID-19 food-insecurity shock, and adult mental health: a 22-year cohort study in Ethiopia, India, and Peru 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.02.26362122v1?rss=1"
</link>
<dc:creator>Diaz Flores, M. A.</dc:creator>
<dc:creator>Jimenez Rivera, W. M.</dc:creator>
<dc:creator>Pena Huaman, G. M.</dc:creator>
<dc:creator>Romero Molina, U.</dc:creator>
<dc:date>2026-09-08</dc:date>
<dc:identifier>doi:10.64898/2026.09.02.26362122</dc:identifier>
<dc:title><![CDATA[Early human capital, the COVID-19 food-insecurity shock, and adult mental health: a 22-year cohort study in Ethiopia, India, and Peru]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-08</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Mental disorders typically emerge before age 25, yet little is known about how childhood human capital and large economic shocks jointly shape mental health into adulthood in low-and middle-income countries (LMICs). We use seven rounds of the Young Lives study (2002-2024), which followed two birth cohorts in Ethiopia, India, Peru, and Vietnam, to examine (i) the long reach of early human capital, proxied by the height-for-age z-score in infancy; (ii) the medium-term association between household food insecurity during the COVID-19 pandemic and adult depressive (PHQ-8) and anxiety (GAD-7) symptoms measured at ages 22 and 29 in 2023-2024; and (iii) whether early human capital buffered the pandemic shock. We estimate value-added, latent-factor, dynamic panel, and mediation models with cluster-robust inference. Early height-for-age strongly predicts adult height (1.6 cm per standard deviation, p < 0.01) but not adult mental health or formal employment. Pandemic food insecurity predicts higher depressive (0.41 points, 0.12 standard deviations) and anxiety (0.41 points, 0.11 standard deviations) symptoms three to four years later (both p < 0.01); per step, the probability of clinically relevant anxiety (GAD-7 of 10 or more; base 7.6 percent) rises by 1.9 percentage points (p = 0.001) and of clinically relevant depression (PHQ-8 of 10 or more; base 5.6 percent) by 1.0 percentage point (p = 0.07). The gradient travels with the persistence of distress and of material hardship, is robust to attrition corrections and bounds, and its causal reading is explicitly bounded, since mental health was first measured during the pandemic itself. Exploratory analyses suggest the gradient differs across countries and may be larger in the older cohort, exposed at about age 26 rather than 19; these contrasts rest on few clusters and are not robust to multiple-comparison adjustment. Early human capital neither predicts adult mental health--a precise null of at most {+/-}0.03 standard deviations--nor moderates the gradient. Protecting household food security during aggregate shocks, especially for young adults, appears central to safeguarding mental health in LMICs.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.04.26362275v1?rss=1">
<title>
<![CDATA[
Association between ABO Blood Group and COVID-19 Pneumonia Severity: A Cross-Sectional Study from Ethiopia's First Designated COVID-19 Treatment Center 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.04.26362275v1?rss=1"
</link>
<dc:creator>Urgecha, E. B.</dc:creator>
<dc:creator>Tefera, F. A.</dc:creator>
<dc:creator>Alemu, Z. A.</dc:creator>
<dc:creator>Mekonen, S. T.</dc:creator>
<dc:creator>Orgecha, E. B.</dc:creator>
<dc:creator>Gidey, S. N.</dc:creator>
<dc:creator>Fissehatsion, F. A.</dc:creator>
<dc:date>2026-09-08</dc:date>
<dc:identifier>doi:10.64898/2026.09.04.26362275</dc:identifier>
<dc:title><![CDATA[Association between ABO Blood Group and COVID-19 Pneumonia Severity: A Cross-Sectional Study from Ethiopia's First Designated COVID-19 Treatment Center]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-08</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
BackgroundCoronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2, spreads rapidly and can cause severe acute respiratory failure; advanced age, chronic disease, and other comorbidities increase the risk of severe infection. By early 2022, more than 477 million cases and 6.11 million deaths had been reported globally. This study assessed the association between ABO blood group and severity of COVID-19 pneumonia among patients admitted to Eka Kotebe General Hospital, Addis Ababa, Ethiopia.

MethodsA hospital-based cross-sectional study was conducted using systematic random sampling; data were abstracted from patient records, and severity was modeled using ordinal logistic regression, with multicollinearity and the proportional odds assumption checked via the variance inflation factor and test of parallel lines, and model fit assessed by likelihood ratio chi-square and goodness-of-fit tests.

ResultsOf 355 patients included (100% response rate), 54.9% were male and 31.0% were older than 61 years (median age, 48 years; interquartile range, 33-65). Overall, 10.14% were asymptomatic, 24.79% had mild/moderate disease, 60.56% had severe disease, and 4.51% had critical disease. Pregnancy and presence of complications were significantly associated with severity (adjusted odds ratio, 0.15 [95% CI, 0.04-0.57] and 14.96 [95% CI, 4.14-54.01], respectively); ABO blood group showed no association with severity.

ConclusionThese findings demonstrate a substantial association between COVID-19 severity and complications and pregnancy, but not ABO blood group.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.04.26362260v1?rss=1">
<title>
<![CDATA[
Aggregation of mortality data by place and cause mask underlying trends in COVID-19 excess mortality 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.04.26362260v1?rss=1"
</link>
<dc:creator>Herdzik, K.</dc:creator>
<dc:creator>Sakrejda, K.</dc:creator>
<dc:creator>Wagner, A.</dc:creator>
<dc:creator>Zelner, J.</dc:creator>
<dc:date>2026-09-08</dc:date>
<dc:identifier>doi:10.64898/2026.09.04.26362260</dc:identifier>
<dc:title><![CDATA[Aggregation of mortality data by place and cause mask underlying trends in COVID-19 excess mortality]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-08</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Difficulties ascertaining the true burden of infection and mortality from SARS-CoV-2 hindered disease surveillance and healthcare resource allocation throughout the COVID-19 pandemic.

Although all-cause excess mortality estimates have long been deployed to avoid the challenges of case detection when testing availability is variable, aggregation of mortality by cause of death and spatial unit may mask underlying patterns and hide underlying associations with social factors. Furthermore, some non-infectious causes of death may have decreased during the pandemic, resulting in all-cause excess mortality capturing a net pandemic effect rather than the direct burden of Covid-19.

Using mortality data in the state of Michigan from January 2015 - November 2019, we calculated the expected mortality for December 2019 - November 2022 using negative binomial regression. Comparing these estimates to the observed mortality, we calculated the burden of excess mortality during the winter 2019 influenza season and COVID-19 pandemic, as divided into 7 distinct periods based on dominant viral strain and pharmaceutical and non-pharmaceutical interventions implemented. All analyses were performed with the data aggregated by cause of death and to the county level and repeated at both the county and census tract level disaggregated into two crude cause of death categories: acute respiratory infections (ARIs) and all other causes (non-acute respiratory infections, non-ARIs). We examined spatial heterogeneity of excess mortality by cause using the Theil index to determine if variation in excess mortality was driven by differences between or within counties.

The excess mortality rate from ARI peaked in the first phase of the pandemic, with a ratio of 10.7 observed to expected deaths (95% CrI: 10.3 - 11.1). However, the all- cause excess mortality rate rose only to 1.20 excess deaths per expected (95% CrI: 1.17 - 1.22) and the non- ARI excess mortality rate was unchanged. Comparing ARI excess mortality rates calculated at the county vs. census tract level demonstrated large and unpredictable variation, with county level estimates ranging from 0.42 to 1.2 times the tract level estimates. However, county level estimates of non-ARI and all- cause excess mortality ratios were consistently closer to tract level estimates. Within county variation of ARI mortality decreased during the pandemic and slowly returned to reference levels, suggesting spatial patterning of ARI mortality became more similar across census tracts as rates rose statewide. Social vulnerability was associated with an increased ARI excess mortality rate ratio at the census tract level during the first pandemic phase (EMRR: 1.1, 95% CrI: 1.08 - 1.13), but this effect was attenuated when aggregated to all-cause mortality or to the county level.

Our findings indicate that using county-level all-cause excess mortality as a proxy for ARI excess mortality obscured the burden of ARI death, particularly during the most acute phases of the COVID-19 pandemic. Relying on aggregated metric of all-cause mortality limits the power to detect large shifts in cause-specific mortality, and that limitation can be mitigated by even using coarse categories such as ARI vs. non-ARI deaths. Similarly, finer scale spatial units allow for the detection of local trends necessary to identify associated social factors.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.06.26362399v1?rss=1">
<title>
<![CDATA[
Using large language models to facilitate literature review and data extraction for infectious disease models: COVID-19 as a test case 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.06.26362399v1?rss=1"
</link>
<dc:creator>Yang, X.</dc:creator>
<dc:creator>Lee, C. Y.</dc:creator>
<dc:creator>Quilty, B. J.</dc:creator>
<dc:creator>Zhang, L.</dc:creator>
<dc:creator>Mu, Y.</dc:creator>
<dc:creator>Jit, M.</dc:creator>
<dc:date>2026-09-08</dc:date>
<dc:identifier>doi:10.64898/2026.09.06.26362399</dc:identifier>
<dc:title><![CDATA[Using large language models to facilitate literature review and data extraction for infectious disease models: COVID-19 as a test case]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-08</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Infectious disease transmission models are governed by parameters informed by systematic review of epidemiological literature. Large language models (LLMs) could facilitate this, but the reliability of the results to inform models has not been tested.

We built an open-source, end-to-end pipeline to simulate LLM performance in a hypothetical scenario where they were available to inform COVID-19 models developed during the first four months of 2020. It screened articles and extracted the reproduction number, serial interval, and incubation period from full-text PDFs. We applied it to 2,067 PubMed/medRxiv records published 31 December 2019-30 April 2020 using four models (GPT-5-mini, GPT-5.4, Claude Opus 4.8 and Gemini 2.5 Pro) and evaluated it against full-corpus human screening and 50-article extraction gold standards. We combined models post hoc, pooled the extracted values into an infectious disease (SEIR) model, and ran sensitivity analyses to test approaches to improve extraction accuracy.

Screening sensitivity was 0.72-0.95 and specificity 0.92-0.99. For articles reporting few values, extraction F1 was 0.90-0.96 with precision 0.91-1.00; across all articles, including those with dozens of stratified estimates, recall fell to 0.38-0.78. No fabricated values observed; errors were misassignments of values filed under the wrong parameter, or borrowed values treated as the studys own. Incomplete extraction from dense articles was mainly due to prompting and output format, not model capability. Ensembling allowed recall-precision trade-offs, and correctness increased with model agreement, from about 30% at one vote to 92-95% at four. The pipeline processed the corpus in hours versus an estimated 130-265 person-hours of manual effort.

Our results show that current models can extract transmission parameters from unstructured literature accurately enough to inform outbreak modelling. The bottleneck lies in task specification, and careful prompt and output schema design are key to reducing misassignment errors. Human effort is best directed at workflow development and provenance validation.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.07.26362459v1?rss=1">
<title>
<![CDATA[
Ensemble SHAP Aggregation and Attribution Variability in Clinical Machine Learning: A COVID-19 Mortality Study 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.07.26362459v1?rss=1"
</link>
<dc:creator>Dai, N.</dc:creator>
<dc:creator>Briceno, R. K.</dc:creator>
<dc:creator>Castaneda, A. N.</dc:creator>
<dc:creator>Tresierra, M. A.</dc:creator>
<dc:creator>Esteban, M. L.</dc:creator>
<dc:creator>Rosas, M. E.</dc:creator>
<dc:creator>Hinojosa, R. C.</dc:creator>
<dc:date>2026-09-08</dc:date>
<dc:identifier>doi:10.64898/2026.09.07.26362459</dc:identifier>
<dc:title><![CDATA[Ensemble SHAP Aggregation and Attribution Variability in Clinical Machine Learning: A COVID-19 Mortality Study]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-08</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
ObjectiveTo combine performance-weighted ensemble SHAP aggregation with resampling-based assessment of feature-importance variability and patient-level attribution alignment for interpreting COVID-19 mortality predictions.

MethodsWe analyzed a prospective cohort of 1,857 patients hospitalized with COVID-19 at two hospitals in Peru. Ten predictive algorithms were evaluated using five-fold cross-validation, and their mean AUROC values determined their attribution-aggregation weights. Within each model and training trial, signed SHAP values were normalized by the mean total absolute attribution across evaluation patients before performance-weighted aggregation. Feature importance was summarized across 30 resampled training trials using means and normal-approximation 95% confidence intervals. Patient-level attribution alignment was assessed using cosine similarity between signed feature-attribution vectors for corresponding patients, with whole-trial patient-correspondence randomization and Benjamini-Hochberg correction. Subgroup observations were reweighted toward the evaluated populations feature distributions for secondary comparisons of existing absolute SHAP values.

ResultsAmong the 1,857 included patients, 982 (52.9%) died during hospitalization. Random forest achieved the highest mean AUROC (0.925 {+/-} 0.010), followed by AdaBoost (0.919 {+/-} 0.017) and logistic regression (0.918 {+/-} 0.007), with variability reported as the SEM. Attribution profiles were more similar across repeated training trials of the same algorithm (mean Pearson r = 0.783; SEM, 0.004) than across algorithms within the same trial (mean Pearson r = 0.369; SEM, 0.006). The largest normalized attribution magnitudes were observed for dexamethasone use at home without oxygen support (6.186%; 95% CI, 5.795-6.577), PaO2/FiO2 ratio (3.014%; 95% CI, 2.787-3.242), shortness of breath (2.774%; 95% CI, 2.592-2.956), and FiO2 (2.560%; 95% CI, 2.284-2.836). Features differed in patient-level attribution alignment, indicating that importance magnitude and robustness provided complementary information. Among 1,763 eligible subgroup-feature comparisons, 64 had nominal one-sided p < 0.05, although none remained below 0.05 after Benjamini-Hochberg adjustment.

ConclusionsAlgorithms with similar predictive performance produced substantially different feature-attribution profiles. Normalized performance-weighted SHAP aggregation provided a representative relative-importance summary across algorithms, while resampling-based alignment assessment qualified the consistency of individual feature contributions. The resulting attribution patterns describe fitted-model behavior and should not be interpreted as causal clinical effects.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.07.26362431v1?rss=1">
<title>
<![CDATA[
Neural characterisation of persistent quantitative and qualitative COVID-19-related olfactory dysfunction: The COVORTS study 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.07.26362431v1?rss=1"
</link>
<dc:creator>Dijk, B. v.</dc:creator>
<dc:creator>Postma, E. M.</dc:creator>
<dc:creator>Leenders, L. M.</dc:creator>
<dc:creator>Smits, P.</dc:creator>
<dc:creator>Kamalski, D. M. A.</dc:creator>
<dc:creator>Smeets, P. A. M.</dc:creator>
<dc:creator>Boesveldt, S.</dc:creator>
<dc:date>2026-09-08</dc:date>
<dc:identifier>doi:10.64898/2026.09.07.26362431</dc:identifier>
<dc:title><![CDATA[Neural characterisation of persistent quantitative and qualitative COVID-19-related olfactory dysfunction: The COVORTS study]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-08</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
The mechanism underlying persistent COVID-19-related olfactory dysfunction (OD) remains unknown. There are indications for both peripheral (within the nose) and central (in the brain) mechanisms. Patients can experience a decrease in olfactory ability (quantitative OD) or a distorted odour perception (qualitative OD). The mechanisms might differ between these two symptom presentations. In this (f)MRI study, we investigated structural and functional brain alterations in patients with persistent (> 1 month) quantitative OD (Sniffin Sticks score < 30.75, n=21) or parosmia (self-reported, n=27) following SARS-CoV-2 infection, aged 19-60 years and, on average, included 472 days after diagnosis (the COVORTS study). Additionally, a control group of 49 normosmic subjects aged 22-60 years was included. Olfactory bulb volume (OBV) was determined by manual segmentation; whole-brain and regional grey matter density (GMD) of olfactory-related areas was assessed using voxel-based morphometry; and odour-induced brain activation was examined with an olfactory fMRI task. When grouped together, patients with OD had a smaller OBV than controls (84.4 vs 95.3 mm3, p=0.026). The two patient groups did not differ in OBV. ROI analysis of olfactory-related brain regions at an exploratory threshold showed lower GMD in primary and secondary olfactory regions in patients compared to controls, which appears to be mainly driven by quantitative OD. No difference in odour-induced brain activation was found. The observed smaller olfactory bulbs, along with modest findings beyond this primary olfactory structure, provide important insights into potential mechanisms of persistent COVID-19-related OD and highlight the need for longer follow-up to evaluate further neural degradation or recovery.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.04.26361413v1?rss=1">
<title>
<![CDATA[
Clinical Phenotypes of Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection: A Longitudinal Cohort Study from Karachi, Pakistan 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.04.26361413v1?rss=1"
</link>
<dc:creator>Khanum, I.</dc:creator>
<dc:creator>Ahmed, K.</dc:creator>
<dc:creator>Munir, T.</dc:creator>
<dc:creator>Zia, H.</dc:creator>
<dc:creator>Saif, W.</dc:creator>
<dc:creator>Sadia, H.</dc:creator>
<dc:creator>Mahmood, S. F.</dc:creator>
<dc:creator>Nasir, N.</dc:creator>
<dc:creator>Ghias, K.</dc:creator>
<dc:creator>Rabinowitz, P.</dc:creator>
<dc:creator>Van Voorhis, W.</dc:creator>
<dc:creator>Iqbal, N. T. T.</dc:creator>
<dc:date>2026-09-08</dc:date>
<dc:identifier>doi:10.64898/2026.09.04.26361413</dc:identifier>
<dc:title><![CDATA[Clinical Phenotypes of Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection: A Longitudinal Cohort Study from Karachi, Pakistan]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-08</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Post-Acute Sequelae of SARS-CoV-2 infection (PASC), commonly referred to as Long COVID, is increasingly recognized as a significant public health concern. However, longitudinal studies examining its clinical course remain limited in South Asia, and the true burden of persistent symptoms in Pakistan is not well established. This study aimed to characterize the long-term clinical manifestations of PASC and investigate the relationship between symptom persistence, faecal viral shedding, and serotonin levels over a one-year follow-up period.

We conducted a prospective longitudinal study involving individuals diagnosed with PASC (n=60). Participants underwent serial assessments for clinical symptoms, stool SARS-CoV-2 RNA detection, and serotonin measurements in platelets rich plasma at multiple time points over 12 months. A symptom score was developed using 22 symptoms reported by more than 30% of participants.

Among the study population, 60% were female, with a mean age of 42.1 {+/-} 12.1 years. Two-thirds (66%) were overweight or obese, and 28.3% reported multiple SARS-CoV-2 reinfections. Longitudinal analysis demonstrated a significant reduction in overall symptom burden at 9 months ({beta} = -2.68, 95% CI: -3.81 to -1.55; p < 0.001) and 12 months ({beta} = -3.00, 95% CI: -4.13 to -1.87; p < 0.001) compared with baseline. Despite this overall improvement, several symptoms persisted throughout follow-up. The prevalence of myalgia remained largely unchanged (60% at baseline vs. 63% at 12 months), while musculoskeletal symptoms persisted at similar levels (59% vs. 60%). Neurocognitive symptoms declined from 40% to 31.3%, whereas psychological symptoms increased slightly from 40% to 45.8% over the study period.

Faecal viral shedding was detected in 56.7% of participants and demonstrated both intermittent and persistent patterns. Although no association was observed between faecal shedding and symptoms at baseline, significant associations emerged at six months, particularly for breathlessness, fatigue, weakness (77.8%), and joint pain (88.9%). Serotonin levels remained broadly comparable to those reported during acute COVID-19 infection.

These findings highlight the prolonged nature of PASC, with persistent symptoms such as myalgia, joint pain, weakness, and fatigue continuing for at least one year after infection. The persistence of symptoms, together with evidence of ongoing faecal viral shedding, suggests that viral persistence and sustained physiological disturbances may contribute to the long-term pathogenesis of Long COVID in a subset of affected individuals.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.06.26362366v1?rss=1">
<title>
<![CDATA[
The COVID-19 Trajectory in Israel: A Comprehensive Analysis of National Surveillance Data on Documented Infections, Test Positivity, and Vaccine-Effectiveness Estimates 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.06.26362366v1?rss=1"
</link>
<dc:creator>Ophir, Y.</dc:creator>
<dc:creator>Sevillya, G.</dc:creator>
<dc:date>2026-09-08</dc:date>
<dc:identifier>doi:10.64898/2026.09.06.26362366</dc:identifier>
<dc:title><![CDATA[The COVID-19 Trajectory in Israel: A Comprehensive Analysis of National Surveillance Data on Documented Infections, Test Positivity, and Vaccine-Effectiveness Estimates]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-08</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
BackgroundIsrael was among the first countries to implement nationwide BNT162b2 vaccination and became an important source of real-world evidence during the COVID-19 pandemic. The present study aimed to characterize the long-term national epidemic trajectory and the evolution of vaccination-associated differences in documented infection across the course of the pandemic.

MethodsFive Israeli Ministry of Health datasets were analyzed from February 2020 through May 2023. National trends in documented infection and test positivity were characterized. Vaccinated- unvaccinated differences were examined using routine-surveillance case rates. To reduce potential bias from differences in prior-infection history and real-world testing intensity, a second age-adjusted analysis compared test positivity among individuals without documented prior infection.

ResultsThe two completed pre-rollout waves declined to [&le;]10% of their peaks within 32 and 43 days, whereas the winter 2020-2021 wave, already underway when vaccination began, required 68 days. Delta and Omicron peaks were 17% and approximately ninefold higher than the January 2021 peak. Routine-surveillance apparent vaccine effectiveness peaked at 94.4% in February 2021, declined to 61.5% by late May, and remained negative from February 2022 onward. The age-adjusted test-positivity analysis among individuals without documented prior infection yielded generally lower estimates, which remained negative from December 2021 onward.

ConclusionsOverall, the early vaccination-associated advantage against documented infection was not stable over extended follow-up. While these observational findings cannot establish causal vaccine effects or address severe outcomes, they underscore the importance of evaluating vaccine-effectiveness estimates over extended follow-up as population immunity, testing practices, and viral variants evolve.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.09.04.749277v1?rss=1">
<title>
<![CDATA[
Allosteric remodelling of the Ebola virus glycoprotein underlies differences in entry mechanisms across species 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.09.04.749277v1?rss=1"
</link>
<dc:creator>Calvaresi, V.</dc:creator>
<dc:creator>Kratochvil, J.</dc:creator>
<dc:creator>Bekauri, A.</dc:creator>
<dc:creator>Kukura, P.</dc:creator>
<dc:creator>Struwe, W. B.</dc:creator>
<dc:date>2026-09-08</dc:date>
<dc:identifier>doi:10.64898/2026.09.04.749277</dc:identifier>
<dc:title><![CDATA[Allosteric remodelling of the Ebola virus glycoprotein underlies differences in entry mechanisms across species]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-08</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
During Ebolavirus transit through the endo-lysosomal pathway, the glycoprotein GP undergoes a series of conformational rearrangements upon cathepsin cleavage and NPC1 receptor binding, culminating in host-virus membrane fusion. While these rearrangements underpin viral entry, their molecular mechanisms remain poorly understood. Here, we combine hydrogen/deuterium-exchange mass spectrometry and mass photometry to resolve structural dynamic and energetic transitions of GP of two major species, Zaire (EBOV) and Sudan (SUDV). We describe the allosteric axes that govern reorganization of the cleavage sites, opening of the receptor binding cavity and priming for fusion upon NPC1 engagement. We show that GP cathepsin cleavage and receptor binding exhibit different mechanisms and kinetics across species, and are allosterically coupled in a species-specific manner. We reveal that fusion priming is optimized via distinct routes in EBOV and SUDV GP. These data suggest that GP structural dynamics and allosteric remodelling underlie differences in entry mechanisms across Ebolavirus species.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.09.03.749134v1?rss=1">
<title>
<![CDATA[
Variant-specific nucleocapsid mutations shape host innate immune trajectories during SARS-CoV-2 infection 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.09.03.749134v1?rss=1"
</link>
<dc:creator>Berger, J. M.</dc:creator>
<dc:creator>Schroeder, J. M.</dc:creator>
<dc:creator>Soh, T. K.</dc:creator>
<dc:creator>Pekarek, N.</dc:creator>
<dc:creator>Breul, L.-M.</dc:creator>
<dc:creator>Doerner, S.</dc:creator>
<dc:creator>Bluemke, P.</dc:creator>
<dc:creator>Huang, J.</dc:creator>
<dc:creator>Bosse, J. B.</dc:creator>
<dc:creator>Pfefferle, S.</dc:creator>
<dc:creator>Uetrecht, C.</dc:creator>
<dc:date>2026-09-08</dc:date>
<dc:identifier>doi:10.64898/2026.09.03.749134</dc:identifier>
<dc:title><![CDATA[Variant-specific nucleocapsid mutations shape host innate immune trajectories during SARS-CoV-2 infection]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-08</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
The SARS-CoV-2 nucleocapsid (N) protein is one of the most highly expressed proteins during infection and plays crucial roles in the protection and packaging of viral RNA, replication, suppression of the immune response and virus assembly. The N gene and the overlapping accessory open reading frame ORF9b have continually evolved throughout the circulation of the virus, likely due to ongoing adaptation to the human host. This genetic variability influences the interplay of the N protein and its interactors. Yet, little is known about how specific mutations within the N/ORF9b locus of Variants of Concern (VOCs) shape the progression and outcome of infection. Here, we use a multi-omics approach to decipher how these genetic alterations reprogram the host cell by creating Wuhan-Hu-1-based recombinant viruses carrying an isogenic backbone with respective N mutations from the VOCs (called rNs) and comparing their effects at the transcriptome and proteome levels. We found that the mutations induce distinct transcriptional and translational alterations: rN-Alpha drives a stealth-like infection characterized by sustained translation efficiency and specific evasion of the 2'-5'-oligoadenylate synthetase (OAS) innate immune sensor, whereas rN-Delta and rN-BA.2 trigger a highly elevated inflammatory response. For rN-Delta, hyperphosphorylation of the N-protein drives cellular stress culminating in necroptotic cell death. Because these viruses differ only within the N/ORF9b locus, N sequence variation emerges as a determinant of infection outcome in its own right, warranting increased surveillance attention.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.02.26362081v1?rss=1">
<title>
<![CDATA[
Laemple: A Benchmarking Framework for Virus Lineage Deconvolution Tools for SARS-CoV-2 from Wastewater 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.02.26362081v1?rss=1"
</link>
<dc:creator>Schedl, A.</dc:creator>
<dc:creator>Bergthaler, A.</dc:creator>
<dc:creator>Amman, F.</dc:creator>
<dc:date>2026-09-07</dc:date>
<dc:identifier>doi:10.64898/2026.09.02.26362081</dc:identifier>
<dc:title><![CDATA[Laemple: A Benchmarking Framework for Virus Lineage Deconvolution Tools for SARS-CoV-2 from Wastewater]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-07</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
1BackgroundCorrect and accurate deconvolution of SARS-CoV-2 lineages from wastewater sequencing data is a challenging task, given the intricacy of wastewater amplicon-sequencing data and the ever-growing complexity of the lineage classification. Existing benchmarking studies made use of artificial spike-in compositions, thereby falling short of reflecting the prevailing complexity of wastewater samples.

ResultsWe present a modular, expandable, simulation-based benchmarking framework as a reproducible Snakemake workflow, named Laemple, to evaluate the performance of virus lineage deconvolution tools. Using in silico simulated data sets of varying complexity and sequencing quality, we demonstrate its utility by evaluating seven publicly available tools, based on their precision, sensitivity, and reproducibility. Freyja showed robust sensitivity and consistent performance across diverse data set complexities, alongside user-friendly installation and documentation, while VaQuERo demonstrated the highest precision.

ConclusionsOur results reveal substantial variation in tool performance across conditions, emphasizing the need to benchmark with diverse and complex scenarios. This framework enables informed tool selection for researchers and public health agencies and allows developers to stress-test their tools during development and maintenance, i.e., updating the lineage definition for newly emerging virus lineages. To this end, Laemple was designed in a modular fashion for customization and future expansion to support ongoing software development across all stages of the application life-cycle management.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.02.26361948v1?rss=1">
<title>
<![CDATA[
Surgical Critical Care Outcomes Before and After the Onset of the COVID-19 Pandemic: A Single-Center Retrospective Comparative Audit 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.02.26361948v1?rss=1"
</link>
<dc:creator>Ali, S. M. H.</dc:creator>
<dc:creator>Yasin, U.</dc:creator>
<dc:creator>Ather, O.</dc:creator>
<dc:creator>Malik, A.</dc:creator>
<dc:date>2026-09-06</dc:date>
<dc:identifier>doi:10.64898/2026.09.02.26361948</dc:identifier>
<dc:title><![CDATA[Surgical Critical Care Outcomes Before and After the Onset of the COVID-19 Pandemic: A Single-Center Retrospective Comparative Audit]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-06</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
This audit aimed to determine whether the pattern of presenting abdominal pathology, procedures performed, and clinical outcomes in our surgical intensive care unit (SICU) changed during the COVID-19 period. We reviewed a total of 356 patients who were admitted to the SICU with 1st March 2020 taken as the reference cutoff date. Two hundred and five (57.6%) cases occurred in the Pre-COVID interval and 151 (42.4%) in the Post-COVID interval. Patients admitted to SICU Post-COVID were significantly older than those admitted Pre-COVID (54.2 vs. 48.3 years, p = 0.005). Hospital and SICU length of stay were unchanged across the pandemic (p = 0.824 and 0.601 respectively). The procedure case-mix shifted significantly (p = 0.014): appendectomy, gastrectomy/sleeve gastrectomy and thoracic procedures fell, while exploratory laparotomy rose, consistent with reduced elective/minimally-invasive activity and a shift toward emergency open surgery. Appendiceal disease was recorded significantly less often as the presenting diagnosis Post-COVID (p = 0.016), and intestinal obstruction showed a non-significant upward trend (p = 0.071). SICU mortality and overall admission outcome were unchanged across the pandemic (p = 1.000 and 0.664).
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.08.31.26356614v1?rss=1">
<title>
<![CDATA[
Prevalence and Functional Outcomes of Post-Exertional Malaise among Adults with prior COVID-19: Results from a Representative Survey of New York City Residents 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.08.31.26356614v1?rss=1"
</link>
<dc:creator>Packard, S. E.</dc:creator>
<dc:creator>Russo, T.</dc:creator>
<dc:creator>Parrott, J.</dc:creator>
<dc:creator>Sisti, J.</dc:creator>
<dc:creator>Lans, A.</dc:creator>
<dc:date>2026-09-02</dc:date>
<dc:identifier>doi:10.64898/2026.08.31.26356614</dc:identifier>
<dc:title><![CDATA[Prevalence and Functional Outcomes of Post-Exertional Malaise among Adults with prior COVID-19: Results from a Representative Survey of New York City Residents]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-02</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
ObjectiveTo estimate the prevalence of Post-Exertional Malaise (PEM) among adults with prior COVID-19 and associated mental health and disability outcomes.

MethodsWe conducted a cross-sectional analysis of data from a survey of 9,620 adults with prior COVID-19 in New York City, collected May - June 2024. PEM was measured with the DePaul Symptom Questionnaire - Post Exertional Malaise, categorized by symptom duration (< 14 vs. [&ge;]14 hours). Weighted prevalence estimates were stratified by socio-demographic and clinical characteristics. Modified Poisson regression was used to assess the association of PEM with depression, anxiety, and disability.

ResultsThe prevalence of PEM symptoms was 20.9% overall and 4.0% with symptom duration [&ge;] 14 hours, representing over 800,000 New Yorkers affected and over 150,000 who meet a diagnostic criterion for ME/CFS. PEM prevalence was higher among women, transgender and non-binary adults, people of color, and lower educational attainment, chronic comorbidities, or disabilities. PEM was associated with 3 - 4 times higher prevalence of mental health outcomes and 4 - 5 times higher disability scores.

ConclusionsPEM symptoms were common and strongly associated with disability and adverse mental health. Screening, pathways to care, and supportive policies are needed to mitigate long-term consequences, particularly among marginalized populations.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.08.28.26359302v1?rss=1">
<title>
<![CDATA[
Impaired memory B-cell formation after mRNA-based COVID-19 booster vaccination in patients with inflammatory bowel disease receiving anti-TNF treatment 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.08.28.26359302v1?rss=1"
</link>
<dc:creator>Gill, P. A.</dc:creator>
<dc:creator>Bradbury, L. R.</dc:creator>
<dc:creator>Wang, A.</dc:creator>
<dc:creator>Hogg, J.</dc:creator>
<dc:creator>Demase, K.</dc:creator>
<dc:creator>McKenzie, J.</dc:creator>
<dc:creator>Fryer, H. A.</dc:creator>
<dc:creator>Geers, D.</dc:creator>
<dc:creator>Zaeck, L. M.</dc:creator>
<dc:creator>Boo, I.</dc:creator>
<dc:creator>Hogarth, M. P.</dc:creator>
<dc:creator>Drummer, H. E.</dc:creator>
<dc:creator>de Vries, R. D.</dc:creator>
<dc:creator>O'Hehir, R. E.</dc:creator>
<dc:creator>Sparrow, M. P.</dc:creator>
<dc:creator>van Zelm, M. C.</dc:creator>
<dc:date>2026-09-02</dc:date>
<dc:identifier>doi:10.64898/2026.08.28.26359302</dc:identifier>
<dc:title><![CDATA[Impaired memory B-cell formation after mRNA-based COVID-19 booster vaccination in patients with inflammatory bowel disease receiving anti-TNF treatment]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-02</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
BackgroundPatients receiving anti-TNF treatment for chronic inflammatory disease display impaired antibody responses, but it remains unclear how immune memory formation is affected. We evaluated antibody responses and memory B cells (Bmem) after COVID-19 booster vaccination in inflammatory bowel disease (IBD) patients receiving anti-TNF treatment.

MethodologyBlood was sampled at baseline, 1, and 6 months after WH1/BA.5 bivalent or XBB.1.5 monovalent vaccination from 27 IBD patients receiving intravenous anti-TNF and 44 controls. Neutralizing antibodies were measured using an infectious virus assay. SARS-CoV-2 spike receptor binding domain (RBD)-specific serum IgG was quantified by ELISA, and RBD-specific Bmem were immunophenotyped by flow cytometry using recombinant proteins from ancestral, Omicron BA.1, BA.5, XBB.1.5, and JN.1 variants.

ResultsSerum IgG to vaccine RBD and neutralizing antibodies in patients increased pre to 1 month post-vaccination, but were lower than controls. Ancestral-, BA.5- and XBB.1.5-specific Bmem increased after vaccination but were significantly lower in patients than controls. Within RBD-specific Bmem, frequencies of recently activated CD21lo cells were increased after vaccination, and were higher in patients than controls. Fewer antigen-specific Bmem in patients expressed IgG4, and more expressed IgG3 or IgD following vaccination. Following vaccination, more RBD-specific Bmem recognized multiple viral variants. However, patients had fewer Bmem that could bind to subvariants than controls.

ConclusionAntibody and Bmem responses to COVID-19 booster vaccination in anti-TNF-treated IBD patients displayed reduced capacity, durability and cross-reactivity, suggesting impaired immune memory for protection against breakthrough infection. This supports the recommendation for annual booster vaccination to prevent severe disease and viral spread.

HighlightsO_LIIBD patients on anti-TNF biologics mount antibody responses and form vaccine-specific memory B cells following WH1/BA.5 bivalent or XBB.1.5 monovalent mRNA COVID-19 booster vaccination.
C_LIO_LIVaccine-specific antibody responses and memory B cell formation in patients are significantly lower than in controls at 1- and 6 months after vaccination, indicative of poorer peak response and durability.
C_LIO_LIDespite multiple vaccinations, vaccine-specific memory B cells from patients display phenotypic alterations and reduced recognition of multiple SARS-CoV-2 Omicron subvariants, potentially a consequence of impaired germinal center responses in patients.
C_LI
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.08.27.26361302v1?rss=1">
<title>
<![CDATA[
Predicting COVID-19 hospitalisation and common disease risk from comorbid diagnoses in 13 million individuals 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.08.27.26361302v1?rss=1"
</link>
<dc:creator>Liu, H.</dc:creator>
<dc:creator>Mizani, M. A.</dc:creator>
<dc:creator>Zhao, Y.</dc:creator>
<dc:creator>Wood, A.</dc:creator>
<dc:creator>Inouye, M.</dc:creator>
<dc:creator>Price, A. L.</dc:creator>
<dc:creator>Jiang, X.</dc:creator>
<dc:creator>CVD-COVID-UK/COVID-IMPACT Consortium,</dc:creator>
<dc:date>2026-09-01</dc:date>
<dc:identifier>doi:10.64898/2026.08.27.26361302</dc:identifier>
<dc:title><![CDATA[Predicting COVID-19 hospitalisation and common disease risk from comorbid diagnoses in 13 million individuals]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-09-01</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Predicting disease risk from prior diagnoses is fundamental to clinical decision-making, particularly during health emergencies such as the COVID-19 pandemic, when individuals with long-term conditions may be disproportionately vulnerable to adverse outcomes. Despite intense interest in developing models to predict disease risk from prior diagnoses 1-3, most prediction models do not estimate effects of each prior diagnosis on disease risk conditional on other diagnoses, limiting interpretability and clinical utility. We developed the Comorbidity Risk Score (CRS), trained on 13 million individuals (age 40-69) from linked electronic health record (EHR) datasets of the entire population of England, to predict COVID-19 hospitalisation and 87 other disease outcomes. CRS was trained at close to saturated sample size and precisely estimated the effects of 212 prior diagnoses on the 88 disease outcomes, conditional on all other prior diagnoses. Correlations of CRS effect sizes across outcomes (e.g. 0.76 for myocardial infarction vs. hyperlipidaemia) matched the corresponding genetic correlations (e.g. 0.79 for myocardial infarction vs. hyperlipidaemia), confirming that comorbidity architectures capture disease aetiology. On average, CRS identified 5% of the population with 3.4-fold higher disease risk, including myocardial infarction (4.4-fold), lung cancer (6.5-fold), and COVID-19 hospitalisation (6.3-fold). Using prior diagnoses alone, CRS outperformed state-of-the-art clinical COVID-19 models 4. Furthermore, CRS (N=13 million) substantially outperformed state-of-the-art AI 1 (N=0.5 million) and linear 3 (N=0.5 million) models in predicting disease risk, suggesting that training sample size outweighs model complexity. CRS attained near-perfect transferability across self-reported ethnicities (e.g., Black vs. White: AUROC ratio = 97.3%). Finally, CRS distinguished independently predictive comorbidities from indirect associations, e.g., lipid metabolism disorder was a strong predictor of myocardial infarction risk but not ischaemic stroke, after conditioning on other prior diagnoses. In conclusion, CRS provides a comprehensive resource for understanding the impact of comorbidities on COVID-19 and other future diseases, revealing disease aetiology while enabling powerful prediction of disease risk.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.08.28.26361631v1?rss=1">
<title>
<![CDATA[
Clinical features of COVID-19 patients hospitalized at the Tashkent State Medical University and risk factors for intensive care unit admission: a cross-sectional study from Uzbekistan, Central Asia 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.08.28.26361631v1?rss=1"
</link>
<dc:creator>Rakhimov, B.</dc:creator>
<dc:creator>Choi, J.</dc:creator>
<dc:creator>Kim, K.</dc:creator>
<dc:creator>Tuychiev, L.</dc:creator>
<dc:creator>Shadmanov, A.</dc:creator>
<dc:creator>Mamatkulov, B.</dc:creator>
<dc:date>2026-08-31</dc:date>
<dc:identifier>doi:10.64898/2026.08.28.26361631</dc:identifier>
<dc:title><![CDATA[Clinical features of COVID-19 patients hospitalized at the Tashkent State Medical University and risk factors for intensive care unit admission: a cross-sectional study from Uzbekistan, Central Asia]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-08-31</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
BackgroundThe clinical course of coronavirus disease 2019 (COVID-19), and the ability to anticipate which patients will require intensive care, were poorly characterized in Central Asia during the first pandemic wave. We aimed to describe the clinical features of hospitalized COVID-19 patients at the Tashkent State Medical University, Uzbekistan, and to identify risk factors for intensive care unit (ICU) admission.

MethodsIn this single-centre cross-sectional study, we reviewed the records of 2500 consecutive patients hospitalized between 11 April and 8 August 2020. Patients were grouped as asymptomatic or symptomatic, and symptomatic patients were compared by ICU versus non-ICU status. Groups were compared with chi-square or Fishers exact and Mann-Whitney U tests. Univariable and multivariable logistic regression identified risk factors for ICU admission.

ResultsOf 2500 patients (median age 36 years; 60.9% male), 989 (39.6%) were asymptomatic and 1511 (60.4%) symptomatic. In total, 129 (5.2%) were admitted to the ICU and 38 (1.5%) died. ICU patients were older (median 56 vs 40.5 years) and more often had bilateral pneumonia, oxygen desaturation and cardiometabolic comorbidity. In the multivariable model (AUC 0.82), the independent predictors of ICU admission were ischemic heart disease (aOR 4.20), shortness of breath (aOR 3.22), hypertensive heart disease (aOR 2.93) and male sex (aOR 2.00).

ConclusionsOlder age, cardiometabolic comorbidity and respiratory compromise identified patients at high ICU risk. As one of the first clinical COVID-19 descriptions from Uzbekistan, these data provide a baseline for preparedness in Central Asia.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.08.27.26361498v1?rss=1">
<title>
<![CDATA[
A Multivariable Plasma Extracellular Vesicle Surface Profile Associated with Post-COVID-19 Syndrome 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.08.27.26361498v1?rss=1"
</link>
<dc:creator>Erhart, D. K.</dc:creator>
<dc:creator>Ressin, H.</dc:creator>
<dc:creator>Balz, L. T.</dc:creator>
<dc:creator>Chatterjee, S.</dc:creator>
<dc:creator>Lule, D.</dc:creator>
<dc:creator>Mueller, S.</dc:creator>
<dc:creator>Lewerenz, J.</dc:creator>
<dc:creator>Muench, J.</dc:creator>
<dc:creator>Tumani, H.</dc:creator>
<dc:creator>Gross, R. M.</dc:creator>
<dc:date>2026-08-31</dc:date>
<dc:identifier>doi:10.64898/2026.08.27.26361498</dc:identifier>
<dc:title><![CDATA[A Multivariable Plasma Extracellular Vesicle Surface Profile Associated with Post-COVID-19 Syndrome]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-08-31</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Post-COVID-19 syndrome (PCS) is characterized by fatigue, neurological impairment and systemic symptoms. This heterogeneity of symptoms hinders biomarker development. Here, we profiled extracellular-vesicle (EV) surface markers in plasma and CSF from 61 participants with PCS (COVIDpost), 80 recovered controls (COVIDreco), and 10 participants with non-SARS-CoV-2 post-viral syndromes. EVs were analysed by bead-based multiplex flow cytometry using tetraspanin-directed (TSPN) and phosphatidylserine-directed lactadherin (PS) detection. Amongst 37 targets covering tetraspanins and vasculature-, immunity- and stemness-associated markers, none met a 1% false-discovery-rate threshold. However, L1-regularized logistic regression under fully nested 5x5 cross-validation identified a distributed plasma EV profile, with mean out-of-fold areas under the receiver operating characteristic curve (AUCs) of 0.788 (95% CI 0.715-0.852) for TSPN and 0.716 (95% CI 0.636-0.792) for PS detection. Across the pooled COVIDpost and COVIDreco population, EV classification scores covaried with clinical group differences, but did not track clinical severity within either cohort. These PCS-EV classification scores decreased at one-year follow-up in COVIDpost participants. Our findings identify an internally cross-validated multivariable EV surface profile associated with COVIDpost versus COVIDreco status and support independent validation and exploration of EV-based biomarkers in post-viral fatigue syndromes.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.08.27.26361488v1?rss=1">
<title>
<![CDATA[
Acute Protein Responses Control SARS-CoV-2-specific Neurocognitive and General Post-Viral Sequelae 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.08.27.26361488v1?rss=1"
</link>
<dc:creator>Liou, T. G.</dc:creator>
<dc:creator>Andrews, R. J.</dc:creator>
<dc:creator>Bass, B. L.</dc:creator>
<dc:creator>Battey, H.</dc:creator>
<dc:creator>Buonfiglio, L. G. V.</dc:creator>
<dc:creator>Cahill, B. C.</dc:creator>
<dc:creator>Cox, J. E.</dc:creator>
<dc:creator>Gibson, S.</dc:creator>
<dc:creator>Hartsell, S. C.</dc:creator>
<dc:creator>Hatton, N.</dc:creator>
<dc:creator>Hazel, M.</dc:creator>
<dc:creator>Helms, M. N.</dc:creator>
<dc:creator>Jensen, J. L.</dc:creator>
<dc:creator>Kartsonaki, C.</dc:creator>
<dc:creator>Kupfer, J.</dc:creator>
<dc:creator>Li, Y.</dc:creator>
<dc:creator>Lopes, F. B. T. P.</dc:creator>
<dc:creator>Manuel, A.</dc:creator>
<dc:creator>Marchetti, M.</dc:creator>
<dc:creator>Marvin, J. E.</dc:creator>
<dc:creator>Middleton, E. A.</dc:creator>
<dc:creator>Mimche, P.</dc:creator>
<dc:creator>Packer, K. A.</dc:creator>
<dc:creator>Paine, R.</dc:creator>
<dc:creator>Szczesniak, R. D.</dc:creator>
<dc:creator>Sturrock, A. B.</dc:creator>
<dc:creator>Tandar, A.</dc:creator>
<dc:creator>Tarbet, B.</dc:creator>
<dc:creator>Ulrich, A.</dc:creator>
<dc:creator>Warner, D.</dc:creator>
<dc:creator>Warren, K.</dc:creator>
<dc:creator>Weis, A. M.</dc:creator>
<dc:creator>Zimmerman, E.</dc:creator>
<dc:creator>Yoon, S.</dc:creator>
<dc:creator>Ownbey, M.</dc:creator>
<dc:creator>Youngquist, S. T.</dc:creator>
<dc:creator>Adler, F. R.</dc:creator>
<dc:date>2026-08-31</dc:date>
<dc:identifier>doi:10.64898/2026.08.27.26361488</dc:identifier>
<dc:title><![CDATA[Acute Protein Responses Control SARS-CoV-2-specific Neurocognitive and General Post-Viral Sequelae]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-08-31</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
After serious infections, many survivors fully recover while others face persistent symptoms including neurocognitive dysfunction, cardiopulmonary instabilities and disabling fatigue, classified broadly as Post-Acute Infection Syndromes (PAIS). Post-Acute Sequelae of COVID19 (PASC) is one special case. To test whether acute infection initiates PAIS, we analyzed proteins in 173 saliva samples collected during severe respiratory viral infections and tracked patient outcomes for five years. We discovered 44 proteins, all derived from interferon stimulated genes, that respond strongly to acute infection. Rates of post-acute syndromes were similar regardless of infection, but the types of Sequelae differed by virus. High expression of 19 proteins predict low General Sequelae rates across all viruses. High expression of 23 overlapping proteins predict low Neurocognitive Sequelae rates only with SARS-CoV-2 infections. We propose that low expressions of these proteins, which control viral replication, innate immunity, and secondary autoimmunity, combine to precipitate PAIS and PASC.

HighlightsO_LIAcute viral infections elicit interferon stimulated gene (ISG) protein responses.
C_LIO_LI23 ISG proteins prevent post-infection General Sequelae for all viral infections.
C_LIO_LI19 ISG proteins prevent post-infection Neurocognitive Sequelae only with SARS-CoV-2.
C_LIO_LIPoor protein responses induce distinct post-viral syndromes with or without COVID19.
C_LI
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.08.28.26361657v1?rss=1">
<title>
<![CDATA[
Understanding RSV Resurgence Following COVID-19 in Ontario, Canada: Evaluating the Roles of Contact Patterns and Maternal Immunity 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.08.28.26361657v1?rss=1"
</link>
<dc:creator>Parpia, A.</dc:creator>
<dc:creator>Wright, J.</dc:creator>
<dc:creator>Gharouni, A.</dc:creator>
<dc:creator>Thampi, N.</dc:creator>
<dc:creator>Fitzpatrick, T.</dc:creator>
<dc:date>2026-08-31</dc:date>
<dc:identifier>doi:10.64898/2026.08.28.26361657</dc:identifier>
<dc:title><![CDATA[Understanding RSV Resurgence Following COVID-19 in Ontario, Canada: Evaluating the Roles of Contact Patterns and Maternal Immunity]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-08-31</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
BackgroundRespiratory syncytial virus (RSV) remains a leading cause of hospitalization in infancy, with severe outcomes influenced by both contact patterns and passive immunity. Non-pharmaceutical interventions (NPIs) during the COVID-19 pandemic suppressed RSV circulation and reduced opportunities for maternal immune boosting, potentially altering protection among newborns. We evaluated whether incorporating time-varying maternal immunity improves the ability of an age-structured transmission model to predict post-pandemic RSV hospitalization patterns in infants.

MethodsWe analyzed population-based RSV hospitalizations among Ontario (Canada) infants (<1 year) from July 2, 2017 to June 25, 2024, using linked administrative databases. A deterministic compartmental model across seven age classes was calibrated against pre-pandemic data using Latin Hypercube Sampling. We compared a model incorporating time-varying contact rates alone against a specification that additionally included time-varying maternal immunity.

ResultsBoth specifications accurately reproduced pre-pandemic seasonality and macro-level post-pandemic resurgence features. The constant maternal immunity model showed slightly better accuracy in capturing the 2021/22 peak compared to the time-varying maternal immunity specification. However, both qualitatively captured the continued near-absence of RSV and the observed peak was captured within the 95% credible intervals. While both models precisely captured the timing and overwhelming surge of admissions that occurred in 2022/23, they failed to capture the premature peak timing and magnitude in 2023/24.

ConclusionsIncorporating time-varying maternal immunity did not improve model accuracy post-pandemic. While maternal protection is essential for evaluating infant immunizations, population-level contact shifts primarily shaped post-pandemic RSV seasonality, indicating that models must account for these mechanisms of RSV transmission dynamics.

SummaryUsing population-based Ontario hospitalization data, we evaluated whether incorporating time-varying maternal immunity improves an age-structured transmission model s ability to reproduce infant RSV disease patterns. While maternal immunity did impact post-pandemic RSV resurgences, we found that population-level contact pattern shifts were primarily responsible.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.08.25.26361355v1?rss=1">
<title>
<![CDATA[
Rural-urban disparities and associated factors of SARS-CoV-2 infection in Zambia: A convergent mixed-methods study using the Proximate Determinant Framework. 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.08.25.26361355v1?rss=1"
</link>
<dc:creator>Wantakisha, E. W. R.</dc:creator>
<dc:creator>Nyirenda, S.</dc:creator>
<dc:creator>Narayani, M.</dc:creator>
<dc:date>2026-08-31</dc:date>
<dc:identifier>doi:10.64898/2026.08.25.26361355</dc:identifier>
<dc:title><![CDATA[Rural-urban disparities and associated factors of SARS-CoV-2 infection in Zambia: A convergent mixed-methods study using the Proximate Determinant Framework.]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-08-31</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
BackgroundRural-urban disparities in SARS-CoV-2 infection epidemiology remain poorly quantified and understood in Zambia despite differences in healthcare access, services and preventive interventions. This study examined the geographical distribution and associated factors of SARS-CoV-2 cases across selected rural and urban districts of Zambia.

MethodsA convergent mixed-methods study comprised of quantitative survey and qualitative interviews was conducted in; Ndola (Urban), Kafue (Peri-urban) and Lufwanyama (Rural). The proximate determinant framework guided variable selection and interpretation. Quantitative combined (Hospital-surveillance data with community survey), while qualitative included In-depth interviews. Participants were sampled using multistage sampling technique. Quantitative data were analysed using STATA version 17, while qualitative data were analysed thematically. Findings were integrated through triangulation.

ResultsA total of 528 participants were included, with a median age 31 years (15-71). Overall SARS-CoV-2 positivity was 12.6%, varying across rural (16.5%), peri-urban (14.9%), and urban (9.9%) settings, though residence was not associated with infection (P<0.132). Participants aged [&ge;]49 years had significantly higher odds of infection (aOR=8.78; 95% CI:1.15-66.99), whereas secondary education (aOR=0.37; 95% CI:0.16-0.86) and hospital-based testing (aOR=0.37; 95% CI:0.15-0.92) were associated with lower odds of infection. Vaccine uptake was highest in urban areas but was not independently associated with infection. Qualitative findings revealed marked rural-urban differences in perceived susceptibility, testing access, vaccine decision-making, and adherence to preventive measures, explaining several quantitative observations.

ConclusionSARS-CoV-2 infection across rural and urban settings in Zambia was influenced by demographic, behavioral, and health-system factors rather than geographic residence alone. These findings highlight the need for context-specific prevention strategies, equitable access to testing, strengthened community surveillance, and targeted risk communication to improve preparedness and response for future respiratory disease outbreaks.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.08.29.26361724v1?rss=1">
<title>
<![CDATA[
Temporal inequalities in the global COVID-19 vaccine rollout: a cross-national observational study of delivery, health-system capacity, and time to coverage 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.08.29.26361724v1?rss=1"
</link>
<dc:creator>Lee, H.-W.</dc:creator>
<dc:creator>Huang, Y.-H.</dc:creator>
<dc:creator>McAndrew, T. C.</dc:creator>
<dc:date>2026-08-31</dc:date>
<dc:identifier>doi:10.64898/2026.08.29.26361724</dc:identifier>
<dc:title><![CDATA[Temporal inequalities in the global COVID-19 vaccine rollout: a cross-national observational study of delivery, health-system capacity, and time to coverage]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-08-31</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
IntroductionBy the end of 2023, many low-income countries had not reached 50% COVID-19 vaccine coverage, while most high-income countries had exceeded 80%. It remains unclear whether receiving vaccine deliveries translated into faster population coverage. We examined cross-national inequalities in the timing of the vaccine rollout and whether deliveries through the COVID-19 Vaccines Global Access (COVAX) facility were associated with subsequent national uptake.

MethodsWe conducted an observational study of 218 countries and territories using country-level data up to December 2023. We used generalized additive mixed models to identify country-level correlates of coverage at an early and a later stage of the pandemic, survival analysis to compare the time to 50% coverage between COVAX Advance Market Commitment (AMC) and non-AMC countries, and an event study to estimate the association between the timing of the first COVAX delivery and subsequent monthly coverage in AMC countries.

ResultsAMC-supported countries reached 50% coverage substantially more slowly than non-AMC countries. The hazard of reaching the threshold was 0.17 times that of non-AMC countries at month 1 (95% CI 0.07 to 0.41) and 0.53 times at month 18 (95% CI 0.33 to 0.85). One year after rollout began, 65.9% of AMC countries (95% CI 56.7 to 76.6) had not reached 50% coverage, compared with 21.1% of non-AMC countries (95% CI 15.1 to 29.5). The timing of COVAX deliveries was not significantly associated with subsequent national uptake in any post-delivery month. In the early stage of rollout, higher maternal mortality was associated with lower coverage, while a larger urban population was associated with higher coverage. By the end of the observation period, larger household size was associated with lower coverage, while higher health expenditure and a larger urban population were associated with higher coverage.

ConclusionReceiving COVAX deliveries was not, on its own, associated with faster coverage. Coverage differences were more consistently associated with country-level structural and health-system characteristics, while we found no significant association with the timing of the first COVAX delivery. Achieving vaccine equality likely requires strengthening the capacity of health systems to convert deliveries into administered doses, and preparedness efforts should invest in last-mile delivery capacity ahead of future emergencies.

Key messagesO_ST_ABSWhat is already known on this topicC_ST_ABSLow-income countries lagged far behind high-income countries in COVID-19 vaccine coverage, and although COVAX was created to narrow this gap, few studies examined whether receiving deliveries translated into faster population uptake.

What this study addsAcross 218 countries and territories, AMC-supported countries reached 50% coverage substantially more slowly than non-AMC countries, and the timing of COVAX deliveries showed no significant association with subsequent national uptake. Coverage was more consistently associated with country-level structural factors, namely maternal mortality and urban population in the early stage and household size, health expenditure and urban population by the end of the period.

How this study might affect research, practice or policyVaccine delivery alone may be insufficient to accelerate coverage. Preparedness efforts should invest in the health-system capacity needed to convert deliveries into administered doses, and should measure success by how quickly populations are protected rather than by doses shipped.
]]></description>
</item>
</rdf:RDF>
